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In certain neurodegenerative diseases such Dementia with Lewy Bodies (DLB), it is 
hypothesised that misfolded α-synuclein (α-syn) and β-amyloid both contribute to pathology. 
α-Syn and β-amyloid have been suggested to synergistically promote one another’s 
accumulation and aggregation, but the mechanisms are unknown. β-Amyloid is generated 
from β-/γ-secretase-mediated processing of the amyloid precursor protein (APP). This study 
investigated how α-syn overexpression in cells affects β-amyloid production from APP, using 
multiplex assays, luciferase reporter assays, and western blotting. Wildtype α-syn expression 
induces β-amyloid generation from APP in SH-SY5Y human neuroblastoma cells, and similar 
changes to APP processing occur in another neuronal cell model. Dominant-negative 
overexpression of α-syn mutants revealed that disrupting the N-terminal domain can increase 
APP amyloidogenic processing. Secretase enzymes that perform APP processing were next 
investigated. γ-Secretase activity, measured by a luciferase reporter, was not increased by 
α-syn overexpression. A higher ratio of β- to α-secretase processing was hypothesised, which 
led to expression and activity studies of the major β- and α-secretases, BACE1 and ADAM10 
respectively. It was shown that the BACE1 protein expression is post-transcriptionally 
upregulated in α-syn cells, with increased APP cleavage in cells. ADAM10 protein expression 
is transcriptionally suppressed in wild-type α-syn cells, reducing total levels of catalytically 
active enzyme. However the change in ADAM10-mediated APP processing may be negligible 
since, critically, plasma membrane expression of ADAM10 appears to be maintained. To aid 
understanding of the mechanism that connects α-syn to APP processing, BACE1 expression 
was used in pharmacological studies of cell stress signalling. This approach revealed that in 
α-syn cells BACE1 lysosomal and/or proteasomal degradation may be disturbed. Additionally, 
BACE1 expression is induced by translational de-repression mediated by eIF2α ser-51 
phosphorylation, which was increased in α-syn cells. Although preliminary, the data suggests 
a role for oxidative stress mediating the increased BACE1 expression in wild-type α-syn cells.
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1.1.1 Parkinson’s disease and other synucleinopathies 
A ‘synucleinopathy’ is a neurodegenerative disease where the primary pathology is 
misfolding of the protein α-synuclein (α-syn). Parkinson’s disease (PD) is the most common 
synucleinopathy, and affects approximately 140 people per 100,000 in the UK (Wales et al. 
2013; Wickremaratchi et al. 2009). PD is also known as a ‘Lewy body disease’, since the most 
visible results of α-syn misfolding are Lewy bodies. ‘Lewy bodies’ are globular inclusions of 
insoluble aggregated proteins, primarily α-syn fibrils, in the cell bodies of neurons (Spillantini 
et al. 1997). The term ‘Lewy neurite’ was coined for a spindle-like neurite inclusion, pictured 
along with Lewy bodies in Figure 1.1 (Braak et al. 2003). PD is diagnosed when a patient 
exhibits characteristic levodopa-responsive motor and autonomic symptoms (‘parkinsonism’), 
with no dementia, and autopsy reveals Lewy bodies and selective loss of dopaminergic 
neurons (Berg et al. 2014).  
The other synucleinopathies are Parkinson’s disease dementia (PDD), dementia with Lewy 
bodies (DLB), and multiple system atrophy (MSA). PDD and DLB patients are characterised 
by parkinsonism and Lewy bodies, like PD, but are additionally defined by dementia 
symptoms. Presentation of dementia more than a year after a PD diagnosis leads to a 
classification of PDD. DLB patients are diagnosed with dementia before, or within a year, of 
emerging parkinsonism (Lippa et al. 2007; McKeith et al. 1996). MSA patients exhibit 
parkinsonism or cerebellar ataxia, a condition where balance and co-ordination are impaired. 
A conclusive diagnosis can only be made with post-mortem histology, since MSA is defined 
by predominantly oligodendroglial inclusions of α-syn, in addition to some neuronal Lewy 
bodies (Gilman et al. 2008; Peelaerts & Baekelandt 2016). 
Alzheimer’s disease is not considered to be a synucleinopathy, despite the frequent 
presence of Lewy bodies in AD brains. Since AD brains have widespread insoluble aggregates 
of other neurodegenerative disease proteins, Lewy bodies are not the major pathology. 
Furthermore, Lewy bodies in AD tend to be confined to the amygdala (Hamilton 2000; 
Parkkinen et al. 2003; Jellinger 2004). 
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Figure 1.1 Images of α-syn-immunopositive inclusions, in the SNpc of PD brains. (A) 
Lewy bodies, (B) Lewy neurites. Taken from (Halliday & McCann 2010). 
1.1.2 A brief history of Parkinson’s disease 
James Parkinson’s ‘An Essay on the Shaking Palsy’ in 1817 is considered to be the seminal 
work on what would later be termed Parkinson’s disease, describing the natural history of the 
disease rather than merely symptoms. Lewy Bodies were identified in 1912 by Fritz Heinrich 
Lewy, and in 1919 Konstantin Tretiakoff found that the key anatomical feature of PD is severe 
lesioning of the substantia nigra pars compacta (SNpc). It took decades for the significance of 
selective SNpc damage to be understood as the root cause of motor symptoms (Lees 2007). 
The discovery of the neurotransmitter dopamine by Arvid Carlsson in the 1950s was key. 
Depleted dopamine levels in the caudate and putamen of PD brains were discovered by 
Hornykiewicz and colleagues in 1960. This was followed by discovery of dopaminergic 
neurons that connect the SNpc to the striatum, and that damage to the SNpc reduces dopamine 
levels in the striatum. Thus the biochemical basis of PD was understood well enough for the 
symptoms of disease to be treated, using new drugs to improve dopaminergic transmission 
(Fahn 2008). The root cause of neurodegeneration was a mystery until a genetic connection 
was uncovered. A large family of Italian descent was found to have a ‘PD gene’ with 85% 
penetrance, in the chromosomal region 4q21–q23. The gene was identified in 1997 as SNCA, 
coding for α-syn, with an A53T point mutation (Polymeropoulos et al. 1997). In the same year, 
α-syn was discovered to be a major insoluble component of Lewy Bodies by Spillantini and 
colleagues (Spillantini et al. 1997). Spillantini et al. predicted that the A53T mutation promotes 
α-syn aggregation into insoluble α-syn fibrils, confirmed a year later (Conway et al. 1998). 
From these discoveries, a new field of research into the role of α-syn in PD emerged. 
Nevertheless, other genetic causes of familial PD have also subsequently been identified: 
Parkin (1998), DJ-1 (2001), PINK1 (2004), LRRK2 (2004), PLA2G6 (2009) and VPS35 
(2011). Mutation of these genes can result in PD-type symptoms, but also some atypical 
characteristics (Houlden & Singleton 2012).  
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1.1.3 A ‘spectrum’ of diseases containing Lewy Bodies 
There is an ongoing debate about whether all forms of genetic and sporadic PD share a 
common mode of pathogenesis, triggered by defects in an interconnected network, or whether 
there are multiple unrelated diseases under the umbrella of ‘PD’ (Houlden & Singleton 2012). 
Furthermore, researchers have puzzled over the relationship between PD, the Lewy body 
dementias, and AD. On the one hand, PDD and DLB are widely accepted to be related to PD 
(Lippa et al. 2007). The genetics are similar: SNCA and LRRK2 mutations appear to manifest 
as PD, PDD, or DLB (Poulopoulos et al. 2012). The neuropathology also suggests common 
origins: diagnosis of PDD/DLB corresponds with the widespread presence of cortical Lewy 
bodies, in addition to brainstem Lewy bodies. Cortical Lewy bodies have been suggested to 
originate from the brainstem (Irwin et al. 2013). Lewy body pathology appears to progress 
along specific neuronal pathways, in a stereotyped manner from the brainstem to the 
neocortex, as characterised by Braak et al. (Figure 1.2) (Braak et al. 2003). Cell-to-cell 
transmission has also been experimentally demonstrated (Walker et al. 2015; Desplats et al. 
2009). On the other hand, some researchers advocate that DLB is equally related to AD as PD. 
Genetic risk factors studied by genome-wide array show that DLB shares about the same 
number of genetic determinants with AD as with PD (Guerreiro et al. 2015). This was 
supported by an independent genetic study, focussing on only major AD and PD genes in 
samples from PDD/DLB patients. A number of mutations and copy-number variants were 
found in both AD-related genes (APP, PSEN1, PSEN2, MAPT) and PD-genes (SNCA, 
LRRK2, PARK2) (Meeus et al. 2012). The genetic evidence clearly supports mechanistic 
overlaps between PD, Lewy body dementias, and AD. Neuropathological evidence also 
suggests a complex picture, for example some DLB brains present little or no cortical Lewy 
body pathology (Irwin et al. 2012; Pletnikova et al. 2005). Furthermore, cognitive impairment 
in PDD/DLB appears to correlate with the appearance of pathologies typical of AD: 
intracellular tau tangles and extracellular β-amyloid plaques (Irwin et al. 2013).  
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Figure 1.2 Illustration of Braak staging. Lewy bodies are hypothesised to spread in a caudal 
to rostral direction, from the brainstem to neocortex. Taken from (Halliday et al. 2011).  
1.1.4 The toxic oligomer hypothesis 
α-Syn-containing insoluble inclusions are the diagnostic feature of Lewy body diseases 
(Berg et al. 2014), and familial point mutations linked with familial PD appear to increase 
aggregation of the protein in vitro (Conway et al. 2000; Li et al. 2001). This naturally led to 
the idea that α-syn aggregates are toxic. Soluble β-sheet-rich oligomers are now widely 
regarded to be the major toxic species of α-syn, a theory known as ‘the toxic oligomer 
hypothesis’. The toxic oligomer hypothesis is not unique to α-syn, in fact other proteins and 
peptides such as Aβ42, a peptide associated with Alzheimer’s disease (AD), can form β-sheet-
rich oligomers that are toxic to cells (Kayed et al. 2003; Kayed et al. 2004). The feature that 
these amyloidogenic proteins have in common is an intrinsically-disordered monomer, which 
can explore a range of conformational states in solution, including conformations with 
β-strands (Uversky 2009). The current model for their formation of amyloid fibrils is one of 
nucleation followed by polymerisation, with a likely structural-conversion step of the 
oligomeric intermediates in between (Figure 1.3) (Cremades et al. 2012; Jarrett & Lansbury 
1992). Under the right conditions, such as agitation at room temperature, the proteins 
spontaneously nucleate small globular oligomers with a core of antiparallel β-strands. These 
oligomers appear to have the ability to permeabilise membranes (Cremades et al. 2012; Kayed 
et al. 2004; Lorenzen et al. 2014; Lashuel et al. 2002; Celej et al. 2012; Kostka et al. 2008; 
Danzer et al. 2007). Small oligomers can grow by monomer addition. Additionally a slow 
conformational change can compact the oligomers into highly structured β-sheet forms, which 
are proteinase-K resistant, appear to be more toxic, and produce high levels of ROS (Cremades 
et al. 2012; Iljina et al. 2016). The compact oligomers polymerise into amyloid fibrils, with 
each additional monomer folding into the parallel β-sheet conformation by templating. 
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Amyloid fibrils can de-polymerise when monomer concentration is low, or may break into 
fragments that nucleate several new fibrils (Cremades et al. 2012; Knowles et al. 2009).  
α-Syn can oligomerise in its wild-type state, particularly if the local concentration of 
monomers is increased, but the process is faster with PD familial point mutations such as E46K 
(Li et al. 2001; Conway et al. 2000; Conway et al. 1998). E46K causes only very subtle 
changes to the monomeric conformation of α-syn, and does not reduce the long-range 
interactions between N- and C-terminus that protect against fibrillisation (Fredenburg et al. 
2007; Bertoncini et al. 2005; Breydo et al. 2012; Rospigliosi et al. 2009). However, E46K does 
disrupt the formation of small α-helical oligomers, increasing the concentration of disordered 
monomeric protein in the cytosol (Dettmer et al. 2015). There is evidence to support multiple 
toxic effects of α-syn toxic oligomers to cells, which is illustrated in Figure 1.4 and has been 
reviewed (Roberts & Brown 2015). It is potentially helpful to consider the features common 
to all toxic oligomers, to reveal where toxicity originates. For instance, Aβ42 aggregates have 
a close correlation between their toxicity and affinity for 1-anilinonaphthalene 8-sulfonate 
(ANS). ANS binds exposed hydrophobic regions in partially unfolded proteins, and responds 
by fluorescing more brightly. It reveals that toxic oligomers of Aβ, and a number of other 
amyloidogenic oligomers, expose hydrophobic patches (Bolognesi et al. 2010). Furthermore, 
the hydrophobic exposure of toxic oligomers could be linked to the ease at which they appear 
to permeabilise membranes. Campioni et al. demonstrated this link using the bacterial protein 
HypF-N as a model. HypF-N reliably forms two types of morphologically similar β-sheet-rich 
oligomer, one of which is toxic and the other benign. The toxic form had a greater tendency 
to bind ANS, less hydrophobic packing of residues, and appeared to permeabilise SH-SY5Y 
cells to calcium influx when added externally (Campioni et al. 2010). The specific ability of 
α-syn oligomers to permeabilise membranes has also been characterised in detail by multiple 
groups (Lorenzen et al. 2014; van Rooijen et al. 2009; Danzer et al. 2007; Kostka et al. 2008).  
  









Figure 1.3 Model schematic of α-syn oligomerisation and amyloid fibril formation. ‘Off-
pathway’ α-syn oligomers can form with little or no β-sheet secondary structure (coloured 
blue), or ‘on-pathway’ oligomers with antiparallel β-structure (coloured red). A structural 
conversion event creates protofibrils with parallel β-structure, which elongate by monomer 

























Figure 1.4 Effects of toxic oligomers. Diagram summarising the proposed links between cell 
processes that are disturbed by α-synuclein toxic oligomers (outer rings), and the properties of 
oligomers (inner ring). ER: endoplasmic reticulum. UPR: unfolded protein response. Adapted 
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1.1.5 Genetic and environmental factors converge to promote α-syn aggregation 
The pathogenic aggregation of α-syn may arise from a combination of genetic and 
environmental factors. One genetic factor is SNCA, which can cause PD through pathogenic 
point mutations or copy number variants. Up to 10% of PD is familial, and Mendelian 
inheritance of α-syn copy number variants comprises about 2% of familial PD (Lesage & Brice 
2009). Some sporadic cases of α-syn gene multiplication have also been detected, and a ‘Rep1’ 
nucleotide polymorphism close to the SNCA promoter is a validated risk factor for sporadic 
PD (Lesage & Brice 2009; Maraganore et al. 2006). Since α-syn multiplications and mutations 
are uncommon, the presence of α-syn aggregates in the majority of PD cases needs 
explanation. One potential reason is the presence of other monogenic loci that affect α-syn 
accumulation. LRRK2 is the most common, with its missense variants accounting for up to 
10% of familial PD and 3.6% of sporadic PD. The G2385R and R1628P variants in Asian 
populations confer a 2-3-fold increased susceptibility for PD (Lesage & Brice 2009). LRRK2 
appears to have an important role in autophagy and lysosomal function that makes it vital for 
the normal degradation of α-syn (Gan-Or et al. 2015). The G2019S mutation, common to 
North African and Ashkenazi Jew PD patients (Lesage & Brice 2009), has been shown to 
inhibit chaperone-mediated autophagy (CMA) and promote accumulation of α-syn, a CMA 
substrate (Orenstein et al. 2013). Several other familial PD genes, and hits from genome-wide 
association studies, appear to converge on autophagy pathways. This suggests that α-syn 
accumulation is frequently downstream of lysosomal dysfunction in PD (Gan-Or et al. 2015). 
Environmental factors and the intrinsic processes of aging are likely to also contribute to 
sporadic PD, and promote downstream α-syn accumulation. Exposure to certain pesticides, 
toxins, and particular metals such as manganese, are linked to increased risk of PD. 
Proteasome inhibition, induced by the pesticides paraquat and maneb, and oxidative stress, 
caused by rotenone or MPTP through respiratory chain inhibition, have been experimentally 
shown to promote α-syn aggregation (Burbulla & Krüger 2011). Neuronal oxidative stress and 
respiratory chain inhibition are also reported in cases of manganese toxicity (Martinez-Finley 
et al. 2013). Manganese exposure causes frontal cortex neurodegeneration in primates, and 
reduced function of nigrostriatal neurons. Curiously, this is accompanied by both intracellular 
α-syn aggregates and diffuse extracellular Aβ aggregates, presumably due to the sensitivity of 
both amyloidogenic proteins to oxidative stress (Verina et al. 2013). The aging process itself 
also appears to lead to selective SNpc α-syn accumulation in healthy humans and primates 
(Chu & Kordower 2007). Aging reduces proteasome and autophagic activity, and also leads 
to defective mitochondria not being degraded and replaced efficiently, increasing oxidative 
stress. α-Syn appears to participate in ‘vicious cycles’ whereby it exacerbates these deficits, 
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as illustrated in Figure 1.5, and forms more toxic species as a result. However, the specific 
vulnerability of the SNpc to α-syn accumulation and neurodegeneration is peculiar, 
particularly given that this phenomenon does not occur in rodents (Bobela et al. 2015). Bolam 
and Pissadaki hypothesise that it is the unusually high energy demands of SNpc dopaminergic 
neurons in humans and primates, caused by their architecture and lack of myelination, which 
makes them more sensitive to oxidative stress and mitochondrial dysfunction (Bolam & 
Pissadaki 2012; Bobela et al. 2015).  
1.1.6 Is α-syn an essential driver of Lewy Body disease? 
α-Syn misfolding is a common denominator in familial and sporadic PD. However, the 
extent to which α-syn drives neurodegeneration is debatable. At one extreme, McGeer & 
McGeer propose an ‘α-syn burden hypothesis’, whereby sporadic PD entirely results from “a 
declining ability to clear α-syn” (McGeer & McGeer 2008). At the other extreme, it is argued 
that α-syn-independent mechanisms of neurodegeneration exist in some types of PD. Evidence 
for this stems experimentally from animal models of rare genetic forms of PD, involving loss-
of-function of GBA1 or ATP13A2. These genetic models experience degeneration of the SNpc 
even when crossed with an α-syn-null background (Keatinge et al. 2015; Kett et al. 2015). 
Furthermore, patients with PARK2 mutations exhibit a juvenile-onset recessive form of PD, 
where Lewy bodies are generally absent (Houlden & Singleton 2012). PARK2 specifically 
regulates mitophagy, demonstrating that mitochondrial dysregulation may be sufficient to 
cause a subtype of PD (Gan-Or et al. 2015). Nonetheless, α-syn-independent 
neurodegeneration in PD is rare, and proves only that PD is a heterogeneous disorder.  
A moderate view is perhaps more widely accepted, whereby α-syn has a major role in 
driving the progression of neurodegeneration in PD, but other genetic and cell factors are also 
important, as discussed in Section 1.1.5. The experimental evidence that α-syn aggregation is 
toxic to cells is robust. Numerous studies have shown that recombinant oligomers of α-syn 
decrease the viability of cell cultures to which they are added, and that A53T, E46K, and H50Q 
disease-associated point mutations enhance both the rate of aggregation and toxicity 
  





Figure 1.5 Simplified schematic showing the proposed convergence of environmental, 
systemic, and genetic factors in Lewy body disease. Mitochondrial dysfunction and ROS 
production are two of the major factors that lead to dopaminergic cell death, but are not the 
only toxic effects of α-syn, which include ER stress and altered Ca2+ signalling. 
Environmental/systemic/genetic factors influence the aggregation of α-syn, in part, through 
impairing the ubiquitin-proteasome system (UPS) or autophagy-lysosome pathway (ALP) 
(Houlden & Singleton 2012). α-Syn aggregation furthermore participates in a ‘vicious circle’ 
that increases mitochondrial dysfunction and ROS production.  
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(Choi et al. 2004; Khalaf et al. 2014; Conway et al. 1998; Pandey et al. 2006). Pharmacological 
inhibition of α-syn aggregation, using baicalein, protected E46K α-syn-treated cells from 
proteasome block and mitochondrial depolarisation (Li et al. 2011). To test the hypothetical 
toxicity of α-syn oligomers a ‘conformation-trapped’ E57K α-syn protein, which promotes the 
formation of β-sheet-rich oligomers but strongly inhibits fibrillisation, was developed by 
structure-based design. Overexpression of E57K α-syn increased the calcium influx and 
reduced the viability of cell cultures. Moreover, severe dopaminergic neuron loss was seen in 
rats injected with E57K α-syn lentivirus, more pronounced than demonstrated with E46K or 
wild-type α-syn (Winner et al. 2011). This evidence supports a leading role for α-syn toxic 
oligomers in PD. 
There is also strong evidence that α-syn aggregates can be transmitted from cell to cell, 
propagating disease (Costanzo & Zurzolo 2013). Native secretion and endocytosis of α-syn 
were demonstrated with conditioned media taken from cell lines. α-Syn in conditioned media 
was endocytosed by primary cortical neurons and promoted cell death. This was prevented by 
either upregulating HSP70 chaperone expression, immunodepleting α-syn from conditioned 
media, or treating conditioned media with oligomer-interfering compounds (Danzer et al. 
2011; Emmanouilidou, Melachroinou, et al. 2010). ‘Seeding’ of endogenous α-syn 
aggregation, by applying exogenous α-syn fibril fragments, was also demonstrated within 
cells, and labelled α-syn transmitted between cells in co-cultures (Volpicelli-Daley et al. 2012; 
Desplats et al. 2009; Hansen et al. 2011). The kinetics of seeding α-syn aggregation was 
described in detail by Iljina et al., who suggest that templated seeding is inefficient by itself, 
but aggregation is strongly aided by the production of ROS by soluble oligomers, illustrated 
in Figure 1.6 (Iljina et al. 2016). In vivo studies also support the propagation of α-syn 
aggregates, (a) in healthy non-transgenic dopaminergic neurons grafted into α-syn transgenic 
rodents (Hansen et al. 2011; Angot et al. 2012); and (b) in neurons of healthy transgenic/wild-
type mice, following injection of recombinant fibrils (Luk, V. M. Kehm, et al. 2012; Luk, V. 
Kehm, et al. 2012). Compellingly, the injection of α-syn fibrils into non-transgenic mice 
appears sufficient to trigger a PD-like cascade of Lewy pathology transmission, between 
anatomically connected regions. Selective dopaminergic neuron loss from the SNpc, sparing 
the adjacent ventral tegmental area, was also observed and is a classic feature of PD (Luk, V. 
Kehm, et al. 2012). Therefore, seeding and propagation experiments support a role for α-syn 
in driving the progression of Lewy Body disease.  
  






Figure 1.6 Two simplified models of α-syn aggregate propagation in Lewy body disease. 
Templated seeding of aggregates, a ‘prion-like’ style of propagation where exogenous 
aggregates are grown by addition of endogenous monomers; (B) Cell-driven aggregation, 
where exogenous aggregates induce cell stress, creating conditions that indirectly promote 
endogenous α-syn aggregation. Taken from (Iljina et al. 2016).  
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1.2 Structure and localisation of α-syn 
1.2.1 The synuclein family of proteins 
Synuclein was first identified in 1988, in the electric organ of the electric ray Torpedo 
californica, and was named for its apparent localisation to both synaptic vesicles and the 
nuclear membrane (Maroteaux et al. 1988). Interestingly, α-syn is still considered to have an 
important role at pre-synaptic vesicles, but its presence and function in the nucleus is 
contentious (Wales et al. 2013). Synuclein was then independently discovered as a brain-
specific bovine protein (1990), a protein involved in synaptic plasticity in songbirds (1995), 
and precursor of the ‘non amyloid component’ (NAC) peptide (1993), abundant in amyloid 
plaques of AD patients (Clayton & George 1998; Uéda et al. 1993; George et al. 1995; Nakajo 
et al. 1990). The NAC precursor was later given the name α-synuclein, and its homologs β-
synuclein and γ-synuclein identified as having similar sequences to the bovine protein and 
Torpedo protein respectively (Jakes et al. 1994; Clayton & George 1998).  
α-Syn, β-syn, and γ-syn have genes at chromosome sites 4q21, 5q35 and 10q23, 
respectively (Wales et al. 2013). A schematic comparison of the synuclein proteins can be seen 
in Figure 1.7. The N-terminal 42 amino acids for the three proteins are highly homologous, 
and β-syn shares 61% of its amino acid sequence with α-syn, differing mainly in the C-terminal 
half (Wales et al. 2013; Jakes et al. 1994). Both α- and β-syn are predominantly expressed in 
the brain, particularly in presynaptic terminals of the frontal cortex, striatum and hippocampus 
(Iwai et al. 1995). α-Syn also appears to be important for the development of lymphocyte cells 
(Shameli et al. 2015). γ-Syn is less closely related to α-syn, and expressed most abundantly in 
the cell bodies and axons of the peripheral nervous system, as well as in brain neurons 
(Buchman et al. 1998).  
Interestingly the hydrophobic domain of β-syn, which corresponds to the amyloid fibril-
forming ‘NAC’ region of α-syn, is missing a stretch of 11 amino acids. (Jakes et al. 1994). In 
vitro and in vivo experiments appear to show that β-syn is more resistant to aggregation than 
α-syn, and even inhibits the fibrillisation of α-syn (Fan et al. 2006; Hashimoto et al. 2001). 
Yet all three synucleins can form fibrils in vitro, although β- and γ-syn require specific 
conditions (Yamin et al. 2005; Uversky et al. 2002). All three synucleins form neuronal 
inclusions when over-expressed in mice (Taschenberger et al. 2013; Ninkina et al. 2009), and 
appear to form aggregates in PD and DLB brains (Surgucheva et al. 2014; Galvin et al. 1999). 
As previously discussed, mutations and gene copy variants of α-syn are associated with 
familial Lewy Body disease. Mutations of β-syn, V70M and P123H, have also been discovered 
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in patients with DLB (Ohtake et al. 2004), and a single nucleotide polymorphism of the γ-syn 
gene confers a significant risk for DLB (Nishioka et al. 2010).  
1.2.2 Disordered monomers and α-helical tetramers 
α-Syn is an intrinsically-disordered protein, which means that it lacks a definitive 
secondary or tertiary structure. In solution, α-syn exists in a range of conformations. The acidic 
C-terminus is entirely unfolded, and the hydrophobic NAC region exists in a compact ‘molten 
globule’ state. The traditional view of α-syn in a cell is that the majority is cytosolic, and 
therefore an unstructured monomer (Breydo et al. 2012). Yet metastable α-helical tetramers 
were reported in 2012, using non-denaturing gels or in vivo cross-linking to prevent their 
dissociation (Bartels et al. 2012). In normal human brains there appears to be twice as many 
tetramers as monomers, depending on the antibody used. Tetramers are assumed to be native 
and non-toxic, given their prevalence in healthy tissues (Dettmer et al. 2015). The issue 
provoked much debate, with publications from various groups either confirming (Bartels et al. 
2012; Dettmer et al. 2013; Gould et al. 2014; Dettmer et al. 2015) or contesting the 
predominance of tetramers (Fauvet et al. 2012; Lashuel et al. 2013). Tetramers have achieved 
more credence for their potential to explain a common mechanism by which familial PD-
associated point mutations affect α-syn. The tetramer:monomer ratio is significantly decreased 
by A30P, E46K, H50Q, G51D, and A53T, relative to the wild-type protein over-expressed in 
cells. Furthermore, additional N-terminal domain E→K substitutions were created in the E46K 
construct, which caused stepwise decreases in the tetramer:monomer ratio and reduced cell 
viability (Dettmer et al. 2015). This demonstrates that tetramers are disrupted by PD-
associated point mutations, confirming previous modelling (Kara et al. 2013; W. Wang et al. 
2011), and that disruption is potentially cytotoxic. The current working hypothesis is that a 
reduction in tetramer formation increases the monomer concentration in the cell, leading to 
greater opportunity for pathological β-sheet rich oligomers to form (Kara et al. 2013; Dettmer 
et al. 2015). 
1.2.3 Membrane-binding and sub-cellular localisation of α-syn 
In addition being cytosolic, up to a third of cellular α-syn binds to membranes as a monomer 
or multimer (Visanji et al. 2011). Membrane-binding imposes some secondary structure upon 
α-syn. Spanning the first 95 residues of α-syn are seven 11-residue repeats, with striking 
resemblance to the amphipathic α-helices found in apolipoproteins (Davidson et al. 1998). 
Upon membrane-binding, the first 100 residues of α-syn become α-helical, whereas the acidic 
C-terminal 101-140 residues remain unstructured (Eliezer et al. 2001). NMR analysis of α-syn 
binding to SDS micelles originally suggested a two-helix model (Bussell & Eliezer 2003). 
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Subsequent EPR and FRET experiments have shown that α-syn can also bind to unilamellar 
vesicles as a single unbroken helix (Figure 1.8), these having less extreme curvature than SDS 
micelles (Alderson & Markley 2013; Jao et al. 2008). 
α-Syn exclusively binds lipids with acidic headgroups, and appears to favour vesicles of 
smaller diameter (20–25 nm) as opposed to larger (~125 nm) vesicles (Davidson et al. 1998). 
The ability of α-syn to sense high curvatures, and membranes with particular lipid 
compositions, has been suggested to contribute to its sub-cellular localisation (Middleton & 
Rhoades 2010). α-Syn localises to pre-synaptic vesicles, which have high curvature and a 
moderate negative charge (George et al. 1995; Snead & Eliezer 2014; Maroteaux et al. 1988). 
Mitochondrial membranes are another site where α-syn has been detected, potentially due to 
their curvature and the preference of α-syn for mitochondrial lipid cardiolipin (Snead & Eliezer 
2014; Nakamura et al. 2011). The mitochondrial dysfunction evident in α-syn transgenic 
models may partly stem from α-syn inner or outer membrane localisation (Nakamura 2013). 
In conjunction with inner mitochondrial membrane localisation, α-syn has been shown to 
specifically and dose-dependently inhibit complex I activity in some models (Devi et al. 2008; 
Loeb et al. 2010; Liu et al. 2009; Chinta et al. 2010), although not in others (Sarafian et al. 
2013; Kamp et al. 2010; Nakamura et al. 2011). The outer membrane localisation of over-
expressed α-syn has been shown to promote mitochondrial fragmentation, through direct 
alteration of the properties of the membrane (Kamp et al. 2010; Nakamura et al. 2011). 
Another, recently discovered, location enriched in α-syn is the sites of ER-mitochondria 
contact, within the specialised ER domain that is rich in anionic phospholipids and cholesterol 
(Calì et al. 2012; Guardia-Laguarta et al. 2014).  
  




Figure 1.7 Schematic comparison of the synuclein proteins. α-Syn (ASYN), β-syn (BSYN), 
and γ-syn (GSYN) have high homology in the N-terminal amphipathic region, but differ in the 
structure of the acidic C-terminal tail. β-Syn is also missing a section of 11 amino acids 




Figure 1.8 Model of 9-89 α-syn in a two-helix and extended helix conformation. The 
extended helix is more common in the presence of SUVs, but highly curved micelles cannot 
accommodate a long extended helix. Adapted from (Alderson & Markley 2013).  
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1.3 Function of α-syn 
1.3.1 Vesicle docking and fusion 
The propensity of α-syn to bind pre-synaptic vesicles was described when it was first 
identified (Iwai et al. 1995; George et al. 1995). Functional studies of α-syn have frequently 
centred on synaptic vesicle regulation. No obvious phenotype results from single or double α-/ 
β-syn knockout in mouse models (Chandra et al. 2004). A triple α-/-β-/γ-syn knockout mouse 
model had reduced striatal dopamine levels, but displayed ‘hyperdopaminergic’ behaviours, 
and striatal dopamine release under electrical stimulation was enhanced (Anwar et al. 2011). 
Conversely, overexpression of α-syn decreases neurotransmitter release from PC12 and 
primary adrenal cells, corresponding with an accumulation of docked synaptic vesicles in the 
presynaptic terminal (Larsen et al. 2006). 
A large number of roles for α-syn in regulating synaptic vesicles have been proposed, 
including vesicle clustering, docking, fusion, and recycling. Figure 1.9 illustrates a few 
hypotheses (Snead & Eliezer 2014). The following summarises two of the key theories about 
the effects of α-syn on vesicle docking and fusion. One prevailing hypothesis is the ‘SNARE 
complex chaperone’ theory. Burré et al. demonstrated that membrane-bound α-syn, potentially 
as α-helical oligomers, promote the assembly of trans-SNARE complexes that mediate 
synaptic vesicle fusion with the plasma membrane (Burré et al. 2010; Burré et al. 2014). α-Syn 
dose-dependently promoted SNARE complex assembly in HEK293T cells, and also primary 
neurons from synuclein knock-out mice. Synaptobrevin-2, a v-SNARE, was shown to bind the 
C-terminus of α-syn, and C-terminal truncated α-syn was incompetent at promoting SNARE 
complex assembly (Burré et al. 2010). Clustering of synthetic synaptic vesicles by α-syn also 
appears to depend on the presence of synaptobrevin-2 (Diao et al. 2013). Despite its 
involvement in SNARE complex assembly, α-syn does not appear to actively promote 
exocytosis in cells. Choi et al. suggest that the role of α-syn is to keep the cis-SNARE complex 
stable in the plasma membrane, rather than directly regulating trans-SNARE complexes (Choi 
et al. 2013).  
In addition to exocytosis, a similar involvement of α-syn with SNAREs has been studied 
in the early secretory pathway between the ER and Golgi. A53T α-syn was found to directly 
interact with membrin and syntaxin-5 of the ER- and Golgi-SNAREs by Thayanidhi et al. 
(Thayanidhi et al. 2010). Formation of ER/Golgi trans-SNARE complexes was inhibited by 
A53T mutant α-syn, and ER-Golgi transport delayed (Thayanidhi et al. 2010). Delayed ER-
Golgi transport is not unique to the mutant α-syn protein. Several mammalian cell models 
overexpressing wild-type α-syn, at physiologically relevant levels, display reduced ER-Golgi 
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trafficking (Oaks et al. 2013; Thayanidhi et al. 2010). Since wild-type α-syn does not appear 
to impair exocytosis (Choi et al. 2013), there are clearly differences in the behaviour of α-syn 
at different membranes. The origin of these differences have been suggested to arise from 
either the protein-binding partners of α-syn (Thayanidhi et al. 2010), or distinct lipid 
compositions of the membrane affecting the oligomeric state of α-syn (Wang & Hay 2015). 
These possibilities remain to be explored. 
The ‘SNARE complex chaperone’ theory of α-syn function is not universally accepted. 
Contradictory evidence exists that suggests α-syn directly inhibits vesicle docking/fusion, 
without acting on other proteins (Snead & Eliezer 2014). Some groups did not find that α-syn 
physically interacts with SNARE proteins, or promotes SNARE complex formation (DeWitt 
& Rhoades 2013; Darios et al. 2010). Kamp et al. additionally demonstrated that α-syn can 
inhibit vesicle fusion in vitro using protein-free assays, and only the membrane-bound 
N-terminal portion of α-syn is necessary for the effect. A suggested model for the reduced 
vesicle fusion involved α-syn stabilising membrane lipid packing defects (Figure 1.10), which 
relieves curvature stress (Kamp et al. 2010; Braun & Sachs 2015). Lai et al. were in agreement, 
using a more complete proteoliposome fusion assay including SNAREs. C-terminal truncated 
α-syn inhibited vesicle fusion as much as the wild-type, which excludes a direct interaction 
with synaptobrevin-2. Additionally, replacement of synaptobrevin-2 with a distantly-related 
yeast SNARE had no effect on the ability of α-syn to inhibit vesicle fusion (Lai et al. 2014).  
1.3.2 Membrane curvature 
The inhibitory effect of α-syn on in vitro vesicle fusion assays, discussed above, reveals 
that α-syn can profoundly influence the stability of curved membranes. A suggested function 
of α-syn is to create and maintain membrane curvature (Bendor et al. 2013). When added to 
solutions of artificial vesicles, α-syn can create networks of membrane tubules, with structures 
resembling budding vesicles. The structures were noted to be similar to the effects of 
specialised curvature-inducing proteins such as amphiphysin (Bendor et al. 2013; Jao et al. 
2008; Varkey et al. 2010). At a molecular level, α-syn binds via a curved amphipathic helix to 
small unilamellar vesicles. Shallow insertion of hydrophobic residues appears to reduce 
surface tension and increase the positive pressure of core hydrocarbon chains, resulting in 
membrane undulations (Braun & Sachs 2015). 
As yet there is only limited evidence that supports the membrane curvature-inducing 
properties of α-syn in vivo. α-Syn localises to outer mitochondrial membranes and/or ER 
mitochondrial-associated membranes (MAM), both of which have high curvature and contain  
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Figure 1.9 Three potential effects of α-syn on synaptic vesicles. α-Syn may promote 
SNARE complex assembly, act as a physical bridge between the vesicle and plasma 
membrane, or cluster together synaptic vesicles. Adapted from (Snead & Eliezer 2014). 
 
Figure 1.10 Model for a direct SNARE-independent effect of α-syn on vesicle fusion. 
Fusion of two adjacent membranes requires defects in lipid packing that allow the membranes 
to be pinched into a fusion stalk. (B) α-Syn stabilises lipid packing defects and may impede 
fusion by this route. Taken from (Kamp et al. 2010).   
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high levels of anionic phospholipids (Kamp et al. 2010; Guardia-Laguarta et al. 2014). 
Overexpression of α-syn dramatically remodels the mitochondrial network in cultured cells 
and primary neurons. Mitochondrial fragmentation appears to be triggered by α-syn 
overexpression, and can occur even in the absence of mitochondrial fission protein Drp1 
(Kamp et al. 2010; Nakamura et al. 2011). α-Syn also appears to promote formation of MAM 
projections from the ER, and enhances calcium transfer from ER to mitochondria (Calì et al. 
2012; Guardia-Laguarta et al. 2014). These observations could be indicative of wider cellular 
functions for α-syn membrane-binding and membrane-remodelling, beyond the synaptic 
vesicle fusion paradigm. 
1.3.3 Iron regulation 
α-Syn is a redox-active metal-binding protein, with a site in the extreme N-terminus that 
complexes Cu (II), and two sites in the C-terminus that can bind Fe (III) (Rasia et al. 2005; 
Davies, Moualla, et al. 2011; Davies, Wang, et al. 2011; Bharathi & Rao 2007; Binolfi et al. 
2006). One interesting proposed function for α-syn, although currently unexplored in vivo, is 
as a cellular ferrireductase (Davies, Moualla, et al. 2011; Brown 2013). Ferrireductase activity 
of α-syn has been demonstrated in vitro, and appears to depend on the presence of copper as a 
cofactor. Cell lines overexpressing α-syn contain elevated cytosolic levels of Fe(II) relative to 
Fe(III) (Davies, Moualla, et al. 2011). A role for α-syn in maintaining cellular iron homeostasis 
is also suggested by the iron-dependent translational control of α-syn. A putative iron 
regulatory element has been identified in the α-syn 5’UTR, and iron chelation reduces α-syn 
mRNA levels (Febbraro et al. 2012; Friedlich et al. 2007). It is not yet clear whether the iron-
reducing activity of α-syn is associated with its function at membranes. Unpublished work 
from our laboratory suggests that the ferrireductase activity of α-syn occurs in a membrane-
bound fraction, so the two functions could be linked (McDowall & Brown, unpublished).  
1.4 Alzheimer’s disease 
1.4.1 A historical overview of Alzheimer’s disease 
Alzheimer’s disease (AD) is named after Alois Alzheimer, who wrote a seminal case study 
in 1907 of a woman with severe dementia, describing senile plaques and neurofibrillary tangles 
found in the cortex upon autopsy. This was by no means the first time that such connections 
had been made: a few months previously neurofibrillary tangles had been linked with dementia 
by S. C. Fuller, and senile plaques had been described in dementia as far back as 1887 
(Ramirez-Bermudez 2012). Neurofibrillary tangles have since been characterised as intra-
neuronal inclusions containing insoluble fibrillar aggregates of the tau protein, a microtubule 
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regulator (Kosik et al. 1988; Goedert et al. 1989). Extracellular senile plaques, otherwise 
known as ‘amyloid plaques’, were shown to be largely composed of fibrillar β-amyloid 
fragments from the amyloid precursor protein (APP), first cloned in 1987 by three independent 
groups (Goldgaber et al. 1987; Kang et al. 1987; Tanzi et al. 1987). As mentioned previously, 
the NAC fragment of α-syn would be subsequently identified as the second most common 
component of amyloid plaques (Uéda et al. 1993). Yet by the early 1990s it seemed clear that 
β-amyloid deposition is the central event of AD, leading to a cascade of pathology including 
neurofibrillary tangles (Hardy & Allsop 1991). This idea was developed and refined into the 
‘amyloid cascade hypothesis’ (Hardy & Higgins 1992). 
In 1991 the first mutation responsible for early onset familial AD (EO-FAD) was 
sequenced, within the APP gene itself (Goate et al. 1991). Subsequently, mutations in the 
presenilin-1 and presenilin-2 genes (PSEN1/2) were found to be more common in EO-FAD 
(Tanzi 2012). Presenilins are essential for the proteolytic cleavage of APP to form β-amyloid, 
and pathogenic mutations can alter the location of cleavage (De Strooper et al. 1999; Wolfe et 
al. 1999; Tanzi 2012). Since then, almost all of the >200 mutations reported in APP, PSEN1, 
and PSEN2 for EO-FAD have proved to be autosomal-dominant and fully-penetrant. Most 
increase the tendency of β-amyloid to aggregate, by enhancing the production of the Aβ42 
variant or by amino acid substitutions within the β-amyloid sequence. The ‘Swedish’ APP 
mutation, and also duplications of the APP gene, increase production of all β-amyloid species 
(Tanzi 2012). Strong links between β-amyloid dysregulation and EO-FAD support the 
amyloid cascade hypothesis. 
Late-onset AD (LOAD), defined as occurring after the age of 65, appears to have a 
heritability of 60-80% (Bergem et al. 1997; Gatz et al. 1997; Pedersen et al. 2001). Yet LOAD 
has not been associated with variants of APP or presenilins, and is considered to be 
multifactorial, which has been used as a criticism of the amyloid cascade hypothesis (Tanzi 
2012; Harrison & Owen 2016). In 1993 a variant of the apolipoprotein E gene, ApoE-ε4, was 
found to be overrepresented in LOAD patients compared with age-matched controls 
(Strittmatter et al. 1993). The instigation of genome wide association studies (GWAS) for AD 
risk factors, from 2007 onwards, allowed other common risk variants to be discovered that are 
present in over 5% of the population. Yet the newly-discovered risk variants, save for TREM2, 
only weakly increase AD risk (Tanzi 2012; Reiman et al. 2007). TREM2 (Triggering Receptor 
Expressed on Myeloid cells 2) is a microglial surface receptor, and has been shown to bind to 
ApoE-ε4. The two proteins may be central to a pathway that promotes microglial phagocytosis 
of apoptotic neurons (Atagi et al. 2015). Other GWAS hits include genes that are proposed to 
have roles in β-amyloid production and clearance, or alter lipid metabolism, cellular signalling, 
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or innate immunity (Tanzi 2012). Rare mutations are excluded from GWAS, but may also 
significantly contribute to the heritability of LOAD. For example, in 2009 two rare loss-of-
function mutations were identified in ADAM10, which is an enzyme that cleaves APP through 
the middle of the β-amyloid sequence (Kim et al. 2009). The complex genetics and 
environmental influences on LOAD may therefore be reconcilable with the amyloid cascade 
hypothesis, if changes in β-amyloid are a common denominator.  
1.4.2 Current state of the amyloid cascade hypothesis 
The amyloid cascade hypothesis is still widely accepted, although modified over the years 
to focus on ‘toxic oligomers’ of β-amyloid as a disease-causing agent. Yet scepticism has 
grown in response to the failures of γ-secretase inhibitors, and immunotherapy against 
β-amyloid oligomers, to arrest the progression of dementia in clinical trials, with a minority 
renouncing the amyloid cascade hypothesis (Drachman 2014; Castello & Soriano 2014). 
Alternative theories for the cause of sporadic AD include impaired microvasculature integrity 
in the brain (Drachman 2014), or neuroinflammation causing cerebral insulin resistance (Clark 
et al. 2012). Researchers still in favour of the amyloid cascade hypothesis see clinical failures 
as resulting from poor trial design, or evidence that β-amyloid accumulation is an early trigger 
of a disease process that becomes self-sustaining (Harrison & Owen 2016; Mullane & 
Williams 2013). Currently there is insufficient reason to abandon the amyloid cascade 
hypothesis, but its future may depend on the success of amyloid-altering drug treatments in 
pre-clinical AD patients. 
1.4.3 Toxic oligomers of β-amyloid 
Amyloid plaques, consisting of extracellular linear fibrils of β-amyloid, are surrounded by 
dystrophic neurites and activated glia in the brain, and appear to have a direct involvement in 
neuronal death (Hardy & Allsop 1991). However, numbers of amyloid plaques do not correlate 
with the severity of AD, and can be detected in brains, on average, about ten years before the 
average age of clinical AD onset (Perrin et al. 2009). Thus the hypothesised toxicity of 
β-amyloid in the aforementioned ‘amyloid cascade hypothesis’ is unlikely to stem from 
amyloid plaques.  
AD is now considered to be a disease of synaptic dysfunction. Synapse loss correlates 
strongly with cognitive decline in AD patients, appearing to have a greater effect on cognitive 
decline than neuron death (Terry et al. 1991). In the 1990s soluble oligomeric species of 
β-amyloid were identified, and Lambert et al. discovered that these could inhibit LTP in 
organotypic CNS cultures, in the absence of fibrils (Lambert et al. 1998; Ferreira et al. 2015). 
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Rodent models confirmed the propensity of β-amyloid oligomers to impair synapse function, 
causing memory impairment (Ferreira et al. 2015). Memory impairments in mice with a 
mutant APP transgene were shown to be easily reversible, by suppression of the transgene, 
despite the persistence of amyloid deposits (Fowler et al. 2014). Similarly, in humans 
β-amyloid oligomers have been linked to memory impairment. AD patients were shown by 
Bjorklund et al. to have β-amyloid oligomers localised hippocampal cell fractions enriched for 
the post-synaptic density marker PSD-95. However in cognitively normal individuals that 
exhibited some amyloid plaques and neurofibrillary tangles, β-amyloid oligomers were absent 
from hippocampal post-synaptic fractions, despite their confirmed presence in the brain 
(Bjorklund et al. 2012). 
β-amyloid oligomers have a multitude of cellular effects that may promote synaptic 
dysfunction (Ferreira et al. 2015). In addition to changes to synaptic plasticity-related receptors 
(Roselli et al. 2005; Hsieh et al. 2006), β-amyloid oligomers appear to cause increased 
oxidative stress (De Felice et al. 2007), ER stress (Ma et al. 2013; Yoon et al. 2012), calcium 
release from intracellular stores (Zempel et al. 2010; Paula-Lima et al. 2011), and also defects 
in axonal transport that may be triggered by calcineurin activation (Ramser et al. 2013).  
1.5 The amyloid precursor protein 
1.5.1 Structure and localisation of APP 
APP is a type I integral membrane protein with a large, extracellular, N-terminal domain 
and small, cytoplasmic, C-terminal domain, illustrated in Figure 1.11. The extracellular 
domain consists of an E1 domain, and E2 domain, followed by the Aβ sequence that partly 
runs into the membrane-spanning region. E1 encompasses a heparin-binding/growth factor-
like domain (HFBD/GFLD), and sub-domains for copper- and zinc- binding. A second 
HFBD/GFLD is found in the E2 domain. Within the cytoplasmic domain is a YENPTY 
protein-interaction motif (Jacobsen and Iverfeldt 2009). APP has two homologs, APLP1 and 
APLP2, with high conservation of the YENPTY, E1 and E2 motifs, which may be responsible 
for their apparent redundancy of function in vivo. Interestingly, the Aβ sequence is exclusive 
to APP (Zheng & Koo 2011). The Aβ sequence is present in three of the major mRNA splice 
isoforms of APP: APP695, APP751, and APP770. APP751 and APP770 are expressed 
ubiquitously, whereas APP695 is confined to neurons and has the highest neuronal expression 
(Tanaka et al. 1989).  
After synthesis in the ER, APP is transported the Golgi to the trans-Golgi network (TGN), 
undergoing phosphorylation and glycosylation along the way. APP is highly abundant in the 
CHAPTER 1: INTRODUCTION 
24 
TGN, due to retention. From there, APP is trafficked to the plasma membrane, and can either 
be ‘secreted’ by α-secretase cleavage of the extracellular domain, or internalised by clathrin-
mediated endocytosis. Endosomal APP is recycled to the plasma membrane or TGN, or 
transported to lysosomes for degradation (Jiang et al. 2014). Delivery of APP to the plasma 
membrane results in localisation with the post-synaptic density, however APP is also detected 
in pre-synaptic vesicles (Del Prete et al. 2014; Hoey et al. 2009). 
 
Figure 1.11 Schematic of APP695, with amino acid numbering based on the full-length 
770 sequence. APP695 is a splice variant missing the Kunitz-type protease inhibitor domain 
(KPI). From the N-terminus there is a heparin-binding/growth factor-like domain 
(HFBD/GFLD), a copper-binding domain (CuBD), a zinc-binding domain (ZNBD), and acidic 
region (DE), a second heparin-binding domain (HFBD2), a random coil region (RC), an 
amyloid-β domain (Aβ), and a YENPTY protein-interaction motif at the C-terminus. The Aβ 
sequence is inset in red, illustrating the typical cleavage sites of α-, β-, and γ-secretase 
(Adapted from Lazarov & Demars 2012).  
1.5.2 Secretase-mediated processing of APP 
Cleavage of APP by α-, β-, and γ-secretases can occur at any point in the 
secretory/endocytic pathway after APP has been O-glycosylated in the Golgi (Tomita et al. 
1998). Sites include the TGN, synaptic vesicles, plasma membrane, and endosomes, shown in 
Figure 1.12 (Del Prete et al. 2014; Jiang et al. 2014). α-Secretase cleavage of APP occurs 
largely at the plasma membrane and TGN (Parvathy et al. 1999; Skovronsky et al. 2000), 
E1 E2 
YENPTY 
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whereas β-, and γ-secretases tend to localise to lipid rafts in endosomes and the TGN, and are 
most active in acidified late endosomes (Ehehalt et al. 2003; Vetrivel et al. 2004). Thus 
changes to the transport or retention of APP in various subcellular compartments can have 
consequences for secretase cleavage (Jiang et al. 2014). 
The β-secretase is β-site APP cleaving enzyme 1 (BACE1), a transmembrane aspartic 
protease, and can cleave APP at Asp1 and Glu11 of the Aβ domain (Vassar et al. 1999). 
γ-Secretase is a large complex of presenilin (PS1/ PS2), the catalytic domain; nicastrin, the 
scaffold; anterior pharynx defective-1 (APH-1), and presenilin enhancer-2 (PEN2), both 
regulatory subunits (Kimberly et al. 2003; Takasugi et al. 2003; Wolfe et al. 1999). γ-Secretase 
cleaves the other, C-terminal, end of the Aβ sequence at multiple sites that produce several 
lengths of Aβ species from 38-43 amino acids. Aβ40 is the most common product in vivo, but 
Aβ42 is more closely linked to AD pathogenesis (Zhang et al. 2012). Several FAD mutations 
to the APP or PS1 genes do not enhance Aβ production significantly, or even reduce 
γ-secretase activity, but cause γ-secretase to favour cleavage that generates Aβ42 (Scheuner et 
al. 1996). Even in sporadic AD, Aβ42 appears to be selectively deposited in amyloid plaques. 
Aβ42 is more hydrophobic than other β-amyloids, has a higher tendency to generate fibrils 
than Aβ40 in vitro, and forms soluble oligomers that appear more toxic to cells (Snyder et al. 
1994; El-Agnaf et al. 2000; Burdick et al. 1992). Three other cleavage products are formed in 
the amyloidogenic pathway from combined β-/ γ-secretase activity, illustrated in Figure 1.13 
(Fodero-Tavoletti et al. 2011). β-Secretase cleavage yields an N-terminal ‘sAPPβ’ domain, 
released into the extracellular or intralumenal space, and on the C-terminal side the β 
C-terminal fragment (βCTF), a 99-amino acid peptide also known as ‘C99’, remains in the 
membrane. C99 is then cleaved by γ-secretase to release the transmembrane Aβ peptide, and 
the C-terminal APP intracellular domain (AICD) (Zhang et al. 2012). 
A further layer of complexity is added by the parallel activity of α-secretase, which partially 
competes with β-secretase for cleavage of the full-length APP (Skovronsky et al. 2000; 
Colombo et al. 2013). Combined α-/ γ-secretase activity on APP is generally referred to as the 
non-amyloidogenic pathway (Zhang et al. 2012). The transmembrane ‘a disintegrin and 
metalloproteases’, ADAM10 and ADAM17, have α-secretase activity. ADAM10 is essential 
for constitutive α-secretase cleavage of APP in neurons, and both ADAM10 and ADAM17 
appear to contribute to activity-stimulated α-secretase cleavage of APP (Kuhn et al. 2010; 
Marcello et al. 2007). In the Golgi network, the ADAM10 proenzyme has an autoinhibitory 
pro-domain, which is cleaved by furin during the secretory pathway (Lammich et al. 1999). 
ADAM10 activity is further regulated by increased trafficking to the plasma membrane and 
decreased exocytosis during LTP (Marcello et al. 2007; Marcello et al. 2013). 
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Figure 1.12 Subcellular localisation of amyloidogenic and non-amyloidogenic processing 
of APP. Full length APP is shown with the N-terminal domain in white, the ‘Aβ’ domain in 
red, and the C-terminal domain in green. Secretase enzymes are in light grey circles, identified 
by their prefix. Adapted from (Agostinho et al. 2015).  
 
Figure 1.13 Secretase-mediated cleavage of APP, represented schematically. Cleavage by 
α-secretase produces sAPPα (α-APPs) and C83, whereas cleavage by β-secretase produces 
sAPPβ (β-APPs) and C99. C83 and C99 can be further metabolised by γ-secretase into p3 and 
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α-Secretase cleaves APP at the 17th amino acid of the Aβ sequence. An N-terminal ‘sAPPα’ 
domain is released, leaving α C-terminal fragment (αCTF) in the membrane, which is an 83-
amino acid peptide otherwise known as ‘C83’ (Figure 1.13). Like the amyloidogenic pathway, 
cleavage of C83 by γ-secretase produces AICD (Zhang et al. 2012). The other peptide created 
by C83 cleavage, called ‘P3’ or ‘Aβ17-42’, is not detected in amyloid plaques of AD brains, 
but is not considered to be entirely benign (Tekirian et al. 1998). P3 is present in diffuse 
deposits in AD brains, and induces caspase-8-mediated apoptosis in cell lines (Tekirian et al. 
1998; Wei et al. 2002). 
1.5.3 Function of APP  
Since its discovery, full-length APP has been proposed to act as a cell surface receptor, 
given that APP shares many features with Notch receptors, and putative ligands such as 
Netrin-1 and F-spondin have been identified. Netrin-1-binding causes APP to complex with 
FE65, a putative adaptor protein, although the cell signalling pathway itself is yet to be 
characterised (Zheng & Koo 2011; Lourenço et al. 2009). One suggestion is that the AICD 
translocates to the nucleus and engages in transactivation of gene expression, in a complex 
with adaptor FE65 and histone acetyltransferase Tip60 (Cao & Südhof 2001; Kimberly et al. 
2001). Doubts have since been cast on the biological relevance of this pathway, particularly 
given reports that AICD is not essential for the transcriptional activity in question (Zheng & 
Koo 2011). Nevertheless, several reports have highlighted a specific effect of AICD on 
neuronal precursor cell proliferation (Lazarov & Demars 2012). For example, expression of 
AICD in APP knock-out mice appears to reduce adult neurogenesis in an age-dependent 
manner (Ghosal et al. 2010). 
In contrast the sAPPα domain of APP, shed by α-secretase processing, appears to promote 
neurogenesis (Zheng & Koo 2011). sAPPα promotes the differentiation of a wide variety of 
cell types in culture, as well as neuronal precursors (Lazarov & Demars 2012). The apparent 
neurotrophic role of sAPPα may be linked to other observed effects of sAPPα, including 
differentiation and synaptic plasticity. sAPPα added to differentiating neuronal precursor cells 
in culture results in enhanced neurite outgrowth (Gakhar-Koppole et al. 2008). Furthermore, 
a dose-dependent increase in NMDA receptor transmission, during long term potentiation 
(LTP), was observed in rat hippocampal slices perfused with sAPPα (Taylor et al. 2008). 
Neurogenic effects also have been reported with full-length APP expression that may be a 
result of increased sAPP. The function of sAPPβ appears to partly overlap with sAPPα. Indeed, 
one study found that recombinant sAPPβ more strongly induces neural differentiation of 
embryonic stem cells than sAPPα (Freude et al. 2011). On the other hand, another study of 
CHAPTER 1: INTRODUCTION 
28 
excitotoxic cell stress in hippocampal neurons found that sAPPα had a strong neuroprotective 
effect whereas sAPPβ was about 100-fold less potent (Furukawa et al. 2002; Nhan et al. 2015).  
In addition to postsynaptic effects, a presynaptic role for APP has been more recently 
proposed. Potentially APP may affect neurotransmission as well as synaptogenesis. Both APP 
and APLP2 have been shown to reside in synaptic vesicles, and although single knock-out 
mice are healthy, double knock-out mice exhibit severe neuromuscular junction defects (Wang 
et al. 2005; Fanutza et al. 2015; Del Prete et al. 2014). This suggests that APP and APLP2 
have redundant roles in synaptic function. Fanutza et al suggest that APP and ALP2 promote 
glutamate neurotransmitter release. In double knock-out mouse hippocampal slices, the 
frequency of reduced miniature excitatory post-synaptic currents is reduced, and the calculated 
‘probability of release’ function reduced. Similar effects could be produced in WT mice using 
an intracellular-targeted dominant-negative peptide for part of the APP cytoplasmic domain. 
This region of APP, in the N-terminal part of AICD, appears to specifically interact with 
synaptic proteins synaptophysin, vesicle-associated membrane protein-2 (Vamp2), and 
synaptotagmin-2 (Fanutza et al. 2015). A physiological involvement in synaptic vesicle 
regulation appears likely, but awaits confirmation.  
Another emerging physiological function for APP is in the regulation of cellular iron. Iron 
has long been known to accumulate abnormally in AD brains (Ayton et al. 2013). Furthermore, 
iron regulates APP expression, via an Iron-Responsive Element (IRE) in the 5’ untranslated 
region of APP mRNA. Reduced intracellular iron levels cause Iron-Regulatory Protein-1 
(IRP-1) to bind to the IRE region of APP mRNA, and inhibit translation of APP. Conversely, 
iron influx into the cell liberates IRP-1 from IREs, and allows more APP protein to be 
translated (Rogers et al. 2002). APP does not bind iron, and does not have iron redox activity, 
despite promoting iron efflux from cells when over-expressed (Duce et al. 2010; Ebrahimi et 
al. 2013; Ebrahimi et al. 2012). Yet full-length APP and sAPPα bind to ferroportin, an exporter 
of ferrous iron, and appear to stabilise it at the plasma membrane, increasing ferroportin 
numbers at the surface available for iron export (McCarthy et al. 2014; Wong et al. 2014). 
This novel role may be one of many independent cell functions of APP that are yet to be 
discovered. 
1.6 Connections between α-syn and APP 
1.6.1 Localisation 
Close physical proximity would present opportunities for α-syn to directly bind APP or 
APP-associated proteins. In neurons, APP tends to accumulate in post-synaptic compartments, 
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and α-syn has a particular affinity for synaptic vesicles (Maroteaux et al. 1988; Hoey et al. 
2009). Yet APP is not exclusively post-synaptic and has in several studies been found, with 
its β-secretase, at synaptic vesicles and the pre-synaptic membrane (Groemer et al. 2011; Del 
Prete et al. 2014; Laßek et al. 2013). There is therefore an opportunity for α-syn to directly 
interact with APP in synaptic vesicles, although this has not yet been studied. It is also 
important to consider potential indirect interactions. Synaptic vesicle clustering, docking, and 
fusion are proposed to be modulated by α-syn, which could affect pre-synaptic APP (Snead & 
Eliezer 2014). Furthermore, α-syn binds other subcellular membranes with high curvature, and 
can impede secretory pathway flux when over-expressed in cell models (Snead & Eliezer 
2014; Oaks et al. 2013; Thayanidhi et al. 2010). APP processing is tightly regulated through 
cycling between the plasma membrane, endosomes, and TGN, so changes to secretory 
pathway flux may disrupt this (Jiang et al. 2014). APP processing is also altered by chronic 
cell stress (Chami & Checler 2012; Ohno 2014). Pathological changes to α-syn are 
hypothesised to trigger a variety of cell stress responses due to oxidative stress, mitochondrial 
dysfunction, calcium dyshomeostasis, or proteasome inhibition (Vekrellis et al. 2011). Despite 
this, there is limited literature on the subject of α-syn/APP interactions. Evidence for direct or 
indirect interactions between α-syn and APP is outlined in the following paragraphs. 
1.6.2 Human pathology 
A connection between α-syn and APP was first suggested by Masliah and colleagues in 
2001, who hypothesised “convergent pathogenic effects” of α-syn and β-amyloid (Masliah et 
al. 2001). Several studies of dementia brains had noted the frequent concurrence of cortical 
amyloid plaques and Lewy Bodies, with mixed symptoms of AD and PD, described as the 
‘Lewy Body Variant’ of AD (Ditter & Mirra 1987; Hansen et al. 1990; Galasko et al. 1994). 
Since 1996, DLB has been recognised as a distinct disease, and not a variant of AD (McKeith 
et al. 1996). In fact, DLB is now generally accepted to be on a spectrum with synucleinopathies 
PDD and PD (Irwin et al. 2013). The dementia symptoms correlate best with levels of cortical 
Lewy bodies, which appear to spread from the midbrain by cell-to-cell transmission (Irwin et 
al. 2013). Interestingly, all studied cases of PD involving SNCA mutations and gene 
multiplications have manifested cortical Lewy bodies and dementia (Poulopoulos et al. 2012). 
β-Amyloid deposition is common in PDD/DLB, although it is not clear whether this is 
connected to the α-syn pathology. In patients with severe β-amyloid deposition there appears 
to be a correlation with cortical Lewy bodies, however it must be noted that both pathologies 
strongly correlate with age (Irwin et al. 2013; Pletnikova et al. 2005; Irwin et al. 2012; Lashley 
et al. 2008). One reason to suspect an α-syn/ β-amyloid interaction in DLB, is that DLB 
amyloid plaques have been reported to contain fragments of α-syn (Yokota et al. 2002; Liu et 
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al. 2005). Furthermore, co-immunoprecipitation of α-synuclein and Aβ can be achieved using 
brain samples from DLB and AD patients. This apparent interaction is absent in ‘non-
demented’ control brains (Tsigelny et al. 2008). 
1.6.3 In vitro studies 
Potential α-syn and Aβ interactions have been examined in vitro. Both proteins have the 
propensity to form amyloid fibrils, and in vitro this can be induced by incubating monomers 
with ‘seeds’ of β-sheet-rich oligomers (Ono et al. 2012). α-Syn and Aβ have been shown to 
participate in ‘cross-seeding’ in vitro. This phenomenon, where fibrillisation is stimulated by 
‘seeds’ of a completely different protein, owes to the common cross β-sheet structure that all 
amyloid fibrils contain (Westermark & Westermark 2013). In a number of in vitro studies, 
α-syn has been shown to seed Aβ40 or Aβ42 fibrils, and Aβ42 seed α-syn fibril formation 
(Masliah et al. 2001; Ono et al. 2012; Mandal et al. 2006; Atsmon-Raz & Miller 2015). In 
addition to fibrils, Tsigelny et al. reported ring-like oligomers resulting from the incubation of 
Aβ42 oligomers with α-syn monomers (Tsigelny et al. 2008). However, cross-seeding in vitro 
has not yet been replicated experimentally in vivo. A major attempt to cross-seed amyloid 
plaques in APP-PS1 transgenic mice using α-syn recombinant ‘pre-formed fibrils’ was 
unsuccessful. Additionally, APP-PS1 mice were injected intracerebrally with α-syn aggregate-
containing brain homogenates from transgenic donor mice. Although seeding of Lewy body-
like α-syn inclusions was detected, there was no cross-seeding of amyloid plaques (Bachhuber 
et al. 2015).  
1.6.4 Cell studies 
Cell culture studies reveal some evidence of synergistic toxicity between α-syn and Aβ. 
Bate et al. used synaptophysin levels to measure synapse damage in mouse primary neurons. 
Recombinant human α-syn added to the neurons caused synapse damage, which was 
significantly potentiated by pre-mixing α-syn with Aβ42 in a 50:1 or 2:1 ratio. Interestingly, 
if 1 nM Aβ42 or 10 nM α-syn were added to neurons as a pre-treatment to the other peptide, 
rather than pre-mixing, the synergism was lost (Bate et al. 2010). The implication is that the 
synergistic toxicity in this model depends on the extracellular stimulus. However it likely 
obscures the intracellular effects of the peptides. Another group looked more specifically at 
intracellular interactions, by studying endogenous levels of Aβ40 in response to the application 
of α-syn recombinant aggregates (Majd et al. 2013). A sub-toxic dose of α-syn aggregates 
increased intracellular and extracellular Aβ40 in rat primary neuron cultures. Additionally, 
reciprocation was apparent when cells were treated with Aβ42 aggregates, which increased 
endogenous α-syn levels (Majd et al. 2013). A similar effect on β-amyloid secretion was 
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demonstrated in an earlier study using PC12 cells treated with un-aggregated α-syn 
(Kazmierczak et al. 2008). Stable overexpression of α-syn is a useful tool for studying the 
chronic effects of α-syn on cells. In SH-SY5Ys, α-syn overexpression has been reported to 
increase APP expression. β-Amyloid production was not measured (Jesko et al. 2014). 
1.6.5 Transgenic mouse models 
In transgenic mouse models, attempts have been made to combine high Aβ production with 
over-expressed wild-type or mutant α-syn, in order to model DLB with co-morbid AD (Clinton 
et al. 2010). Two of these models exhibit accelerated neurodegeneration compared with 
transgenic mice that had a single pathology. Neurodegeneration temporally coincided with 
increased levels of insoluble Aβ- or α-synuclein-containing aggregates (Masliah et al. 2001; 
Clinton et al. 2010). A third mouse model also potentiated synapse loss, but with paradoxical 
reduction of amyloid pathology. In this study, A30P α-syn transgenic mice were bred with an 
APP-PS1 mouse model, with high background amyloid burden. The resulting APP-PS1 × 
[A30P]α-syn mice had significantly less hippocampal amyloid plaques than APP-PS1 mice, 
and increased CSF levels of β-amyloid. No changes to β-amyloid secretion were detected in 
cultured APP-PS1 × [A30P]α-syn primary neurons. Since synapse loss was nevertheless 
increased in APP-PS1 × [A30P]α-syn mice, the reduced amyloid plaque deposition may be 
detrimental. Oligomers of β-amyloid were not measured, but potentially an inhibition of fibril 
formation may allow toxic oligomers to accumulate (Bachhuber et al. 2015). 
1.7 Future directions 
The existing studies of α-syn and Aβ are both patchy and contradictory. Synergism of their 
synapse toxicity has been suggested in both cell and rodent models, but the mechanism for this 
is unknown. Direct interactions between α-syn and Aβ have been demonstrated in vitro and 
also in material from Lewy Body disease patients (Tsigelny et al. 2008; Ono et al. 2012; 
Masliah et al. 2001; Mandal et al. 2006). The physical interaction appears in vitro to promote 
oligomer and fibril formation by cross-seeding, but in rodent models may inhibit fibrillisation 
(Bachhuber et al. 2015). Additionally, an indirect effect of α-syn increasing β-amyloid 
production and secretion has been proposed. Evidence in favour of this has been obtained from 
a models of recombinant α-syn protein added to cell cultures (Majd et al. 2013; Kazmierczak 
et al. 2008). However, a better model to study the chronic intracellular effects of 
synucleinopathy would be to overexpress α-syn in cells. At present, the effect of α-syn 
overexpression on β-amyloid production has not been investigated. The field would benefit 
from more detailed characterisation of the effect of α-syn on β-amyloid production, and the 
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role of APP expression. Furthermore, the potential cellular mechanism is unexplored, and 
could one day reveal new therapeutic targets for DLB. 
1.8 Aims of the thesis 
A clear gap in the literature exists for a comprehensive mechanistic study of β-amyloid 
production in α-syn overexpression cell models. Broadly, the thesis aims to fit into this niche, 
and its particular focus on APP secretase-mediated processing is novel in this context. The 
thesis primarily aims to study in detail how APP secretase-mediated processing is altered by 
α-syn. The secondary aim is to attempt to find a cell mechanism by which α-syn affects APP 
processing. 
In the literature, neuronal cells treated with recombinant α-syn upregulate β-amyloid 
secretion (Kazmierczak et al. 2008; Majd et al. 2013). Chapter 3 aims to confirm that 
overexpression of α-syn in neuronal cells has the same impact on β-amyloid, using a multiplex 
assay to determine β-amyloid concentration in conditioned media. From this starting point the 
investigation proceeds in three dimensions: studying the underlying changes to APP 
amyloidogenic processing, the effect of using different cultured cell models, and the effect of 
mutating α-syn. α-Syn mutations may have a dominant-negative effect when over-expressed, 
and could indicate whether changes to APP metabolism result from α-syn function or toxicity.  
The two successive chapters aim to make inroads into the mechanism by which α-syn 
affects APP processing. Chapter 4 narrows the focus onto the secretase enzymes that regulate 
APP amyloidogenic processing. The chapter aims to ascertain whether α-syn cells exhibit 
changes to expression and activity of α-, β-, and γ-secretases. The activity of γ-secretase will 
be studied in-cell with a luciferase reporter. The expression and in vitro activity of the 
β-secretase BACE1 and the α-secretase ADAM10 will furthermore be characterised. Chapter 
5 will use the secretase expression/activity phenotype in α-syn cells to identify potential 
upstream cell signalling targets from the literature. Multiple candidate pathways will be 
selected from the literature, based on their induction by α-syn, and their ability to affect 
secretase expression/activity. A primarily pharmacological approach will be used to test the 
contribution of the candidate pathways to secretase expression/activity, using a single 
phenotypic readout. Ultimately it is hoped that one or two candidate cell mechanisms will 
emerge from this initial pass, and be investigated in further detail as potential mediators of the 
effect of α-syn upon APP processing.  
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DMEM high glucose with L-Glutamine, and Ham’s F-12 were from Lonza. B-27 AO was 
from Gibco. V-PLEX Plus Aβ Peptide Panel 1 (6E10) Kit was from Meso Scale Discovery. 
FuGene HD and Dual-Reporter Luciferase Assay Kit were from Promega. SensoLyte® 520 
ADAM10 and BACE1 Activity Assay Kits were from Eurogentec. Pierce™ Cell Surface 
Protein Isolation Kit was from Thermo Scientific. TAPI-1, Amyloid Precursor Protein β-
Secretase Inhibitor (βSI), and β-Secretase Inhibitor IV (βIV) were from Merck Millipore. 
DAPT was from Tocris. CM-H2DCFDA molecular probe was from Life technologies. 
Dantrolene, PKR inhibitor, salubrinal, and SP600125 were from Santa Cruz. 
Clastolactacystin-β-lactone, FK-506, and sc-514 were from Enzo Life Sciences.  
All other chemicals, including A23187, ammonium chloride, cycloheximide, and 
tunicamycin, were from Sigma. 
2.2 Plasmids 
The pFR-Luciferase reporter (pLuc) containing the firefly (Photinus pyralis) luciferase 
gene under the control of a synthetic promoter consisting of five tandem repeats of the yeast 
GAL4 activation sequence upstream of a minimal TATA box, and phRL-thymidine kinase 
(pTK) vector containing the sea pansy (Renilla reniformis) luciferase gene under the control 
of the HSV (herpes simplex virus)-TK promoter, were from Promega.  
The APP cleavage luciferase reporter (APP-Gal4), a pRC-CMV vector containing a cDNA 
encoding for human APP695 fused in-frame at its C terminus via a 5 glycine hinge to the yeast 
transcription factor Gal4 containing both the DNA-binding and activation domains, was kindly 
provided by Dr. Robert J. Williams (Department of Biology & Biochemistry, University of 
Bath), as described in (Hoey et al. 2009).  
The Notch cleavage luciferase reporter (Notch-Gal4), a pSecTag2 vector containing cDNA 
encoding for human Notch3 fused in frame at its C terminus to the yeast transcription factor 
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Gal4 was also kindly provided by Dr. Robert J. Williams (Department of Biology & 
Biochemistry, University of Bath), as described in (Cox et al. 2014). 
Human BACE1 promoter luciferase reporter, a pGL3-Basic vector containing a 4.3 kb 
fragment of BACE1 promoter from -4372 to -1 of the promoter sequence, was cloned 
previously (McHugh et al. 2012). 
Human ADAM10 promoter luciferase reporter, a pGL3-Basic vector containing a 2.2 kb 
fragment of ADAM10 promoter from -2179 to -1 of the promoter sequence, was first described 
in (Prinzen et al. 2005) and was a kind gift from Prof. F. Fahrenholz. 
2.3 Cell culture and stable transfections 
Transgenic SH-SY5Y, N2A, and HEK293 cell cultures were maintained in media grown 
in 1:1 DMEM (high glucose with L-Glutamine, Lonza) and Ham’s F-12 (Lonza), 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin, 
and 0.4 mg/ml G418. Growth conditions were maintained at 37°C and 5% CO2 in a humidified 
incubator. The full complement of transgenic cell lines used in this thesis are listed in Table 
1. Stable transfection of mammalian cells was achieved using FuGene HD transfection reagent 
(Promega). 25 μl of FuGene HD was incubated with 4.5 μg purified plasmid DNA in 430 μl 
of DMEM for 12 minutes to form reagent:DNA complexes, which were applied to a T25 flask 
of cells, plated the day before to reach 50% confluence. 24 hours later, G418 solution was 
added to a final concentration of 0.8 mg/ml, and the cells maintained in 0.8 mg/ml G418 for 
3-4 weeks to select for G418 resistance. Stable expression of the plasmid gene was determined 
by western blotting.  
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Table 1 Details of all transgenic cell lines used. A Primers: 5’-CAAATGTTGGAG-
GAGCAGTGGAGGGAGCAGGGAGCA-3’ and 5’-TGCTCCCTGCTCCCTCCACTGCT-
CCTCCAACATTTC-3’. B Primers: 5’-GAAATGCCTGCTGAGGAAGGG-3’ and 5’-CC-
CTTCCTCAGCAGGCATTTC-3’. C Primers: 5’-GAAATGCCTGATGAGGAAGGG-3’ and 
5’-CCCTTCCTCATCAGGCATTTC-3’. D RefSeq accession number NG_042823.1. E 
Detailed in (Lau et al. 2000)  
2.4 Western blotting 
For extraction of the total complement of cellular proteins, confluent T25 flasks or 6-well 
plates of cells were lysed in 180 μl or 100 μl of cold PBS with 0.5% Igepal CA-630 and 
‘complete’ protease inhibitor cocktail (Roche) respectively. Lysates were scraped into 0.5 ml 
centrifuge tubes on ice, sonicated 3 x 3 seconds, and centrifuged 10 000 xg for 3 minutes. 
Supernatants were removed and the pellets discarded. A Bio-Rad protein assay was used with 
Cell 
type
Transgenic cell line Plasmid






Empty vector/ pcDNA Dr Jennifer McDowall pcDNA3.1(+) Invitrogen, UK
WT (v1) Dr Jennifer McDowall pcDNA3.1(+)-α-syn X. Wang et. al., 2010
WT (v3) Miss Hazel Roberts pcDNA3.1(+)-α-syn X. Wang et. al., 2010
WT (v4) Miss Hazel Roberts pcDNA3.1(+)-α-syn X. Wang et. al., 2010
Δ2-9 Prof. David Brown pcDNA3.1(+)-α-syn Δ2-9 X. Wang et. al., 2010
ΔNAC Miss Hazel Roberts pcDNA3.1(+)-α-syn Δ71-82 Previously made by site-
directed mutagenesis A
A30P Prof. David Brown pcDNA3.1(+)-α-syn A30P X. Wang et. al., 2010
E46K Miss Hazel Roberts pcDNA3.1(+)-α-syn E46K X. Wang et. al., 2010
A53T Prof. David Brown pcDNA3.1(+)-α-syn A53T X. Wang et. al., 2010
S129A Dr Jennifer McDowall pcDNA3.1(+)-α-syn S129A Previously made by site-
directed mutagenesis B
S129D Dr Jennifer McDowall pcDNA3.1(+)-α-syn S129D Previously made by site-
directed mutagenesis C
β-syn Dr Jennifer McDowall pcDNA3.1(+)-β-syn Wright, McHugh, Pan, 
Cunningham, & Brown, 2013
Steap3 Miss Ye Ding pcDNA3.1(+)-Steap3 Previously cloned D
pCI Miss Hazel Roberts pCI-neo Prof. Christopher Miller, KCLE





Empty vector/ pcDNA Miss Hazel Roberts pcDNA3.1(+) Invitrogen, UK
WT Miss Hazel Roberts pcDNA3.1(+)-α-syn X. Wang et. al., 2010
Δ2-9 Miss Hazel Roberts pcDNA3.1(+)-α-syn Δ2-9 X. Wang et. al., 2010






Empty vector/ pcDNA Miss Hazel Roberts pcDNA3.1(+) Invitrogen, UK
WT Miss Hazel Roberts pcDNA3.1(+)-α-syn X. Wang et. al., 2010
Δ2-9 Miss Hazel Roberts pcDNA3.1(+)-α-syn Δ2-9 X. Wang et. al., 2010
E46K Miss Hazel Roberts pcDNA3.1(+)-α-syn E46K X. Wang et. al., 2010
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1:20 dilutions of the supernatants to determine their protein concentration, according to the 
manufacturer’s instructions (Bradford 1976). Supernatant protein concentrations were 
normalized, and were boiled for 5 minutes with 1 x Laemmli SDS-PAGE buffer. Samples 
were loaded into 12% acrylamide gels for Tris SDS-PAGE, run at 250V/35 mA for 45 minutes. 
The separated proteins were transferred to a PVDF membrane by a semi-dry transfer 
apparatus, run at 25V/100 mA for 1.3 hours. Membranes were blocked in 5% w/v non-fat milk 
powder in TBS-T for 30 minutes, incubated with primary antibody for 1-2 hours, and washed 
3 x 5 minutes in TBS-T. Primary antibodies are listed in Table 2. Membranes were blocked 
again and incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour. 
A further 3 x 10 minute washes were performed, and the membranes developed with Luminata 
Crescendo or Luminata Forte ECL substrate (Thermo Scientific), and imaged with either 
X-ray film (Amersham) or a Fusion SL CCD imaging system (Vilber Lourmat). Band 
intensities were quantified using Fusion-Capt Advance software (Vilber Lourmat). Raw data 
was normalised by division with the mean OD of the experiment for that antibody, and then 
the optical density (OD) of the ‘test’ antibody divided by the OD of the ‘housekeeping’ 
antibody (usually α-tubulin). Each western used 2 technical replicates. 
 
Table 2 Details of antibodies used for western blotting. 
Protein target Species raised ID Source Dilution 
α-synuclein Rabbit MJFR1 Abcam 1:5000
α-synuclein Mouse 610787 BD Biosciences 1:2000
α-tubulin Mouse T5168 Sigma 1:10 000
β-synuclein Mouse ab167607 Abcam 1:500
ADAM10 Rabbit ab10926 Millipore 1:2000
APP C-terminus Rabbit Y188 Abcam 1:2000
BACE1 Rabbit D10E5 Cell signalling 
technology
1:1500
eIF2α Rabbit 9722 Cell signalling 
technology
1:2000
Phospho-eIF2α Rabbit 9721 Cell signalling 
technology
1:1000
Steap3 Rabbit 72513 Abcam 1:1000
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2.5 Luciferase reporter assays 
Cells were plated to 40% confluence the day before transfection in 24-well plates, and 
transfected with plasmid DNA using 1.5 μl of FuGene HD (Promega) per well. Plasmids are 
listed in Table 3. The APP-Gal4 luciferase based reporter assay was as previously described 
(Hoey et al. 2009), and used 50 ng APP-Gal4 plasmid co-transfected with 50 ng pLuc per well. 
Figure 2.1 illustrates how the assay works. The Notch-Gal4 luciferase based reporter assay 
was as previously described (Cox et al. 2014), and follows similar principles, except using 100 
ng Notch-Gal4 plasmid co-transfected with 50 ng pLuc per well. For the BACE1 (McHugh et 
al. 2012) and ADAM10 promoter reporter assays (Prinzen et al. 2005), 200 ng plasmid was 
used per well. All reporter plasmids were additionally co-transfected with 50 ng pTk, as an 
internal transfection control. Any chemical or pharmacological treatments were diluted in 
serum- and antioxidant-free DMEM supplemented with ‘B-27 AO’ (Gibco), and applied to 
the cells 6 hours post-transfection. Luciferase activity was measured 20-22 hours post-
transfection using the Promega Dual-Luciferase Report Kit as per the manufacturer’s 
instructions. Assays were carried out using a FLUOstar Omega plate spectrophotometer (BMG 
Labtech). Raw data was normalised by division with the mean firefly or Renilla luminescence 
for the experiment. Relative Luciferase Units (RLU) for each well were then calculated by 
division of the firefly signal by the Renilla signal. Each experiment used 3-5 biological 
replicates. 
 
Table 3 Details of plasmid combinations used for luciferase reporter assays. 
Plasmid
Quantity plasmid required for assay/ ng







pTK 50 50 50 50
pLuc 50 50 - -
APP-Gal4 50 - - -
Notch-Gal4 - 100 - -
ADAM10 
promoter
- - 200 -
BACE1 
promoter
- - - 200
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Figure 2.1 Illustration of the APP-Gal4 luciferase reporter assay for β-/γ-cleavage of 
APP.Plasmids pFRLuc and APP695-Gal4 were co-transfected into SH-SY5Y cells. 
APP695-GAL4 fusion protein is cleaved by endogenous secretases, liberating AICD-GAL4 
peptides. AICD-GAL4 activates transcription and expression of the inducible firefly luciferase 
gene of the pFRLuc plasmid. Relative levels of luciferase enzyme were measured by 
luminometer after addition of luciferin substrate, which triggers a chemiluminescent reaction.  
 
2.6 SDS-PAGE for APP C-terminal fragments 
The overall workflow for this is described in Figure 2.2. Cells were plated to 50% 
confluence in 6 well plates, and after 24 hours were treated with 2 µM DAPT in B-27 
supplemented DMEM for 16 hours. 80 µL of PBS with 0.5% Igepal CA-630 and ‘complete’ 
protease inhibitor cocktail (Roche) was used to lyse the cells. Lysates were scraped into 0.5 
ml centrifuge tubes on ice, sonicated 3 x 3 seconds, and centrifuged 10 000 xg for 3 minutes. 
Supernatants were removed and the pellets discarded. A Bio-Rad protein assay was used with 
1:20 dilutions of the supernatants to determine their protein concentration, according to the 
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were boiled for 5 minutes with Laemmli buffer. Samples were loaded onto a 16% acrylamide 
gel (16% Acrylamide (v/v), 990 mM Tris-HCl/SDS pH 8.45, 10% Glycerol (v/v), 0.025% 
APS (w/v), 0.05% TEMED (v/v)), which was placed into an electrophoresis tank with an 
anode buffer of 200 mM Tris-HCl pH 8.9, and a cathode buffer of 100 mM Tris, 100 mM 
Tricine, and 1% SDS (w/v). The 16% gel was electrophoresed at 100 V, 4 °C, for several 
hours. Western blotting was then performed as described previously. 
 
Figure 2.2 Illustration of western blotting for APP C-terminal fragments. Incubation with 
γ-secretase inhibitor (DAPT) allows the β-cleavage APP CTFs (C99) and α-cleavage APP 
CTFs (C83) to accumulate to a measurable level before cell lysis. Cell proteins are separated 
on a 16% SDS-PAGE gel and immunoblotted for the C-terminus of APP (Y188, Abcam).  
 
2.7 Meso Scale Discovery multiplex assay for secreted Aβ40 and Aβ42 
Cells were seeded onto 24-well plates at a range of densities (30-60% confluence) in full 
media, and after 24 hours changed to 800 µl serum-free B-27-supplemented DMEM, with 
compounds where indicated. Conditioned media was collected after 72 hours and immediately 
assayed without further manipulation, using the V-PLEX Plus Aβ Peptide Panel 1 (6E10) Kit 
from Meso Scale Discovery, according to the manufacturer’s instructions (Figure 2.3). The 
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were calculated by Meso Scale Discovery Workbench software, with reference to a standard 
curve. Data was normalised by division with the mean peptide concentration of the 
experiment. 
 
Figure 2.3 Illustration of the Meso Scale Discovery multiplex assay for Aβ40 and Aβ42 
peptides.  An aliquot of conditioned media from 72-hours of cell culture is applied to the MSD 
96-well 4-spot plate. Each well contains spots of immobilized capture antibody specific for 
Aβ40 and Aβ42 individually, which bind peptides from the media. After washing the plate, 
the ‘sulfo-tag’ 6E10 detection antibody is applied, which binds any affixed Aβ peptide and 
forms a sandwich. Electrification of the plate triggers an electro-chemiluminescent reaction in 
the ‘sulfo-tag’ of the 6E10. Adapted from the assay protocol (Meso Scale Discovery).  
 
2.8 Immunofluorescent staining and confocal microscopy for α-synuclein 
Cells were seeded at a density of approximately 1x106 cells /ml onto poly-D-lysine-coated 
coverslips in a 24-well plate. After 24 hours, the coverslips were washed with PBS/CM (10 
mM Na2HPO4, 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, 0.9 mM CaCl2, 0.33 mM 
MgCl2.6H2O), then fixed in 4% paraformaldehyde in PBS for 30 minutes at room temperature. 
After two washes with PBS/CM, permeabilisation was performed in 0.1% Triton X-100 (in 
PBS/CM) for 10 minutes at room temperature. Coverslips were blocked for 30 minutes in 10% 
FBS in PBS/CM, and incubated overnight at 4 °C with the primary antibody MJFR1 (1:100, 
Abcam, #ab138501) for α-syn. Primary antibody was diluted in wash buffer: 2% FBS + 0.05% 
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Triton X-100 in PBS/CM. Coverslips were then washed three times with wash buffer and three 
times with PBS/CM. The secondary antibody anti-rabbit IgG-AlexaFluor®568 (1:10,000, 
Abcam #ab175471) was applied for 1 hour at room temperature. Coverslips were washed three 
times in PBS/CM, and mounted on slides with Mowiol mounting media and a DAPI 
counterstain (600 nM). Slides were stored in a light protective box overnight and examined on 
a Zeiss LSM510 Meta at the relevant wavelengths (AlexaFluor®568 Ex/Em= 578/603 nm, 
DAPI Ex/Em= 364/454 nm). 
2.9 Fluorometric BACE1 and ADAM10 activity assays 
The β-secretase activity of BACE1 from cell homogenates was measured using the 
‘SensoLyte® 520 β-Secretase Assay Kit’ (Eurogentec), and the secretase activity of ADAM10 
measured using the 'Sensolyte® 520 ADAM10 activity assay kit' (Eurogentec). Cell 
homogenates were obtained by addition of 60 µl/well of the ADAM10 kit buffer to confluent 
6-well plates. Cell material was scraped into centrifuge tubes, homogenised by pipetting, and 
incubated on ice for 10 minutes. Lysates were clarified by centrifuging 10 000 xg for 5 
minutes, and total protein concentrations quantified by Bradford assay. 150 µg of total protein 
was prepared in 150 µl of kit assay buffer, and 50 µl loaded onto a black optical 96-well plate. 
The BACE1 or ADAM10 fluorometric substrate was prepared and added, according to the kit 
instructions, and fluorescent readings (Ex/Em=490/520 nm) taken in a FLUOstar Omega plate 
spectrophotometer (BMG Labtech) at every 5-10 minutes for one hour. Raw fluorescence at 
30 minutes was averaged for duplicate wells, and normalised to the mean for the experiment. 
2.10 Cell surface biotinylation assay for plasma membrane localization of 
ADAM10 
The Pierce™ Cell Surface Protein Isolation Kit (Thermo Scientific #89881) was used to 
biotinylate intact cells, lyse, and purify biotinylated proteins. Confluent 6-well plates of cells 
were washed twice with cold PBS/CM (refer to section 2.8), and incubated with 0.5 mg/ml 
sulfo-NHS-SS-biotin on ice for 30 minutes. Free biotin was quenched with 50 µl of Quenching 
Solution (Thermo Scientific), and cells scraped into centrifuge tubes and pelleted by 
centrifugation at 500 xg for 3 minutes. The cell pellet was washed once with TBS, then 
resuspended in 180 µl cold lysis buffer. Lysates were sonicated on a low power with 5 brief 
pulses, and incubated 30 minutes on ice. Large debris was pelleted and discarded, and the 
protein concentration of the supernatant quantified by Bradford assay. Samples were adjusted 
to have equal concentrations, and a 40 µl aliquot removed to serve as an input control for SDS-
PAGE, boiled with Laemmli buffer. The rest of the supernatant was incubated with 
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Neutravidin beads (Thermo Scientific), overnight at 4 °C with rotation. Beads were collected 
by centrifugation at 1000 xg for 3 minutes and washed three times with ice-cold Wash Buffer 
(Thermo Scientific). The biotin-labelled proteins were eluted from the beads by boiling with 
80 µl of Laemmli buffer (containing 50 mM DTT), at 100 °C for 15 minutes. Samples were 
run on an SDS-PAGE gel, and western blotting for ADAM10 performed, as described above. 
2.11 Fluorometric assay for reactive oxygen species using CM-H2DCFDA 
Cells were seeded at a density of approximately 1x106 cells/ml onto a poly-D-lysine-coated 
48-well plate. After 48 hours, cells were incubated with 10 µM CM-H2DCFDA probe in 
HEPES-buffered media (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 5 mM NaHCO3, 1.2 mM 
Na2HPO4, 1.2 mM CaCl2, 5.5 mM glucose) for 20 minutes. The probe was removed and 300 
µl of HEPES-buffered media added. Fluorescence intensity (Ex/Em= 488/534 nm) was 
measured every 5-10 minutes for 60 minutes. The linear rate equation was determined from a 
kinetics plot using MS Excel, and the rate at 60 minutes calculated. Individual rates were 
normalised to the mean rate of the experiment. 
2.12 Statistical analysis 
Student’s t tests were two-tailed and performed using MS Excel, with an assumption of 
equal variance. Pairwise t-tests with Holm adjustment, and one-way ANOVA with post-hoc 
Tukey HSD, were performed using ‘R Studio’. Normal distribution was assumed, and the 
homogeneity of variances were assessed using a Bartlett’s test in ‘R Studio’. Differences 
between treatments were defined as statistically significant when p < 0.05. 
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3.1.1 Effect of α-syn on APP and β-amyloid  
A number of studies have proposed potential interactions of α-syn with β-amyloid 
fragments of APP. These have largely focussed on pathology: synergism of toxicity when the 
recombinant proteins are added to cells (Bate et al. 2010), and synergism of the aggregation 
of toxic oligomers and amyloid fibrils in vitro (Ono et al. 2012; Tsigelny et al. 2008; Atsmon-
Raz & Miller 2015). This focus on aggregation could be misguided given the recent evidence 
that α-syn overexpression appears to reduce the formation of amyloid plaques in mice. The 
same study found no changes to β-amyloid secretion from primary neurons with over-
expressed A30P α-syn (Bachhuber et al. 2015). However, the result was obtained using 
APPPS1 mice that already have abnormally high β-amyloid, which would easily mask any 
subtler effects of α-syn. 
Very few studies address the potential interactions between α-syn and APP in cells. There 
is some evidence in the literature that α-syn affects β-amyloid generation in cells. Enhanced 
β-amyloid production was observed when cell cultures were treated with toxic levels of 
unaggregated α-syn (10 µM), or sub-toxic levels of α-syn aggregates (1 µM) (Kazmierczak et 
al. 2008; Majd et al. 2013). Stable overexpression of α-syn in SH-SY5Ys was reported to 
increase APP expression. However it was not established whether this affected β-amyloid 
production of the cells (Jesko et al. 2014). This gap in the literature will be addressed within 
the current chapter, which will measure β-amyloid production in an α-syn cell overexpression 
model. Amyloidogenic processing of APP will additionally be probed, this has not previously 
been studied in α-syn cell models. 
3.1.2 The N-terminal domain of α-syn in function 
The chapter will also investigate a number of α-syn mutations, and how they influence the 
generation of β-amyloid. Truncations of the α-syn N-terminal domain will be investigated. 
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The N-terminal domain spans the first 95 amino acids of the 140 amino acid sequence of α-syn. 
It is distinguished from the C-terminal domain by its tendency to form secondary structure. In 
a membrane-associated state, the N-terminal domain interconverts between a single extended 
α-helix, and a pair of amphipathic α-helices separated by a flexible linker: ‘Helix 1’ (3-37 aa) 
and ‘Helix 2’ (45-92 aa) (Ulmer et al. 2005).  
Deletion of either helix sequence has been shown to reduce the binding of α-syn to artificial 
membranes. Furthermore this appears to translate into reduced synaptic targeting of α-syn in 
primary neurons (Burré et al. 2012). Some studies have found that just a small section of the 
extreme N-terminus, encompassing the first 8 to 11 amino acids, is vital for membrane 
binding. Evidence from in vitro, isolated mitochondria, and yeast experiments indicate a loss 
of membrane binding with a Δ2-8 or Δ2-11 deletion (Robotta et al. 2012; Vamvaca et al. 2009; 
Burré et al. 2012). However, little effect of Δ2-11 on membrane binding is seen in neuronal 
cell lines (Vamvaca et al. 2011; Wang et al. 2010). Rather than reducing α-syn membrane 
association, it is likely that Δ2-8/Δ2-11 affects the subcellular localisation of α-syn. In primary 
neurons the synaptic targeting of α-syn is significantly reduced by Δ2-8 (Burré et al. 2012). 
The function of α-syn as a SNARE complex chaperone is proposed to require the N-terminal 
domain for membrane-binding, and the C-terminal domain to interact with synaptobrevin-2 
(Burré et al. 2010). Deletion of either, or both, of these sequences strongly disturbs the 
formation of SNAP25-reactive SNARE complexes, when lentivirally-expressed in primary 
neurons. Counterintuitively, although the Δ2-8 mutation reduces α-syn synaptic targeting, it 
does not significantly affect SNARE complex formation (Burré et al. 2012).  
In addition to interacting with membranes, the N-terminal domain of α-syn may interact 
with other proteins. Calmodulin has been shown to interact with the first 20 amino acids of the 
α-syn N-terminus (Gruschus et al. 2013). The calcium-bound form of calmodulin appears to 
compete with membranes for binding to α-syn, and their shared involvement in regulating 
exocytosis suggests that the interaction may have a biological role (Gruschus et al. 2013; 
Snead & Eliezer 2014; Lee et al. 2002).  
3.1.3 The N-terminal domain of α-syn in toxicity 
As well as being important for the putative physiological function of α-syn, the N-terminal 
domain is implicated in disease. The central section of α-syn, residues 61-95, contains the 
‘non-amyloid component’ (NAC) sequence. Although normally within the helical N-terminal 
region, in disease NAC forms the β-sheets at the core of toxic oligomers and amyloid fibrils 
of α-syn (Li et al. 2002). Removal of the NAC from α-syn makes it incapable of aggregating 
into toxic oligomers and is neuroprotective, as shown in Drosophila models (Periquet et al. 
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2007). In this chapter, NAC-truncated α-syn mutant will be utilised, with the aim of preventing 
oligomer-mediated toxicity.  
This chapter will also feature toxicity-inducing A30P, E46K, and A53T point mutations, 
discovered in familial PD or DLB (Krüger et al. 1998; Zarranz et al. 2004; Polymeropoulos et 
al. 1997). The biophysical properties of these mutant proteins may be important for 
understanding the toxicity of α-syn. The point mutations endow different changes to the 
membrane affinity of α-syn: E46K enhances the membrane affinity of α-syn, A53T has no 
effect, and A30P reduces it (Bodner et al. 2010). In vitro fibrillisation of the disease mutations 
is also different: A53T and E46K fibrillise faster than wildtype protein whereas A30P 
fibrillises slower. Yet a common feature is toxic oligomer formation. All three mutants recruit 
monomers from solution to form soluble oligomeric species at a faster rate than the wildtype 
(Conway et al. 2000; Choi et al. 2004). 
A biophysical explanation for the behaviour of α-syn disease-associated point mutants has 
been proposed to involve destabilisation of the N-terminal domain. When membrane-bound, 
the N-terminal α-helix may be unusual short, only 25 residues. This would expose an 
unstructured NAC region, and potentially encourage β-sheet interactions between adjacent 
α-syn molecules (Bodner et al. 2010). Recently another explanation has been proposed, which 
is that the mutations reduce the safe sequestration of cytosolic α-syn. In the neuronal cytosol 
α-syn exists predominantly as a non-aggregating tetramer (Bartels et al. 2012; Dettmer et al. 
2013). In silico modelling of tetramers appears to show that disease-associated point mutations 
would interfere with tetramer assembly and promote monomeric α-syn in solution (Kara et al. 
2013). Hypothetically, the increase in free disordered monomers should encourage β-sheet 
rich α-syn oligomers to form. The predicted effect of reduced tetramer: monomer ratios was 
eventually verified in a variety of disease mutant-expressing cell models, including A53T 
iPSCs, using intact-cell crosslinking and fluorescent protein complementation methods 
(Dettmer et al. 2015).  
Aggregation of α-syn into toxic oligomers is also promoted by copper, which co-ordinates 
with the extreme N-terminus of α-syn in both the membrane and cytosol (Wright et al. 2009; 
Wang et al. 2010; Dudzik et al. 2013). Removal of the 2-9 residues creates an aggregation-
resistant α-syn protein, that protects against copper-induced toxicity in neuroblastoma cells 
(Wang et al. 2010). 
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3.1.4 Role of C-terminal phosphorylation of α-syn in disease 
The C-terminus of α-syn is unstructured and negatively charged. When α-syn is membrane-
associated the C-terminal domain may be a site for regulatory protein-protein interactions. 
However in cytosolic form the C-terminal domain may be auto-inhibitory, forming long-range 
interactions that shield the NAC region from solution (Bertoncini et al. 2005). Post-
translational modifications of the C-terminal domain can have a profound effect on α-syn. 
Calpain-1 cleavage of the C-terminus generates pro-aggregatory 1-120 α-syn, which is a 
normal cellular process that appears upregulated in synucleinopathy brains (Li et al. 2002; Li 
et al. 2005). Another modification of the C-terminus linked with disease is phosphorylation of 
serine-129. S129 phosphorylation is an uncommon and transient modification in normal cells, 
but was discovered to occur on around 90% of the α-syn protein in urea-insoluble extracts of 
DLB brains (Fujiwara et al. 2002). Although long linked with pathology the biological role of 
this modification is unclear, but it appears to mediate autophagic clearance of α-syn (Oueslati 
et al. 2013), and may be involved in α-syn interactions with vesicle trafficking proteins 
(McFarland et al. 2008).  
This chapter will include S129A and S129D α-syn in the investigation of APP processing. 
Point mutations S129D and S129A have been used in cell models to artificially mimic or block 
the phosphorylation site respectively (Chen & Feany 2005). S129 mutations do not affect 
α-syn aggregation itself (Lázaro et al. 2014), but S129A fails to induce the autophagic 
clearance of insoluble α-syn aggregates in yeast (Tenreiro et al. 2014). Controversy still exists 
over whether S129A is neuroprotective (Chen & Feany 2005; Kragh et al. 2009; Febbraro et 
al. 2013), or promotes neurodegeneration (Gorbatyuk et al. 2008; Kuwahara et al. 2012), or 
has no effect on toxicity (Sato et al. 2011; McFarland et al. 2009). A recent paper suggests that 
S129 phosphorylation does not alter the overall dopaminergic neuron loss caused by 
synucleinopathy in rodent models, but does modulate the rate of disease progression. S129A 
slowed the loss of striatal dopaminergic terminals, and S129D accelerated neurodegeneration 
relative to WT α-syn (Febbraro et al. 2013). 
3.2 Aims 
The aim of this chapter is to characterise the impact of α-syn expression on APP 
amyloidogenic processing, in stable transgenic cell lines. Initially, levels of secreted β-amyloid 
will be determined in α-syn overexpressing SH-SY5Ys. The amyloidogenic processing of APP 
will then be measured with two complementary techniques: (A) Indirect quantitation of 
amyloidogenic processing, performed with a luciferase reporter for endogenous β- and 
γ-secretase activity; (B) A direct, semi-quantitative method, using western blotting to detect 
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cell levels of C99, a peptide precursor to β-amyloid. Next, α-syn-induced changes to APP 
processing will be studied in other cell lines: the mouse neuronal cell line ‘N2A’, and human 
fibroblast-like cell line ‘HEK293’. Finally, the role of α-syn primary structure in mediating 
effects to APP processing will be investigated, using a dominant-negative mutant approach. 
Mutants include α-syn lacking sections of the N terminal domain, Δ2-9 and Δ71-82 
(henceforth known as ‘ΔNAC’). Disease-associated point mutations A30P, E46K, and A53T, 
will also be included. Additionally, the role of phosphorylation at S129 will be examined with 
S129A and S129D α-syn SH-SY5Ys, to block or mimic serine phosphorylation respectively. 
All mutants are illustrated in Figure 3.1. 
 
 
Figure 3.1 Schematic diagram of the mutations of α-syn over-expressed in SH-SY5Ys. 
The N-terminal domain is residues 1-95 and consists of a maximum of two α-helices in the 
membrane-bound state, as indicated with diagonal stripes. The ‘non-amyloid component’ 
region is residues 61-95. Disease-associated point mutations are indicated by stars, and the 
phosphorylation mutants by an oval. Truncation mutants are displayed beneath. Adapted from 
Burré et al (Burré et al. 2012). 
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3.3 Results 
3.3.1 Stable overexpression of α-syn was achieved in three independent SH-SY5Y lines 
SH-SY5Ys were transfected with pcDNA 3.1 (+)-α-syn (Wang et al. 2010) and selected 
for G418-resistance, to generate a polyclonal population of stably-transfected cells. Polyclonal 
selection avoids any phenotypic effects specific to the site of recombination, however the 
resulting population is not 100% transgenic. A few SH-SY5Y cells are able to develop 
resistance to G418 in the absence of plasmid, and this non-transgenic subset of cells can vary 
in proportion over time and between cell lines. To control for the inherent instability of a single 
polyclonal line, three independent WT α-syn SH-SY5Y lines were produced: ‘WT (v1)’, ‘WT 
(v3)’, and ‘WT (v4)’. For β-amyloid measurement and some minor experiments only WT (v1) 
was used, but key experiments were performed using all three WT lines to ensure 
reproducibility. Robust 6- to 9-fold over-expression of α-syn was achieved in the three WT 
lines (Figure 3.2). Yet expression of α-syn is significantly lower in the WT (v1) line compared 
with the other two, when measured over a two-week period. In a polyclonal line, the level of 
protein overexpression may be lessened by proliferation of non-transgenic cells. Western 
blotting does not provide information about the proportion of transgenic cells in each line, but 
this was estimated by immunofluorescent staining for α-syn. Cells stained positive for α-syn 
were counted from 20x confocal microscope images, and compared with the number of DAPI+ 
nuclei (Figure 3.3). The population of non-transgenic cells is negligible in the ‘WT (v3)’ and 
‘WT (v4)’ lines, but appeared to be more than a third of cells in the ‘WT (v1)’ line. The 
estimate is a snap-shot from a single point in time, but may account for the lower α-syn 
expression on average in the ‘WT (v1)’ line. A fourth line named ‘WT (v2)’ was discarded, 
due to more than 80% of the cells appearing to be non-transgenic. 
  






Figure 3.2 Levels of over-expressed α-syn in three lines of WT α-syn SH-SY5Ys. Whole 
cell lysates were tested for α-syn and α-tubulin by western blotting. Mean α-syn OD: α-tubulin 
OD for 5 independent experiments ± S.E. ** p <0.01 relative to empty vector, # p <0.05 





















































WT (v1) 312 490 64 
WT (v3) 625 650 96 
WT (v4) 436 476 92 
 
 
Figure 3.3 Estimated percentage of α-syn-overexpressing cells in three lines of WT α-syn 
SH-SY5Ys. Immunofluorescent staining for total α-syn was performed, with a DAPI 
counterstain for the cell nuclei. A single 20x objective view was imaged with an LSM 510 
Meta confocal microscope (Zeiss), shown with α-syn (red) and DAPI (blue) staining overlaid. 
Both the number of α-syn-stained cells and the number of DAPI-stained nuclei were counted 
separately using the Cell Counter plugin of ImageJ. The percentage of transgenic cells is given 
as the percentage of α-syn+ cells relative to DAPI+ nuclei.  
  
WT (v1) WT (v3) 
WT (v4) 
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3.3.2 α-Syn and APP do not alter one another’s expression 
A simple way by which two proteins may indirectly interact is through the regulation of 
protein levels. Changes to transcription, translation, or protein stability can affect protein 
levels. A previously published study in α-syn SH-SY5Ys found that APP protein expression 
was increased (Jesko et al. 2014). Therefore, total APP protein levels were measured in α-syn 
SH-SY5Ys. APP protein expression proved to be unaltered by α-syn (Figure 3.4a). The reverse 
of this effect was also studied: the impact of APP overexpression upon α-syn protein levels. 
SH-SY5Ys stably overexpressing the 695 spliced isoform of APP, were generated using a 
pCI-neo APP695 plasmid construct (Chris Miller, KCL). Levels of α-syn protein were 
determined by western blotting, and were not affected by APP overexpression (Figure 3.4b). 
  






Figure 3.4 α-Syn does not affect APP expression, and APP does not affect α-syn 
expression in SH-SY5Ys. (A) Western blotting for APP in lysates of three α-syn SH-SY5Y 
lines. Mean APP OD: α-tubulin OD for 4 independent experiments ± S.E, and a bar 
representing an average of the three WT lines. No significant differences between individual 
WT α-syn lines and the empty vector, calculated by one-way ANOVA with a Tukey HSD 
post-hoc test. (B) Western blotting for α-syn in lysates of APP SH-SY5Ys. Mean α-syn OD: 
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3.3.3 α-Syn, but not β-syn, expression increases extracellular secretion of β-amyloid in 
SH-SY5Ys 
The action of β- and γ-secretases on APP within endosomal compartments of a cell releases 
β-amyloid peptides of variable length. The most common β-amyloid peptide is Aβ40, but it is 
the less abundant Aβ42 that has the greatest potential to form toxic aggregates (Hubin et al. 
2014). β-Amyloid is secreted, and in cell cultures accumulates in the extracellular medium 
over a number of days to a detectable level. An ELISA-style kit supplied from Meso Scale 
Discovery was used to accurately determine Aβ40 and Aβ42 peptide concentration in 
conditioned media from cell cultures (Figure 2.3) (Oh et al. 2010).  
β-Amyloid secretion was measured in WT (v1) α-syn SH-SY5Ys in the presence and 
absence of secretase inhibitors (Figure 3.5). Secretase inhibitors were used to validate the 
extent to which measured β-amyloid reflects β-/γ-secretase-mediated processing of APP. 
Other factors can affect levels of extracellular β-amyloid, including amyloid-degrading 
enzymes. β-/γ-Secretase-mediated processing of APP is rate-limited by the γ-secretase step, 
which can be inhibited using the compound DAPT. DAPT incubation with WT α-syn SH-
SY5Ys caused strong reductions in Aβ40 and Aβ42 levels. The sensitivity of the assay to 
β-secretase inhibition was not tested, due to the short half-life of the peptide inhibitor. 
α-Secretase contribution to the measured β-amyloid was tested, using the inhibitor TAPI-1. In 
empty vector and WT α-syn SH-SY5Ys, TAPI-1 treatment appeared to promote Aβ40 and 
Aβ42 production. Statistical significance of p<0.05 was achieved only for Aβ42 secretion in 
WT cells. This suggests a mitigating role for α-secretase upon β-amyloid production. Overall, 
extracellular Aβ40 and Aβ42 levels clearly demonstrate sensitivity to changes in 
amyloidogenic processing of APP.  
α-Syn overexpression appears to enhance the extracellular secretion of β-amyloid. Aβ40 
and Aβ42 were significantly more concentrated in the media of WT (v1) α-syn compared with 
empty vector cells (Figure 3.5). On average, Aβ40 peptide concentrations were 66 pg/ml in 
WT α-syn conditioned media, whereas Aβ42 was about ten-fold less abundant (6 pg/ml).  
In addition to testing α-syn, another member of the synuclein family was included to 
determine whether it shares the same effect on β-amyloid (Figure 3.5). β-Syn has high 
homology to α-syn, and some apparent functional redundancy in knockout mouse models 
(Chandra et al. 2004). A line of SH-SY5Ys transfected with pcDNA 3.1 (+)-β-syn (Wright et 
al. 2013), was confirmed to overexpress β-syn protein (Figure 3.6). Levels of β-amyloid were 
unaltered in β-syn SH-SY5Ys. It is likely that β-syn does not share the particular cellular 
activity of α-syn that influences β-amyloid levels.  
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Figure 3.5 WT α-syn expression increases Aβ40 and Aβ42 secretion. (A) Aβ40 and (B) 
Aβ42 in conditioned media from SH-SY5Ys. Cells were treated with α-secretase inhibitor 
TAPI-1 (50 µM) or γ-secretase inhibitor DAPT (10 µM) for 72 hours. The conditioned media 
was analysed by Meso Scale Discovery Aβ Peptide Panel 1 (6E10) multiplex assay. Peptide 
concentrations were calculated by Meso Scale Discovery Workbench software, with reference 
to a standard curve. Data was normalised by division with the mean peptide concentration of 
each experiment, and multiplied by the mean of the means. Bar chart represents mean Aβ 
concentration for 3-4 independent experiments ± S.E. * p <0.05, ** p <0.01 relative to empty 
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Figure 3.6 β-Syn expression in WT α-syn and WT β-syn SH-SY5Ys. Western blotting was 
used to test whole cell lysates for β-syn protein by Dr Jennifer McDowall. Staining in the α-syn 
lane may be due to cross-reactivity of the β-syn antibody with α-syn, due to protein homology.  
3.3.4 α-Syn expression enhances the amyloidogenic processing of APP in SH-SY5Ys 
The activity of β-and γ-secretases on APP, known as ‘amyloidogenic processing’, generates 
β-amyloid in cells. An indirect measurement of endogenous β-and γ-secretase activity can be 
obtained by transfecting cells with the APP-Gal4 luciferase reporter, described in Figure 2.1. 
Three WT α-syn SH-SY5Y lines were transiently transfected with the APP-Gal4 reporter. 
Cleavage of the APP-Gal4 reporter was nearly doubled in WT α-syn SH-SY5Y lines, on 
average (p <0.01, Figure 3.7a). There were no significant differences between the three 
independent WT lines, determined by one-way ANOVA. Interpretation of the APP-Gal4 
reporter signal as ‘amyloidogenic processing’ depends on the Gal4 tag being liberated solely 
by β- and γ-cleavage. The use of secretase inhibitors in the assay provides some evidence in 
favour of this interpretation (Figure 3.7b). A γ-secretase inhibitor, DAPT, strongly suppressed 
cleavage of APP-Gal4, proving that γ-cleavage is indispensable for reporter activity. Neither 
of two β-secretase inhibitors, ‘βSI’ and ‘β-IV’, had a significant impact, but a small reduction 
in activity is apparent. α-Secretase inhibition, using TAPI-1, significantly upregulated APP-
Gal4 cleavage. One likely explanation for this is that inhibiting α-secretase may reduce the 
competition for APP ‘substrate’ with β-secretase, allowing greater β-cleavage to occur. In 
conclusion, the APP-Gal4 construct appears to preferentially report β-/γ-cleavage over α-/γ-
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Figure 3.7 WT α-syn expression increases amyloidogenic processing of APP. (A) 
APP-Gal4 reporter activity is increased in WT α-syn SH-SY5Y lines. Mean RLU for 4 
independent experiments ± S.E, and a bar representing an average of the three WT lines. ** p 
< 0.01 relative to empty vector cells, calculated by Student’s t-test. (B) APP-Gal4 assay 
preferentially reports β-/γ-secretase processing in empty vector (spotted bars) and WT α-syn 
SH-SY5Ys (solid bars). Secretase inhibitors and fresh media were given 6 hours post-
transfection, and incubated for 16 hours before lysis. Inhibition of α-secretase was with 50 µM 
TAPI-1 (EMD Millipore), β-secretase with 10 µM ‘βSI’ (Amyloid Precursor Protein 
β-Secretase Inhibitor, Calbiochem) or 10 µM ‘β-IV’ (β-secretase Inhibitor IV, Calbiochem), 
and γ-secretase with 10 µM DAPT (Tocris). Mean RLU for 3-6 independent experiments ± 
S.E. * p <0.05, relative to (untreated) empty vector; # p <0.05, ## p <0.01 relative to 
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Another method of measuring amyloidogenic processing is western blotting for an 
intermediate APP fragment named ‘C99’, formed after β-secretase cleavage of APP, but prior 
to γ-secretase cleavage (Nunan & Small 2000). C99 is the β-cleaved C-terminal fragment 
(CTF) of APP, of 99 amino acids length, and runs at around 10 kDa on an SDS-PAGE gel. It 
can only be distinguished from the CTF resulting from α-secretase cleavage, ‘C83’, by the 
small difference in SDS-PAGE migration (Figure 2.2). The CTFs accumulate to detectable 
levels when their degradation by γ-secretase is inhibited, using DAPT. In WT α-syn SH-SY5Y 
lines, C99 levels were compared either as a ratio of the full length APP protein (Figure 3.8a), 
or as a ratio of the α-cleavage fragment C83 (Figure 3.8b). In both comparisons WT α-syn 
cells accumulated higher C99, on average, than empty vector cells (p <0.05). Individual WT 
α-syn lines showed some variability but are not significantly different to one another, 
determined by one-way ANOVA. The increased ratio of C99:full-length indicates increased 
β-secretase cleavage of APP. Yet the effect is weaker when displayed as a ratio of C99:C83. 
Given that total APP protein levels are known to remain constant, there are two potential 
explanations for this. Either an overlap in signal between the close C99 and C83 bands blurs 
any existing differences, or α-secretase cleavage of APP is also enhanced in WT α-syn cells, 
in addition to β-secretase cleavage. 
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Figure 3.8 Increased β-cleaved APP in WT α-syn SH-SY5Y lines. Western blots of whole-
cell lysates were probed with antibody raised against the C-terminus of APP (Y188, Abcam). 
(A) The β-CTF C99 band (~10 kDa) expressed as a ratio to the full-length band (~95 kDa). 
(B) The C99 band (~10 kDa) expressed as a ratio to the α-CTF C83 band (~9 kDa). 
Representative western blot included. Mean C99 OD: full-length OD, or mean C99 OD: C83 
OD, for 4 independent experiments ± S.E, and a bar representing an average of the three WT 
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3.3.5 Induction of APP amyloidogenic processing by α-syn is replicated in another neuronal 
cell line N2A, but is not evident in non-neuronal HEK293 
Having established that α-syn overexpression in SH-SY5Ys results in enhanced 
amyloidogenic processing of APP, it was appropriate to investigate the effect in other cell 
models. HEK293s were chosen as a non-neuronal human cell line, known to express α-syn 
and APP (Jacobsen & Iverfeldt 2009; Febbraro et al. 2012). N2As were chosen as a neuronal-
type mouse cell line. Stably-overexpressing WT α-syn lines were generated with both cell 
types, and α-syn expression confirmed by western blotting (Figure 3.9a and Figure 3.11a).  
WT α-syn HEK293s were initially tested for levels of secreted β-amyloid (Figure 3.9). It 
was clear that overexpression of α-syn had no effect on the accumulation of extracellular Aβ40 
and Aβ42. Amyloidogenic processing of APP was then assayed using the APP-Gal4 luciferase 
reporter, as described previously. WT α-syn overexpression significantly reduced 
amyloidogenic processing (Figure 3.10a). This apparent negative control of amyloidogenic 
processing by α-syn is a stark contrast to the results obtained in SH-SY5Ys. A mechanism can 
be suggested from studying the effects of secretase inhibitors (Figure 3.10b). In WT α-syn 
HEK293s, the activity of the APP-Gal4 reporter is blocked by γ-secretase inhibitor, and 
increased by α-secretase inhibitor, consistent with reporting of β-/γ-cleavage of APP. 
However, in the empty vector HEK293s the higher levels of APP-Gal4 cleavage are not 
increased by α-secretase inhibition. A likely explanation for the difference is that the ratio of 
α-cleavage:β-cleavage of APP is lower in empty vector cells than WT α-syn HEK293s. 
Potentially α-secretase activity may increase with α-syn expression in HEK293s. This would 
fit better with the data than a decrease in β-secretase activity, because decreased β-secretase 
activity would not cause cells to become more sensitive to α-secretase inhibition. Overall, the 
changes have a negligible effect on β-amyloid secretion. 
WT α-syn N2As were only assessed for levels of amyloidogenic processing by luciferase 
reporter assay. Unlike the HEK293s, the N2As appeared to exhibit the same 
pro-amyloidogenic effect as SH-SY5Ys. WT α-syn N2As showed a robust 1.4-fold increase 
in amyloidogenic processing relative to empty vector cells (Figure 3.11). The similar results 
in human and murine neuronal-precursor cells suggest that the effects of α-syn are neuron-
specific. 
  





Figure 3.9 Aβ40 and Aβ42 secretion from HEK293s is not enhanced by WT α-syn 
overexpression.  (A) Overexpression of WT α-syn confirmed by western blotting. Whole cell 
lysates were tested for α-syn and α-tubulin. (B) Conditioned media from WT α-syn HEK293s 
was analysed for Aβ40 and Aβ42 peptides by the Meso Scale Discovery Aβ Peptide Panel 1 
(6E10) multiplex assay. Peptide concentrations were calculated by Meso Scale Discovery 
Workbench software, with reference to a standard curve. Data was normalised by division with 
the mean peptide concentration of each experiment, and multiplied by the mean of the means. 
Bar chart represents mean Aβ concentration for 3 independent experiments ± S.E. No 
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Figure 3.10 Amyloidogenic processing is reduced in WT α-syn HEK293s.  (A) APP-Gal4 
reporter activity in WT α-syn HEK293s. Mean RLU for 5 independent experiments ± S.E, 
Student’s t-test. (B) APP-Gal4 assay preferentially reports β-/γ-secretase processing in WT 
α-syn HEK293s (solid bars), but this cannot be confirmed in empty vector cells (spotted bars). 
Secretase inhibitor treatments are detailed in Figure 1.8. Mean RLU for 3 independent 
experiments ± S.E. * p <0.05, ** p <0.01 relative to empty vector, ## p <0.01 relative to 
untreated WT α-syn, one-way ANOVA with a Tukey HSD post-hoc test.  
 
Figure 3.11 Amyloidogenic processing is increased in WT α-syn N2As.(A) Overexpression 
of WT α-syn confirmed by western blotting. Whole cell lysates were tested for α-syn and 
α-tubulin. (B) APP-Gal4 reporter activity in WT α-syn N2As. Mean RLU for 5 independent 
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3.3.6 Mutant α-syn SH-SY5Ys have similar expression and subcellular distribution of α-syn 
to the wildtype lines 
To understand better the structural and functional basis by which α-syn mediates an effect 
on APP processing, a number of pcDNA 3.1(+) - α-syn plasmids with genetic mutations were 
purified from existing bacterial stocks (supplied by Prof. David Brown), and stably transfected 
into SH-SY5Ys. Δ2-9, A53T, and E46K α-syn plasmids were as previously described (Wang 
et al. 2010). The ΔNAC mutant was generated previously by site-directed mutagenesis of 
pcDNA3.1(+)-α-syn, using the primer sequences 5’-CAAATGTTGGAGGAGCAGTGGA-
GGGAGCAGGGAGCA-3’ and 5’-TGCTCCCTGCTCCCTCCACTGCTCCTCCAACATT-
TC-3’. Levels of α-syn protein expression in mutant lines were monitored periodically, and 
did not significantly differ from the WT (v1) line on average (Figure 3.12).  
The effect of these mutations on the subcellular distribution and aggregation of α-syn was 
of interest, to provide extra information on the functional status of α-syn in these cells. As 
noted in the chapter introduction, mutations in the N-terminus may alter the membrane-
binding properties or synaptic targeting of α-syn. Strong alterations to α-syn subcellular 
localisation can be identified under a confocal microscope with immunofluorescent staining. 
Immunofluorescent staining of α-syn was performed on the wildtype and mutant α-syn SH-
SY5Ys. Changes to the cellular distribution of α-syn were determined qualitatively, and 
representative images shown in Figure 3.14 Aggregates of mutant α-syn in SH-SY5Ys. WT 
α-syn cells are distinctly ringed by a bright band of α-syn close to the plasma membrane, in 
addition to diffuse cytoplasmic staining. This juxtamembrane staining is repeated in all of the 
mutants except for Δ2-9 α-syn cells, which appear to have only a homogenous cytoplasmic 
stain. This suggests that the Δ2-9 α-syn SH-SY5Ys may have altered subcellular distribution. 
Confirmation of this would require other methods, as strong α-syn overexpression itself could 
saturate membranes and appear to increase cytoplasmic staining. Additionally, subtle changes 
to α-syn subcellular localisation cannot be detected by this method. 
The presence of insoluble intracellular aggregates of α-syn should also be highlighted by 
immunofluorescent staining. Examination of all three WT α-syn lines did not reveal any 
strongly uneven staining (data not shown). SH-SY5Y lines expressing the disease-associated 
point mutants E46K and A53T were scrutinised for any evidence of bright inclusions, with 
twenty 63x confocal microscope images of each line. No completely unequivocal inclusions 
were identified. Figure 3.14 shows selected images where E46K and A53T SH-SY5Ys have 
some bright patches of α-syn staining. However, these are unlikely to be genuine α-syn 
aggregates, given their diffuse edges and rarity. More likely the brighter staining represents 
narrow protrusions of the plasma membrane, with which α-syn associates. 





Figure 3.12 α-Syn protein levels in mutant α-syn SH-SY5Y lines. Whole cell lysates were 
tested for α-syn and α-tubulin by western blotting. Mean α-syn OD: α-tubulin OD for 7 
independent experiments ± S.E.* p<0.05 relative to empty vector, no significant difference 
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Figure 3.13 Distribution of mutant α-syn in SH-SY5Ys. α-Syn immunofluorescent staining 
in WT, Δ2-9, ΔNAC, E46K, and A53T α-syn SHSY5Ys (representative images). Images were 
viewed with a 63x objective (Zeiss Anti-Flex Plan-Neofluar x63 /1.25 Oil Ph3) on an LSM 
510 Meta confocal microscope (Zeiss). Scale bar: 25 μm.  
WT
(v4)
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Figure 3.14 Aggregates of mutant α-syn in SH-SY5Ys. Irregular α-syn immunofluorescent 
staining in E46K and A53T α-syn SHSY5Ys (not representative of most images). Images were 
viewed with a 63x objective (Zeiss Anti-Flex Plan-Neofluar x63 /1.25 Oil Ph3) on an LSM 
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3.3.7 Specific mutations of α-syn enhance β-amyloid secretion when over-expressed in 
SH-SY5Ys 
β-Amyloid secretion was measured in SH-SY5Y lines overexpressing mutant α-syn (Figure 
3.15). Two N-terminal truncations, Δ2-9 and ΔNAC, were used to ascertain whether the effect 
of α-syn on β-amyloid is influenced by N-terminal domain structure. A dominant-negative loss 
of function was predicted, potentially resulting in decreased β-amyloid secretion. Interestingly, 
Δ2-9 and ΔNAC did not decrease secreted β-amyloid levels, relative to the WT (v1) line. In 
fact there was 3-fold higher β-amyloid levels in the conditioned media of Δ2-9 α-syn 
SH-SY5Ys. No significant change to β-amyloid was evident in the ΔNAC α-syn cells. 
Additionally, β-amyloid secretion was measured in cells with the disease-associated point 
mutations E46K or A53T. In E46K cells, secreted β-amyloid was significantly elevated by 
1.25-fold. A53T had no significant effect, perhaps surprising given its relatively close 
sequence proximity to E46K. β-Amyloid secretion can clearly be potentiated by mutated forms 
of α-syn, but the confinement of this effect to particular unrelated mutations does not suggest 
an obvious mechanism. 
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Figure 3.15 Specific mutants of α-syn increase Aβ40 and Aβ42 secretion.(A) Aβ40 and 
(B) Aβ42 in conditioned media from SH-SY5Ys. The conditioned media was analysed by 
Meso Scale Discovery Aβ Peptide Panel 1 (6E10) multiplex assay. Peptide concentrations 
were calculated by Meso Scale Discovery Workbench software, with reference to a standard 
curve. Mean Aβ concentration for 3-6 independent experiments ± S.E. ** p <0.01 relative to 
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3.3.8 Specific mutations of α-syn modulate the amyloidogenic processing of APP when 
over-expressed in SH-SY5Ys 
Amyloidogenic processing of APP was investigated in mutant α-syn SH-SY5Ys, using the 
aforementioned APP-Gal4 luciferase reporter assay. In comparison to the β-amyloid 
measurements, a wider selection of mutants were screened for changes to amyloidogenic 
processing by this method. In addition to the truncation mutants Δ2-9 and ΔNAC, and disease 
mutants E46K and A53T, a third disease-associated point mutation was screened, A30P (Wang 
et al. 2010). Two mutations of a phosphorylation site at S129 were also included, S129A and 
S129D. S129A was generated previously by site-directed mutagenesis of pcDNA3.1(+)-α-syn, 
using the primers 5’-GAAATGCCTGCTGAGGAAGGG-3’ and 5’-CCCTTCCTCAGCAG-
GCATTTC-3’. S129D was generated using the primers 5’-GAAATGCCTGATGAGGAAG-
GG-3’ and 5’-CCCTTCCTCATCAGGCATTTC-3’. 
N-terminal truncation mutant Δ2-9 had a strong potentiating effect on APP-Gal4 cleavage, 
as did the other truncation mutant ΔNAC (Figure 3.16). The strong effect of Δ2-9 on APP-Gal4 
cleavage, a 7-fold increase over WT, mirrors its 3-fold potentiation of β-amyloid secretion. 
However, the robust 3-fold upregulation of APP-Gal4 cleavage in ΔNAC does not reflect the 
unaltered β-amyloid levels measured in this line. 
The disease-associated point mutations, A30P, A53T, and E46K, all slightly enhanced 
APP-Gal4 cleavage, but this is only statistically significant for A53T (Figure 3.16). Given the 
subtlety of the change, one cannot be certain that the increase in APP-Gal4 cleavage is not 
influenced by varying expression levels of α-syn. The disease-mutant line that significantly 
increased APP-Gal4 cleavage (A53T) is not the same one that significantly increased 
β-amyloid secretion (E46K).  
Phosphorylation site mutations of Ser-129 were also examined, since the block (S129A) or 
mimicry (S129D) of Ser-129 phosphorylation is thought to have opposing effects on the 
toxicity of α-syn. S129A slightly reduced APP-Gal4 cleavage (p <0.05) compared with the 
wildtype, whereas S129D had little effect (Figure 3.16). The reduced APP-Gal4 cleavage in 
S129A cells is significant in isolation. Significance of all individual mutations was calculated 
with unadjusted Student’s t-tests, since they were largely assayed separately. However the 
S129A and S129D mutations were compared simultaneously with the wildtype, so analysis of 
variance would be appropriate. ANOVA testing with post-hoc Tukey HSD shows no 
significant effect of S129A/D compared with WT, yet the difference in APP-Gal4 cleavage 
between the two phosphorylation mutants is significant (p <0.05). The implication is that 
Ser-129 phosphorylation could subtly potentiate the effect of α-syn on APP-Gal4 cleavage.  







Figure 3.16 APP-Gal4 reporter activity in mutant α-syn SH-SY5Y lines.Mean RLU for 3-
5 independent experiments ± S.E. * p <0.05, ** p <0.01 relative to WT α-syn, calculated by 
Student’s T-test. # p <0.05 between S129 mutants, calculated by one-way ANOVA with a 
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Amyloidogenic processing was also studied for several of the mutant lines with a different 
technique, measuring the intracellular generation of APP C-terminal fragments, C99 and C83. 
As previously, these were detected by western blotting for APP in extracts of cells treated with 
a γ-secretase inhibitor, causing CTFs to accumulate. The effect of wildtype α-syn had been to 
enhance C99 production (β-cleavage) as a ratio of full-length protein, and increase the ratio of 
C99 to C83 (α-cleavage). CTFs were measured in Δ2-9, ΔNAC, E46K, and A53T. Only E46K 
significantly enhanced C99 production as a ratio of full-length protein (Figure 3.17a). A 
marked difference between the mutants and WT (v1) line emerges when C99 levels are 
expressed as a ratio of C83. When compared with C83, C99 levels were significantly higher 
in ΔNAC, E46K and A53T α-syn SH-SY5Ys than the wildtype line (Figure 3.17b). Curiously, 
there is little variation between the mutants, compared with the differences in APP-Gal4 
cleavage. In particular one would expect Δ2-9 α-syn cells have greater C99 levels than the 
other mutants. Potentially the level to which C99 fragments can accumulate under γ-secretase 
inhibition may be limited, by degradation or negative feedback processes, creating a ceiling 
that erases differences between the mutant lines. Full-length APP protein levels are not altered 
by mutant α-syn overexpression (Figure 3.18), as demonstrated previously with the WT lines, 
so the changes to CTF production are likely reflect altered APP processing. 
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Figure 3.17 Increased β-cleaved APP in mutant α-syn SH-SY5Y lines.Western blots of 
whole-cell lysates were probed with antibody raised against the C-terminus of APP. (A) The 
β-CTF C99 band (~10 kDa) expressed as a ratio to the full-length band (~95 kDa). (B) The 
C99 band (~10 kDa) expressed as a ratio to the α-CTF C83 band (~9 kDa). Representative 
western blot shown, including a negative control from empty vector cells not treated with 
DAPT. Mean C99 OD: full-length OD, or mean C99 OD: C83 OD, for 4 independent 
experiments ± S.E. * p <0.05 relative to WT (v1) α-syn, calculated by one-way ANOVA with 














































































Figure 3.18 Levels of full-length APP protein are unaltered in mutant α-syn 
SH-SY5Ys.Western blots of whole-cell lysates were probed with antibody raised against the 
C-terminus of APP. Mean APP OD: α-tubulin OD for 4 independent experiments ± S.E. No 
significant differences between individual mutant α-syn lines and the WT, calculated by one-
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3.3.9 α-Syn mutant protein modulates the amyloidogenic processing of APP in N2As and 
HEK293s 
The potentiating effect of wildtype α-syn upon APP amyloidogenic processing was 
previously shown to be cell-type specific, occurring in neuron-like SH-SY5Y and N2A cell 
lines, but not in the fibroblast-like HEK293. Having established differential effects of α-syn 
mutations in transgenic SH-SY5Ys, it was hypothesised that a similar pattern could be detected 
in the mouse neuronal cell line N2A, and perhaps a different effect in non-neuronal HEK293s. 
Two mutations were selected: the Δ2-9 truncation because it most strongly enhanced 
amyloidogenic processing in SH-SY5Ys, and the disease-associated mutation E46K, which 
had a weaker effect on amyloidogenic processing but still enhanced β-amyloid generation. 
Δ2-9 and E46K were stably transfected into N2A cells and HEK293 cells, and α-syn 
expression confirmed by western blotting (Figure 3.19a, Figure 3.20a).  
Mutant HEK293 lines appear to have comparable α-syn expression to the WT α-syn line 
(Figure 3.19a). Previously it was shown that WT α-syn has an anti-amyloidogenic effect on 
APP processing in HEK293 cells, the opposite effect to neuronal cells. Interestingly, the two 
α-syn mutants appear to change APP-Gal4 cleavage in the pro-amyloidogenic direction 
(Figure 3.19b). The Δ2-9 mutation had limited effect on APP-Gal4 and is not significantly 
different to the WT. Yet the E46K mutant strongly enhanced APP-Gal4 cleavage, i.e. 
abolishing the anti-amyloidogenic effect of WT α-syn in HEK293 cells. Indeed there is no 
significant difference in APP-Gal4 cleavage between E46K and the empty vector (not shown). 
A better mechanistic understanding would be needed to determine whether E46K reduces a 
signal by α-syn or introduces a new opposing signal.  
In the two mutant N2A lines, α-syn expression also dissimilar to the WT. Levels of α-syn 
were significantly lower in Δ2-9 N2A, and significantly higher in E46K N2A (Figure 3.20a). 
This needs to be taken into account when interpreting amyloidogenic effects. It was 
hypothesised that amyloidogenic processing would be strongly potentiated by Δ2-9, and 
weakly potentiated by E46K, which was the effect in SH-SY5Ys. In contrast with the SH-
SY5Y data, the Δ2-9 mutant N2As did not significant enhance amyloidogenic processing 
relative to WT α-syn N2As (Figure 3.20b). The E46K N2As appeared to strongly upregulate 
APP cleavage. It is important to note that APP-Gal4 reporter activity in the α-syn lines closely 
mirrors α-syn expression levels. No conclusions can therefore be made about the impact of 
mutant α-syn in N2As. 
  





Figure 3.19 Amyloidogenic processing is increased in E46K α-syn HEK293s. (A) 
Overexpression of α-syn confirmed by western blotting. Whole cell lysates were tested for 
α-syn and α-tubulin. A representative western blot is shown. (B) APP-Gal4 reporter activity 
in mutant α-syn HEK293s. Mean RLU for 5 independent experiments ± S.E. ## p <0.01 
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Figure 3.20 Amyloidogenic processing is potentiated in E46K α-syn N2As. (A) 
Overexpression of α-syn confirmed by western blotting. Whole cell lysates were tested for 
α-syn and α-tubulin. Mean α-syn OD: tubulin OD for 5 independent experiments. (B) APP-
Gal4 reporter activity in mutant α-syn N2As. Mean RLU for 5 independent experiments ± S.E. 
** p <0.01 relative to empty vector; # p <0.05, ## p <0.01 relative to WT, calculated by 
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3.4 Discussion 
The results presented in this chapter show that, in a neuronal overexpression model, 
wildtype α-syn promotes the β-/γ-cleavage of APP, coinciding with greater extracellular levels 
of β-amyloid. These results support previous reports that rat neuronal cells treated with α-syn 
protein upregulate β-amyloid secretion (Kazmierczak et al. 2008; Majd et al. 2013). However, 
this is the first time that both increased β-cleavage of APP and increased extracellular 
β-amyloid have been described in an α-syn overexpressing cell model. The effect of wildtype 
α-syn overexpression is relatively small, but three independent cell lines used to study 
amyloidogenic processing were in agreement.  
Three different, but complementary, techniques were used to study amyloidogenic 
processing, providing robustness to the conclusions. Each has different strengths and 
limitations, and measures a different aspect of amyloidogenic processing. The first, an ELISA-
style multiplex assay for secreted Aβ40 and Aβ42, has the advantage of being quantitative and 
precise. However, the levels of extracellular Aβ40 and Aβ42 are affected by more factors than 
β-/γ-cleavage of APP. Degradation of β-amyloid by proteases such as neprilysin and insulin-
degrading enzyme is also important (Wang et al. 2006). Another limitation of the method is 
that in order to accumulate a measurable quantity of β-amyloid peptides, the conditioned media 
is collected after 72 hours, which could limit nutrient availability to the cells. The second 
assay, an APP-Gal4 luciferase reporter for endogenous β-/γ-cleavage activity at APP, is also 
quantitative but has the advantage not being confounded by protease activity. Yet 
measurement is indirect, may alter APP localisation, and is heavily reliant on uniform 
transfection efficiency. Thirdly, western blotting was performed on the cells for the immediate 
proteolytic products of β- (C99) and α- (C83) secretase cleavage in the presence of a 
γ-secretase inhibitor. This is advantageous for being direct and allowing endogenous 
β-secretase activity to be isolated from γ-secretase activity. However western blotting is not 
fully quantitative, and the perturbation of γ-secretase activity may affect transcription of the 
β-secretase protein BACE1 (Tamagno et al. 2008). It is this important to view the results from 
these three assays collectively. Together they strongly suggest that β-cleavage of APP, and 
total levels of secreted Aβ, are specifically elevated by α-syn overexpression. 
Interestingly the Aβ42:Aβ40 ratio was unaltered when α-syn was over-expressed, despite 
being more highly secreted. Aβ42 and Aβ40 result from the heterogenous cleavage pattern of 
γ-secretase, which also creates trace amounts of other Aβ peptides (Hubin et al. 2014). γ-
Secretase preferentially produces Aβ40, but saturation of the enzyme with its substrate, C99, 
leads to longer Aβ products such as Aβ42 (Svedružić et al. 2012). Paradoxically, the 
Aβ42:Aβ40 ratio can be increased by γ-secretase inhibition DAPT, due to C99 saturation 
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(Svedružić et al. 2013). The γ-secretase inhibitor DAPT did increase Aβ42:Aβ40 in the present 
study, but all other ratios were constant. One can infer from this that γ-secretase activity is not 
limiting in α-syn cells. 
The experiments focus on a synucleinopathy cell model where α-syn is stably over-
expressed in a neuronal cell line. Although this model is fairly ubiquitous in the literature, 
there is a dearth of literature using the model to study APP processing, which needs to be 
addressed. Only one paper studied APP in α-syn SH-SY5Ys but focussed on APP expression 
rather than processing (Jesko et al. 2014). The data in this thesis does not support changes to 
APP expression when α-syn is over-expressed, or vice versa. Others have approached the 
question of whether α-syn affects APP by applying recombinant α-syn protein to cells 
(Kazmierczak et al. 2008; Majd et al. 2013). α-Syn protein addition to cells, whether 
aggregated or non-aggregated, risks causing only acute toxicity, which is a good model of cell 
death but a poor model for studying the cell biology of a chronic condition. Inducible 
expression has a similar issue. For example intracellular calcium levels and calcineurin activity 
were demonstrated to be exquisitely sensitive to inducible α-syn expression, in a variety of 
cell models, resulting in dose-dependent cell death (Caraveo et al. 2014). Stable α-syn 
overexpression avoids acute toxicity, since there is selection for the cells that thrive so cells 
necessarily adapt to α-syn production. The limitation of this approach is that α-syn 
overexpression may cause it to saturate physiological sites of action and build up in non-
physiological sites (Kahle et al. 2000). Yet reduced α-syn clearance may be a major feature of 
synucleinopathy disease, leading to pathological accumulation in cells (Stefanis 2012). High 
intracellular levels of α-syn are known to profoundly alter cell biology, independently of toxic 
aggregates. α-Syn overexpression may, through its interaction with membranes, impede the 
secretory pathway and negatively affect the regulation of mitochondrial networks (Su et al. 
2010; Wang & Hay 2015; Kamp et al. 2010; Nakamura et al. 2011; Guardia-Laguarta et al. 
2014). α-Syn is also proposed to interact with histones and appears to alter histone acetylation 
(Jin et al. 2011; Kontopoulos et al. 2006; Goers et al. 2003). One study highlights that α-syn 
expression alters transcription of approximately 600 genes, in wildtype α-syn transgenic mice. 
Importantly, the gene expression profile is radically changed by aging (Miller et al. 2007). One 
can thus easily argue that stable α-syn overexpression models have relevance to disease. 
The pro-amyloidogenic effect of α-syn that was observed in SH-SY5Ys appears to be 
specific to neuronal cell types. APP and secretase expression is conserved in non-neuronal 
cells (Jacobsen & Iverfeldt 2013), yet differences to the regulation of the amyloidogenic 
pathway have been reported between neuronal and non-neuronal cells (Belyaev et al. 2010; 
Hong et al. 2012; Jacobsen & Iverfeldt 2013). The difference could potentially arise from 
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direct competition of α-secretase and β-secretase for APP. This ‘coupling’ of activity is strong 
in non-neuronal cells, but appears weaker or absent in neuronal cells (‘incomplete coupling’). 
For example, pharmacological induction of α-secretase activity decreases β-amyloid 
production in non-neuronal cells (e.g. HEK293, CHO), but does not reduce β-amyloid in 
SH-SY5Ys and primary neurons (LeBlanc et al. 1998). Inhibition of α-secretase activity 
increases β-amyloid production in non-neuronal cells (Skovronsky et al. 2000), but does not 
affect β-amyloid production in primary neurons (Blacker et al. 2002). The APP CTF data in 
Section 3.3.4 suggests that α-secretase and β-secretase activity are both enhanced in wildtype 
α-syn SH-SY5Ys, supporting incomplete coupling. APP CTFs were not measured for the 
HEK293s but one could hypothesise that the α-CTF and β-CTF would exhibit an inverse 
relationship due to coupling. 
Mutant α-syn constructs were tested to shed some light on the structural characteristics of 
α-syn that may be involved in its effect upon APP processing. Perhaps surprisingly, many 
different mutations of α-syn acted to increase its effect on APP in SH-SY5Ys. N2A lines with 
mutant α-syn were also tested for APP-Gal4 cleavage, but interpretation of the data was 
complicated by differences in α-syn protein expression. In SH-SY5Ys, both aggregate-
promoting (A30P, E46K, A53T) and aggregate-inhibiting (ΔNAC) mutations potentiated 
APP-Gal4 cleavage in SH-SY5Ys. The mutation with greatest effect was Δ2-9, which may 
alter the subcellular localisation of α-syn and inhibit aggregation (Burré et al. 2012; Wang et 
al. 2010). It is therefore likely that loss-of-function, rather than gain-of-toxicity, is responsible 
for the effects of α-syn. Clearly the underlying mechanism is somehow influenced by the 
structural conformation of the N-terminal domain of α-syn, but there is insufficient 
information to suggest a mechanism. Interestingly, a phosphorylation-blocking point mutation 
of S129 in the C-terminal domain appeared to slightly reduce APP-Gal4 cleavage. This result 
is intriguing given that the S129A mutation has been shown in certain models to delay 
synuclein-induced neurodegeneration (Chen & Feany 2005; Kragh et al. 2009; Febbraro et al. 
2013; Sato et al. 2011). S129 phosphorylation has been shown to mediate the protein-protein 
interactions of α-syn to proteins such as Rab8a, involved in vesicle trafficking (Yin et al. 
2014). When over-expressed, α-syn appears to disturb the function of Rab proteins in vesicle 
trafficking (Gitler et al. 2008). Perhaps the disruption of vesicle trafficking could be involved 
in α-syn-induced amyloidogenic processing of APP. 
Changes to APP-Gal4 activity in SH-SY5Ys were only partially echoed by the production 
of β-CTFs and β-amyloid. In ΔNAC and A53T cells there was an increase in APP-Gal4 
cleavage but not β-amyloid secretion. A weaker upregulation of β-amyloid than APP 
processing is logical, since increased amyloidogenic processing of APP is known to enhance 
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expression of the amyloid degrading enzyme neprilysin (Pardossi-Piquard et al., 2005). The 
effects of upregulating amyloidogenic processing may therefore be attenuated. However, the 
effect of E46K on β-amyloid secretion is much higher than one would anticipate based on its 
APP-Gal4 cleavage. E46K had little effect on APP-Gal4 cleavage but robustly increased 
β-CTF production and β-amyloid secretion. This highlights the value of using multiple 
techniques to study a complex phenomenon. 
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4.1.1 Secretases in synucleinopathy disease 
The previous chapter revealed changes to secretase-mediated processing of APP in α-syn 
cell lines. Without increasing APP expression, cells overexpressing α-syn performed more 
amyloidogenic processing and appeared to secrete more β-amyloid. Increased amyloidogenic 
processing must result from either elevated β- or γ-secretase activity on APP, or decreased 
α-secretase activity. The purpose of this study is to identify which secretases have altered 
activity in α-syn cells, and investigate secretase expression. The wealth of literature on the 
secretase regulation, summarised briefly in this introduction, means that specific changes to 
secretase expression can hint at a mechanism by which α-syn acts. 
The effect of α-syn upon secretase enzymes has not been previously investigated. Yet 
potential changes to secretases have been detected in synucleinopathy brains. One study of 
post-mortem brain tissue noted that PD and DLB brains had elevated BACE1 mRNA levels 
in the superior frontal gyrus relative to healthy controls, an effect not seen in AD brains 
(Coulson et al. 2010). In another study, a major component of the γ-secretase complex, 
presenilin 1 (PS1), was shown to interact with α-syn in amygdala of cognitively normal human 
brains. DLB amygdala tissue showed elevated interaction of PS1 and α-syn, independently of 
whether or not amyloid plaques were detected (Winslow et al. 2014). This finding is intriguing, 
although it remains to be seen whether the interaction has physiological consequences. 
4.1.2 Cell regulation of ADAM10 activity 
The ‘A Disintegrin And Metalloproteinase’ 10 (ADAM10) is one of several members of 
the ADAM family of zinc-binding transmembrane proteinases, two of which have been 
proposed to perform α-secretase activity (Endres & Fahrenholz 2012). Only ADAM10 has 
been convincingly shown to significantly reduce α-secretase activity when knocked-out in 
primary neurons (Kuhn et al. 2010) or animal models (Jorissen et al. 2010).  
CHAPTER 4: EFFECT OF α-SYN ON THE SECRETASES 
81 
Transcription of ADAM10 can be controlled by two regulatory elements in the ADAM10 
promoter that bind retinoid X-receptor (RXR). RXR binds as a heterodimer, with either the 
retinoic acid receptor (RAR) (Prinzen et al. 2005), or the peroxisome proliferator-activated 
receptor-α (PPARα) (Corbett et al. 2015). It has been demonstrated that RXR-RAR dimers, 
activated by retinoic acid, can increase ADAM10 transcription (Prinzen et al. 2005; Tippmann 
et al. 2009). Interestingly, upregulation of ADAM10 expression using the synthetic retinoid 
acitrecin results in decreased Aβ levels, in the cortex of AD mice (Tippmann et al. 2009). 
Another transcriptional regulator of ADAM10 is a spliced isoform of X-box binding protein 
1 (XBP1), generated as a product of the unfolded protein response. ADAM10 mRNA levels 
increase when ER stress is induced using thapsigargin or tunicamycin. (Reinhardt et al. 2014). 
XBP-1, introduced by targeted gene therapy, protected mice from dopaminergic neuron death 
in a neurotoxin-based model of PD (Valdés et al. 2014). ADAM10 transcription is also 
positively regulated by SRY-related high mobility group box 2 (Sox-2), a transcription factor 
that controls stem cell fate and adult neurogenesis. Sox-2 levels are reduced in AD brains, and 
negatively correlate with disease severity (Sarlak et al. 2015). 
Translation of ADAM10 can be negatively regulated via binding of a microRNA, miR-144, 
to the ADAM10 3’UTR. Levels of miR-144 are elevated in AD patients, and appear to be 
regulated by AP-1/c-Jun (Cheng et al. 2013). ADAM10 undergoes post-translational cleavage 
of an auto-inhibitory pro-domain (Anders et al. 2001), and then N-terminal glycosylation in 
the Golgi (Escrevente et al. 2008). Tight regulation of ADAM10 activity occurs after 
maturation, through translocation between plasma membrane and Golgi compartments. 
ADAM10 is most active as an α-secretase at the plasma membrane, although some α-cleavage 
of APP occurs in the Golgi (Agostinho et al. 2015). In response to receptor-mediated activation 
of protein kinase C (PKC), synapse-associated protein-97 (SAP97) binds ADAM10 in Golgi 
outposts and increases its delivery to the post-synaptic membrane (Saraceno et al. 2014). Long 
term depression (LTD) also stimulates ADAM10 translocation to the plasma membrane, and 
long term potentiation (LTP) stimuli have the opposite effect, increasing internalisation of 
ADAM10. LTP activates clathrin-mediated endocytosis of ADAM10, through enhanced 
association with the clathrin adaptor AP2 (Marcello et al. 2013). AD brains exhibit reduced 
SAP97 activation by PKC (Saraceno et al. 2014), and increased ADAM10-AP2 association 
(Marcello et al. 2013). 
4.1.3 Cell regulation of BACE1 activity 
BACE1 is a type I transmembrane protease, and the β-secretase enzyme responsible for 
amyloidogenic processing of APP. A homologous enzyme, BACE2, also cleaves APP but in 
a different site that does not produce β-amyloid peptides (Agostinho et al. 2015). The BACE1 
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promoter can be regulated by a huge array of transcription factors, including AP1, AP2, CREB, 
GRE, Sp-1, and NF-κB (Sambamurti et al. 2004), peroxisome proliferator-activated receptor-
gamma (PPARγ) (Sastre et al. 2006), HIF-1α (Zhang et al. 2007), and NFAT3 (Mei et al. 
2015). Many of the transcription factors are activated by cell stress. For example, NF-κB and 
AP1 are activated by oxidative stress, HIF-1α by hypoxia, and PPARγ by inflammation 
(Tamagno et al. 2012). CREB is activated by a component of oxidised LDL, and NFAT3 by 
increases in intracellular calcium levels (Shi et al. 2013; Mei et al. 2015). 
Translational regulation of BACE1 is another key regulatory pathway, as the BACE1 
mRNA is translationally repressed by its GC-rich 5’ UTR (Lammich et al. 2004). 
De-repression of BACE1 translation occurs when the translational initiation factor eIF2α is 
phosphorylated by eIF2 kinases, under conditions of nutrient deprivation, oxidative stress, or 
endoplasmic reticulum stress (Devi & Ohno 2014; Mouton-Liger et al. 2012; O’Connor et al. 
2008). Phosphorylation of eIF2α at Ser-51 leads to global translation repression, except for a 
sub-set of mRNAs, largely stress-response genes, that contain an upstream open-reading frame 
(Harding et al. 2000). These mRNAs, including BACE1, are translationally upregulated 
(O’Connor et al. 2008).  
BACE1 protein exits the ER with an auto-inhibitory pro-domain, which is cleaved 
before N-terminal glycosylation. The mature protein is constitutively secreted to the post-
synaptic plasma membrane, but is most active as a secretase enzyme at low pH. Therefore the 
majority of β-cleavage of APP occurs in endosomes. APP and BACE1 are internalised by 
different routes, but are brought together by sorting between early endosomes (Jiang et al. 
2014). The endocytic interaction of APP and BACE1 is limited by proteins that promote 
trafficking of BACE1 to the TGN, including VPS35 in the retromer complex and GGA1, a 
member of the Golgi-localized γ-adaptin ear-containing ADP ribosylation factor binding 
proteins (GGAs) (Wen et al. 2011; Wahle et al. 2005; Jiang et al. 2014). Another GGA protein, 
GGA3, targets BACE1 to lysosomes for degradation. GGA3 is sensitive to caspase cleavage 
during apoptosis, and inversely correlates with BACE1 expression in the temporal cortex of 
AD brains (Tesco et al. 2007). 
4.1.4 The γ-secretase complex 
γ-Secretase is an aspartic protease complex of at least four proteins that are essential for its 
activity: presenilin (PS1/2), presenilin enhancer-2 (PEN2), nicastrin, and anterior 
pharynxdefective-1 (APH-1). The catalytic protein is PS1 or PS2, and is regulated by PEN2. 
Nicastrin and APH-1 scaffold the complex and nucleate assembly. The majority of mature 
γ-secretase complexes cycle between the ER and Golgi, but about 5% is transported to the 
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plasma membrane and endocytosed (Agostinho et al. 2015). Trafficking of γ-secretase to the 
plasma membrane increases if APP is knocked-down, or if phospholipase D1 is 
over-expressed. Cholesterol-rich lipid rafts in the TGN and endosomes are particularly 
enriched with γ-secretase complexes (Vetrivel et al. 2004). Lipids rafts also bind APP and β-
secretase, but not α-secretase, and their structural integrity is important for cell β-amyloid 
production (Ehehalt et al. 2003). 
γ-Secretase binds C99, the membrane-bound product of β-secretase cleavage of APP. C99 
is cleaved to form a long Aβ peptide of 48 or 49 residues, which is then further cleaved by 
γ-secretase 3 amino acids at a time, sequentially producing shorter Aβ peptides. The most 
common product is Aβ1-40, but detectable levels of Aβ1-42 also result, which is more 
hydrophobic and considered to be more toxic. Interestingly, around 244 familial AD mutations 
are recorded to affect PS1, PS2, or the region of γ-secretase cleavage in APP (Cruts et al. 
2012). These mutations can increase or decrease Aβ1-40 production from cells, but it appears 
that their pathogenicity is closely linked to a reduction in maximal catalytic activity of 
γ-secretase. For example, L166P mutant PS1 is associated with an age of disease onset of 24, 
and is estimated to have a maximal activity that is only 28-42% of the wildtype protein 
(Svedružić et al. 2015). Operating close to its maximal activity means that the γ-secretase 
active site is saturated with C99 substrate. This appears to result in an increased ratio of 
Aβ1-42: Aβ1-40 production, and more release of long Aβ peptides that may also be toxic, e.g 
Aβ1-43 (Svedružić et al. 2012; Svedružić et al. 2015).  
In addition to cleaving the cytoplasmic domain of APP, releasing the APP intracellular 
domain (AICD), γ-secretase has an important role in Notch processing (De Strooper et al. 
1999). Notch processing is performed by γ-secretase and α-secretase, but not β-secretase (De 
Strooper et al. 1999). In this chapter a luciferase reporter for Notch cleavage will be used as a 
tool for measuring γ-secretase activity (Cox et al. 2014).  
4.2 Aims 
Chapter 3 showed that α-syn overexpression in neuronal cell types has a pro-amyloidogenic 
effect on APP processing. This chapter aims to investigate whether specific changes to the 
expression and activity of the α-, β-, and γ-secretases underpin the pro-amyloidogenic effect 
of α-syn. Endogenous γ-secretase activity will be assayed in α-syn SH-SY5Ys, using a 
luciferase reporter. For the inducible α-secretase ADAM10 and the β-secretase BACE1, a 
more detailed exploration of transcriptional activity, protein expression and maturation will be 
performed. Once secretase expression and activity has been characterised in WT α-syn cells, 
the effects of α-syn mutations will be investigated. 
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4.3 Results 
4.3.1 A post-transcriptional reduction in mature ADAM10 protein within WT α-syn 
SH-SY5Ys  
α-Secretase activity upon APP prevents the formation of β-amyloid by β-secretase 
cleavage. The extent to which direct substrate competition occurs is not clear, given that 
mature α- and β-secretases localize to separate membranes, but also co-exist in the TGN. 
However, in Chapter 3 it was shown that α-secretase inhibition in SH-SY5Ys significantly 
enhances the signal of a luciferase reporter assay for β-/ γ-secretase activity. Thus it is 
important to investigate changes to α-secretase expression and activity in α-syn SH-SY5Ys. 
ADAM10 is the major α-secretase (Kuhn et al. 2010). Expression of ADAM10 was initially 
measured by testing its promoter activity. A construct with a fragment of human ADAM10 
promoter in control of a luciferase gene was transfected into WT (v1) α-syn SH-SY5Ys. 
Known regulatory elements for transcription factors RXR and XBP-1 were present in the 2.2 
kb promoter fragment (Prinzen et al. 2005; Reinhardt et al. 2014). No significant reduction in 
promoter activity is evident (Figure 1.1a). ADAM10 protein levels were then measured by 
western blotting, using whole cell extracts of the WT (v1) α-syn cells (Figure 4.1b). In contrast 
with the promoter activity, ADAM10 protein levels were significantly decreased in α-syn 
cells. The change in expression is likely post-transcriptional.  
Decreased ADAM10 expression does not necessarily mean that α-secretase activity will be 
reduced. ADAM10 is produced as an inactive precursor that undergoes maturation in the 
Golgi, so changes in ADAM10 levels could be counteracted by an opposite change in 
maturation. To measure the overall ADAM10 activity of the cells, a commercial in vitro 
activity assay was used on whole-cell lysates. The assay specifically tests ADAM10 
α-secretase activity with a cleavable fluorometric peptide reporter (Eurogentec), incubated 
with equal concentrations of cell protein. Fluorescence increased linearly for an hour, and was 
compared between cell extracts at the 30 minute time-point. ADAM10 catalytic activity was 
15% lower in extracts from WT α-syn SH-SY5Ys relative to empty vector cells (Figure 4.1c). 
This is comparable with the 20% reduction in levels of ADAM10 protein, which may be 
entirely responsible for the decreased in vitro activity. The evidence suggests that there is an 
overall reduction in mature ADAM10 in α-syn SH-SY5Ys. More evidence would be needed 
to support a real decrease in α-secretase cleavage of APP, since this is also controlled by 
sub-cellular localisation.  
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Figure 4.1 In WT α-syn SH-SY5Ys there is a post-transcriptional reduction in levels of 
active ADAM10. Transcriptional activity of ADAM10 in WT α-syn SH-SY5Ys, measured 
with a luciferase reporter for a fragment of the human ADAM10 promoter. Mean RLU for 4 
independent experiments ± S.E. (B) ADAM10 total protein levels in WT α-syn SH-SY5Ys, 
measured by western blotting ADAM10 in whole cell lysates. Mean ADAM10 OD: α-tubulin 
OD for 9 independent experiments ± S.E. (C) In vitro ADAM10-mediated catalytic activity 
from cell extracts of WT α-syn SH-SY5Ys. 50 µg of total protein from whole cell lysates were 
incubated with 5-FAM FRET substrate (SensoLyte® 520 ADAM10 Activity Assay Kit, 
Eurogentec). Mean fluorescence for 4 independent experiments ± S.E. * p<0.05, ** p<0.01 





















































































Figure 2.1 In WT α-syn SH-SY5Ys there is a post-transcriptional reduction in levels of active
ADAM10. (A) Transcriptional activity of ADAM10 in WT α-syn SH-SY5Ys, measured with a luciferase
reporter for a fragment of the human ADAM10 promoter. Mean RLU for 4 independent experiments ± S.E.
(B) ADAM10 total protein levels in WT α-syn SH-SY5Ys, measured by Western blotting ADAM10
(AB10926, Millipore) in whole cell lysates. Mean ADAM10 OD: α-tubulin OD for 9 independent
experiments ± S.E. (C) In vitro ADAM10-mediated catalytic activity from cell extracts of WT α-syn SH-
SY5Ys. 50 µg of total protein from whole cell lysates were incubated with 5-FAM FRET substrate
(SensoLyte® 520 ADAM10 Activity Assay Kit, Eurogentec), and the fluorescence increase resulting from
its cleavage was monitored for 30 minutes. Mean fluorescence for 4 independent experiments ± S.E. *
p<0.05, ** p<0.01 relativ to mpty vector, calculated by Student’s t-test.
(B)
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4.3.2 Increased translocation of ADAM10 to the plasma membrane may counteract α-syn-
induced changes ADAM10 expression 
Levels of active ADAM10 protein were reduced in WT α-syn SH-SY5Ys, but it was 
unclear whether this necessitated a reduction in its cleavage of APP. Secretase activity is 
highly compartmentalised, and α-cleavage of APP is thought to mostly occur at the plasma 
membrane, regulated by receptor-stimulated trafficking (Agostinho et al. 2015). Therefore the 
cell surface expression of ADAM10 was measured biochemically in WT (v1) α-syn 
SH-SY5Ys (Figure 4.2). Proteins on the surface of intact cells were biotinylated, the cells 
lysed, and biotinylated proteins affinity-purified with NeutrAvidin beads. Western blotting 
was used to compare ADAM10 levels in the purified fraction with input homogenates. A 
significantly higher proportion of cell surface ADAM10 was detected in WT α-syn SH-SY5Ys 
compared with empty vector cells. Note that input homogenate ADAM10 levels are not 
identical, so it is not clear that cell surface expression of ADAM10 is genuinely higher. At the 
very least, the data suggests that decreased ADAM10 expression in WT α-syn cells does not 
limit its cell surface availability. One can see that the 26% increase in proportional cell surface 
expression of ADAM10 is of a similar magnitude to the 20% decrease in total ADAM10 
protein levels. It is likely that the two balance out, resulting in similar levels of ADAM10 
being localised to the plasma membrane in WT α-syn and empty vector cells. 
  




Figure 4.2 Cell surface expression of ADAM10 protein in WT α-syn SH-SY5Ys. The cell 
surface proteins of intact cells were labelled with Sulfo-NHS-SS-Biotin, then lysed and 
affinity-purified using NeutrAvidin agarose beads (Cell Surface Protein Isolation Kit, Thermo 
Scientific). Western blotting for ADAM10 was performed on both purified cell surface protein 
and the input homogenates. Data shown as the mean ratio of cell surface: total ADAM10 for 
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4.3.3 The effect of α-syn on ADAM10 expression is unaltered by selected α-syn mutations 
Overexpression of WT α-syn reduced the levels of active ADAM10 protein in SH-SY5Ys. 
The role of the α-syn N-terminal domain sequence was subsequently investigated, using the 
mutant α-syn SH-SY5Y lines characterised in Chapter 3. The transcriptional activity of 
ADAM10 in mutant lines was measured by a luciferase reporter construct, as described 
previously. Similar to the WT line, human ADAM10 promoter activity was unaltered by any 
of the disease-associated point mutations (A30P, A53T & E46K; Figure 4.3a). Unexpectedly, 
the two N-terminal truncations (Δ2-9 & ΔNAC) caused a significant increase in the apparent 
promoter activation of ADAM10. 
Total levels of ADAM10 protein were also measured by western blotting of whole-cell 
lysates (Figure 4.3b). Westerns included the two N-terminal truncation mutants (Δ2-9 & 
ΔNAC), two disease-associated mutants (E46K & A53T), and two phosphorylation mutants 
(S129A & S129D). Compared with the WT (v1) α-syn line in adjusted t-tests, none of the 
mutations have a significant effect on ADAM10 protein levels. Clearly although the 
N-terminal truncations appeared to upregulate ADAM10 transcription, production of the 
ADAM10 protein is highly regulated and did not increase. 
The in vitro catalytic activity of ADAM10 was previously shown to closely follow 
ADAM10 protein expression in cell extracts. A fluorometric peptide reporter was used that 
mimics the α-secretase cleavage site of APP (Eurogentec). At the same time as WT (v1) α-syn, 
cell extracts from the mutant α-syn lines were assayed in vitro for ADAM10 catalytic activity 
(Figure 4.3c). In agreement with the measured levels of ADAM10 protein, there were no 
significant differences in ADAM10 catalytic activity between the mutant lines and WT α-syn 
SH-SY5Ys.  
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Figure 4.3 α-Syn-mediated reduction of ADAM10 is not affected by mutations. (A) 
Transcriptional activity of ADAM10 in mutant α-syn SH-SY5Ys, measured with a luciferase 
reporter for a fragment of the human ADAM10 promoter. Mean RLU for 4-5 independent 
experiments ± S.E. (B) ADAM10 total protein levels in mutant α-syn SH-SY5Ys, measured 
by western blotting ADAM10 in whole cell lysates. Mean ADAM10 OD: α-tubulin OD for 3-
7 independent experiments ± S.E. (C) In vitro ADAM10-mediated catalytic activity from cell 
extracts of mutant α-syn SH-SY5Ys. 50 µg of total protein from whole cell lysates were 
incubated with 5-FAM FRET substrate (SensoLyte® 520 ADAM10 Activity Assay Kit, 
Eurogentec). Mean fluorescence for 3-4 independent experiments ± S.E. ** p<0.01 relative to 
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4.3.4 BACE1 expression in WT α-syn SH-SY5Ys is increased  
The β-secretase, BACE1, is responsible for amyloidogenic processing of APP. Research 
has shown that just small increases in BACE1 expression can lead to large increases in 
β-amyloid production (Li et al. 2006). BACE1 can be regulated at a transcriptional and 
translational level. Transcriptional activity at the BACE1 promoter was investigated with a 
luciferase reporter construct, using a fragment of human BACE1 promoter upstream of the 
firefly luciferase gene (McHugh et al. 2012). All putative transcription factor sites for BACE1 
are contained within the promoter fragment (Sambamurti et al. 2004). Promoter activity 
appeared to be significantly reduced in WT α-syn SH-SY5Ys (Figure 4.4).  
BACE1 protein expression was then assessed by western blotting (Figure 4.5a). In contrast 
to the diminished promoter activity, BACE1 protein levels were significantly elevated in three 
WT α-syn lines. Interestingly, levels of BACE1 form a similar pattern to α-syn levels in the 
same cell extracts, highest in ‘(v3)’ and lowest in ‘(v1)’ (Figure 3.2). Like ADAM10, BACE1 
protein is synthesised as an inactive precursor, and matured by pro-domain cleavage and 
N-terminal glycosylation. Therefore increases in BACE1 expression do not necessarily mean 
more active BACE1 enzyme. To quantify levels of active BACE1 in cell lysates, a commercial 
β-secretase activity kit (Eurogentec) was used. Similar to the ADAM10 activity assay, a 
cleavable fluorometric peptide reporter was mixed with samples of equal protein 
concentration, and fluorescence recorded at 30 minutes. β-Secretase activity appears higher in 
the WT (v1) α-syn SH-SY5Ys, but the increase is not statistically significant (Figure 4.5b). 
Significance may have been affected by high noise in the assay. Increased β-secretase activity 
in WT α-syn SH-SY5Ys is suggested by data in Chapter 3 that showed elevated production of 
the β-cleaved C-terminal fragments of APP, ‘C99’. Overall, it appears that α-syn 
overexpression is linked to increased BACE1 protein levels in SH-SY5Ys, and that higher 
β-cleavage of APP results. 
  








Figure 4.4 BACE1 promoter activity is reduced in α-syn SH-SY5Ys. Transcriptional 
activity of BACE1 was measured with a luciferase reporter for a fragment of the human 
BACE1 promoter. Mean RLU for 5 independent experiments ± S.E. * p<0.05, ** p<0.01 























Figure 4.5 BACE1 protein expression is enhanced in α-syn SH-SY5Ys. (A) BACE1 total 
protein levels in WT α-syn SH-SY5Ys, measured by western blotting BACE1 in whole cell 
lysates. Mean BACE1 OD: α-tubulin OD for 9 independent experiments ± S.E. (B) In vitro 
BACE1-mediated catalytic activity from cell extracts of WT α-syn SH-SY5Ys. 50 µg of total 
protein from whole cell lysates were incubated with HiLyte™ Fluor 488 FRET substrate 
(SensoLyte® 520 β-Secretase Assay Kit, Eurogentec), and the fluorescence increase resulting 
from its cleavage was monitored for 30 minutes. Mean fluorescence for 4 independent 
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4.3.5 The effect of α-syn on BACE1 expression is dose-dependent in SH-SY5Ys 
BACE1 protein levels were observed to be highest in the WT α-syn SH-SY5Ys with 
greatest average α-syn expression, so a dose-dependent effect was hypothesised. In stably-
transfected cells, the degree of overexpression cannot be controlled and may vary over time. 
To clarify whether a correlation between α-syn and BACE1 expression exists, SH-SY5Ys 
were transiently transfected with different quantities of α-syn plasmid. Both α-syn and BACE1 
proteins were measured by western blotting of cell extracts after 48 hours. Transfection of 
α-syn plasmid results in a strong dose-dependent increase in α-syn protein levels (Figure 4.6a). 
Correspondingly, BACE1 protein levels appear to mirror the increasing levels of α-syn (Figure 
4.6b). The effect is weak however, since only a 1.2- to 1.4-fold change in BACE1 results from 
a 5.5- to 12-fold change in α-syn. To control for the potential cell stress provoked by over-
expression of protein, which alone could account for BACE1 expression, the closely related 
β-synuclein gene was transfected into SH-SY5Ys. β-Syn does not significantly enhance 
BACE1 expression, indicating that the effect on BACE1 is specific to α-syn transfection. A 
small increase in α-syn levels was detected in β-syn cells, but it is likely that there is some 
cross-reactivity of the α-syn antibody for β-syn. Overall this experiment confirms that BACE1 
expression responds to different levels of α-syn overexpression. Furthermore, the result 
clarifies that a significant change in BACE1 expression occurs within 48 hours, so the effect 
is not a long-term adaptation by the cell population to selective pressure. 
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Figure 4.6 Transfection of α-syn dose-dependently increases BACE1 expression. (A) 
BACE1 and (B) α-syn total protein levels in SH-SY5Ys transiently overexpressing WT α-syn 
or β-syn. SH-SY5Ys were transfected with 0.5 μg, 1 μg, or 2 μg of pcDNA 3.1(+) - α-syn, or 
1 μg of pcDNA 3.1(+) - β-syn. A mock transfection with no plasmid was also performed to 
control for transfection-specific effects. Cells were lysed after 48 hours. Whole cell lysates 
were tested for, α-syn, and α-tubulin by western blotting. Representative blot shown. Mean 
BACE1/ α-syn OD: α-tubulin OD for 4 independent experiments ± S.E. * p<0.05, ** p<0.01 









































































Figure 2.6 Transfection of α-syn dose-dependently increases BACE1 expression. (A) BACE1 and (B)
α-syn total protein levels in SH-SY5Ys transiently overexpressing WT α-syn or β-syn. SH-SY5Ys were
transfected with 0.5 μg, 1 μg, or 2 μg of pcDNA 3.1(+) - α-syn, or 1 μg of pcDNA 3.1(+) - β-syn. A mock
transfection with no plasmid was also performed to control for transfection-specific effects. Cells were
lysed after 48 hours. Whole cell lysates were tested for BACE1 (#5606, Cell Signaling Technology), α-syn
(ab138501, Abcam), and α-tubulin (T6793, Sigma) by Western blotting. Representative blot shown. Mean
BACE1/ α-syn OD: α-tubulin OD for 4 independent experiments ± S.E. * p<0.05, ** p<0.01 relative to
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4.3.6 BACE1 expression is positively correlated with α-syn expression in transgenic rat 
striatum 
The potential association of α-syn overexpression with BACE1 expression was further 
investigated in vivo. Brain material was obtained from both hemispheres of from rats that were 
unilaterally injected with α-syn-containing lentivirus into the substantia nigra (Prof. Bernard 
L. Schneider, EPFL, Switzerland). α-Syn is thought to largely function at presynaptic 
terminals, and is known to undergo short-range neuron-neuron transmission at synapses 
(Desplats et al. 2009). Thus the striatum of an infected hemisphere, innervated by 
dopaminergic neurons from the substantia nigra, is likely to be affected by over-expressed 
α-syn. Striatal homogenates were tested for BACE1 and α-syn protein levels by western 
blotting. The striatal samples ipsilateral to the site of vector injection were compared with 
contralateral samples, acting as internal controls. BACE1 expression was significantly 
enhanced in the overall population of α-syn-transduced striata relative to controls (Figure 4.7 
BACE1 expression is upregulated in α-syn-transduced rat striata).  
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Figure 4.7 BACE1 expression is upregulated in α-syn-transduced rat striata. Striata were 
obtained from the right and left hemispheres of 8 animals (16 samples in total) that had been 
unilaterally injected with α-syn lentivirus into the substantia nigra, with thanks to Prof. 
Bernard L. Schneider (EPFL, Switzerland). Homogenates were tested for BACE1, α-syn, and 
α-tubulin by western blotting. Representative western blot image of BACE1 expression in 
three individual rats, of striata ipsilateral (‘Inf’) and contralateral (‘Con’) to the injection site. 
Graph displays mean BACE1 OD: α-tubulin OD for 8 animals, ** p< 0.01 relative to control, 
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4.3.7 Specific α-syn mutations can induce BACE1 promoter activation  
In Chapter 3, several mutations in the N-terminal domain of α-syn were found to potentiate 
APP amyloidogenic processing. Earlier in the current chapter these mutations were shown to 
not affect ADAM10 expression, the hypothetical negative regulator of amyloidogenic 
processing. Another potential route of influence could be the expression and activity of the 
β-secretase. Initially, the transcriptional activity of BACE1 was investigated. A luciferase 
reporter for BACE1 promoter activity was used in several of the mutant α-syn SH-SY5Y lines, 
as previously described. Similar to the wildtype, activity of the BACE1 promoter reporter was 
not altered by disease mutants (A30P, E46K, & A53T; Figure 4.8). Interestingly, the Δ2-9 
mutation caused a robust upregulation of BACE1 promoter activity by 2.5-fold. Deletion of 
residues 71-82 (ΔNAC) also upregulated BACE1 promoter activity, by 1.5-fold. This pattern 
is familiar from the earlier study of ADAM10 promoter activity. In the case of ADAM10, 
upregulated promoter activity by Δ2-9 and ΔNAC did not result in an overall change to 
ADAM10 protein levels. BACE1 protein levels will be discussed next. 
 
Figure 4.8 Truncation mutants of α-syn increase BACE1 promoter activity. 
Transcriptional activity of BACE1 was measured with a luciferase reporter for a fragment of 
the human BACE1 promoter. Mean RLU for 6-7 independent experiments ± S.E. * p<0.05, 














Figure 2.8 Truncation mutants of α-syn increase BACE1 promoter activity. Transcriptional
activity of BACE1 was measured with a luciferase reporter for a fragment of the human BACE1
promoter. Mean RLU for 6-7 independent experiments ± S.E. * p<0.05, ** p<0.01 relative to empty
vector, calculated by pairwise t-tests with a Holm adjustment.
**
*
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4.3.8 α-Syn mutations can potentiate its upregulation of BACE1 protein expression  
BACE1 protein levels were post-transcriptionally increased by WT α-syn. The result of 
expressing α-syn mutants upon BACE1 protein levels could aid understanding of how they 
affect APP amyloidogenic processing. Levels of BACE1 protein were measured in all of the 
mutant α-syn cell lines for which APP processing was previously characterised (Chapter 3). 
Mutations are clustered in three groups of relatedness: two N-terminal truncations (Δ2-9 & 
ΔNAC), three disease-associated point mutations (A30P, A53T, & E46K), and two C-terminal 
mutations of the ser-129 phosphorylation site (S129A & S129D). Both N-terminal domain 
truncations robustly elevated BACE1 protein expression (Figure 4.9), mirroring changes to 
BACE1 promoter activity. Compared with the WT α-syn line, Δ2-9 increased BACE1 protein 
expression by 1.6-fold, and ΔNAC by 1.2-fold, showing marginally weaker potentiation of 
protein levels than promoter activity. The disease-associated point mutations, A30P and A53T 
had little effect on BACE1 protein levels. Of the ‘disease’ mutants only E46K significantly 
enhanced the effect of α-syn upon BACE1. The phosphorylation site mutants S129A and 
S129D also both appeared to significantly increase BACE1 protein expression. Overall, the 
changes to BACE1 expression in mutant α-syn lines partially reflect changes to amyloidogenic 
processing. 
  




Figure 4.9 BACE1 protein expression is potentiated by several mutations of α-syn. 
N-terminal domain mutations of α-syn, and C-terminal domain ser-129 mutations of α-syn 
were over-expressed in SH-SY5Ys. Whole cell lysates were tested for BACE1 and α-tubulin 
by western blotting. Mean BACE1 OD: α-tubulin OD for 5-12 independent experiments ± S.E. 
* p <0.05, ** p <0.01 relative to WT (v1), comparisons with WT (v1) were made in three 
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4.3.9 γ-Secretase activity is not affected by WT α-syn overexpression in SH-SY5Ys 
Amyloidogenic cleavage of APP and the secretion of β-amyloid are both dependent on 
γ-secretase activity. Consequently, this is another factor that could potentially contribute to the 
effect of α-syn expression on amyloidogenic processing. γ-Secretase activity was determined 
using a Notch-Gal4 luciferase reporter for Notch cleavage (Dr Robert J. Williams, University 
of Bath). Similar to the APP-Gal4 reporter used in Chapter 3, intracellular γ-secretase cleavage 
releases the Notch intracellular domain with its fused Gal4 tag, allowing Gal4-mediated 
transcription of a luciferase construct (pLuc) (Cox et al. 2014). Unlike APP-Gal4, there is no 
requirement for α/β-secretase activity preceding cleavage of the Notch intracellular domain by 
γ-secretase. The specificity of the assay for γ-secretase activity was verified using secretase 
inhibitors (Figure 4.10a). The α-secretase inhibitor TAPI-1 was previously shown to promote 
APP-Gal4 cleavage, but has no effect on Notch-Gal4 cleavage. γ-Secretase inhibition by 
DAPT strongly prevents Notch-Gal4 cleavage as one would expect. When transfected into 
WT α-syn SH-SY5Ys the Notch-Gal4 signal is not significantly altered, which suggests that 
α-syn has no effect on levels of active γ-secretase (Figure 4.10b).  
4.3.10 N-terminal truncated α-syn upregulates γ-secretase activity  
γ-Secretase activity is not enhanced in SH-SY5Ys with over-expressed WT α-syn, when 
measured with a Notch-Gal4 reporter. Levels of active γ-secretase complexes were 
subsequently measured in several mutant α-syn lines, with the Notch-Gal4 luciferase reporter 
(Figure 4.11). A striking 4.5-fold increase in Notch-Gal4 cleavage was detected in Δ2-9 α-syn 
SH-SY5Ys, compared with the WT (v1) line. The other N-terminal truncation, ΔNAC, did not 
enhance γ-secretase activity. Disease-associated point mutations A30P, E46K, and A53T also 
had no significant effect on γ-secretase activity. In the literature, γ-secretase activity has been 
shown to affect BACE1 transcription (Tamagno et al. 2008), so it is notable that the Δ2-9 line 
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Figure 4.10 Notch-Gal4 reporter for γ-secretase activity in SH-SY5Ys. (A) Notch-Gal4 
cleavage is dependent on γ- but not α-secretase. Empty vector SH-SY5Ys were transfected 
with pTK, pLuc, and Notch-Gal4 constructs. α-Secretase inhibitor TAPI-1 (50 µM) and 
γ-secretase inhibitor DAPT (10 µM) were added 6 hours post-transfection, and incubated 16 
hours before lysis. Mean RLU for 3 independent experiments ± S.E. (B) Notch-Gal4 cleavage 
in WT (v1) α-syn SH-SY5Ys. Mean RLU for 8 independent experiments ± S.E. ** p <0.01 
relative to empty vector control, calculated by one-way ANOVA with Tukey post-hoc test.  
 
Figure 4.11 γ-Secretase activity appears enhanced by over-expressed Δ2-9 α-syn. 
Notch-Gal4 reporter was used to measure γ-secretase activity in mutant α-syn SH-SY5Ys. 
Cells were transfected with pTK, pLuc, and Notch-Gal4 constructs. Mean RLU for 5-8 
independent experiments ± S.E. ** p <0.01 relative to WT (v1), calculated by pairwise t-tests 
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4.4 Discussion 
The previous chapter observed that the secretase-mediated processing of APP becomes 
more amyloidogenic when α-syn is stably over-expressed in neuronal cell lines. Enhanced 
production of toxic β-amyloid peptides was also detected from α-syn SH-SY5Ys. A complex 
balance between amyloidogenic and non-amyloidogenic pathways of APP processing exists, 
involving the expression, activity, and subcellular localisation of three secretase enzymes. This 
current chapter aimed to discover any major changes to α-, β-, and γ-secretase activity and 
expression that may underlie the effects of α-syn on APP processing. It was hypothesised that 
wildtype α-syn may increase β-secretase and/or γ-secretase activity, or reduce α-secretase 
activity. Expression of WT α-syn in SH-SY5Y cells did not seem to affect γ-secretase activity, 
so no further investigation was made into γ-secretase. Yet changes to both the α-secretase 
ADAM10 and the β-secretase BACE1 were revealed. 
WT α-syn reduced ADAM10 protein levels. Since promoter activity was not reduced, the 
effect must be post-transcriptional and not involve transcriptional regulation by RXR 
complexes or XBP-1 (Prinzen et al. 2005; Reinhardt et al. 2014). Potentially, translational 
repression could cause the reduction in ADAM10 protein, and this is known to be performed 
by at least one micro-RNA responsive to cell stress (Cheng et al. 2013). However the increased 
degradation of ADAM10 protein cannot be ruled out without further investigation. Despite the 
clear reduction in total levels of active ADAM10 enzyme, confirmed by in vitro activity 
assays, it is not clear whether a physiological reduction in α-secretase activity results. 
α-Secretase cleavage of APP is thought to largely occur at the plasma membrane, and 
ADAM10 trafficking to the cell surface is highly regulated (Agostinho et al. 2015). Cell 
surface levels of ADAM10 were actually found to be increased, as a ratio of the total ADAM10 
protein in WT α-syn SH-SY5Ys. Since total ADAM10 is reduced, one cannot conclude that 
WT α-syn cells have significantly higher cell surface expression than empty vector cells. Yet 
at the very least this indicates that the overall reduction in ADAM10 protein expression is not 
reflected in cell surface levels of ADAM10. Further experiments are needed to clarify the role 
of ADAM10 in α-syn-regulated APP processing. 
BACE1 protein levels are increased by WT α-syn overexpression, and it is likely that this 
increases the pool of catalytically active BACE1. Results of in vitro activity assays failed to 
confirm this, due to high noise. However, indirect evidence of high β-secretase activity in the 
WT α-syn SH-SY5Ys was previously shown in Chapter 3, in the elevated production of C99 
APP. C99 C-terminal fragments of APP are only produced by β-secretase cleavage, and the 
presence of a γ-secretase inhibitor prevented further metabolism. Paradoxically, BACE1 
promoter activity was reduced in WT α-syn SH-SY5Ys, at odds with the increased BACE1 
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protein levels. This is not without precedent in the literature; overexpression of the prion 
protein PrP in SH-SY5Ys was previously shown to both reduce human BACE1 promoter 
activity (same construct) and increase BACE1 protein levels (McHugh et al. 2012). 
Additionally, the translational upregulation of BACE1 in response to nutrient deprivation 
corresponds with a drop in BACE1 mRNA levels (O’Connor et al. 2008). It is possible that 
the drop in BACE1 transcription is a negative feedback response to increased BACE1 
translation/stability. NF-κB is a likely candidate, reported to cause both Aβ-induced 
transcriptional repression of BACE1, and Aβ-induced transcriptional activation of BACE1. 
The latter is observed when Aβ production is pathologically high, and the former under 
physiological conditions (Chami et al. 2012). Regardless, the effect of α-syn on BACE1 
protein appears to be post-transcriptional in origin. Likely mechanisms include the eIF2α-
dependent translation of BACE1 mRNA, and the degradation of BACE1 protein by autophagic 
and proteasomal pathways. Both of these regulatory pathways for BACE1 expression will be 
investigated in the next chapter. 
BACE1 protein expression was further investigated, by examining a range of α-syn 
expression levels in SH-SY5Ys and rat striatum samples. Transient transfection of SH-SY5Ys 
with α-syn revealed a positive trend in BACE1 protein levels, with increasing α-syn dose. In 
transiently transfected SH-SY5Ys it was noticeable that a large 5-fold increase in α-syn levels 
caused only a 20% increase in BACE1. The weakness of the effect of α-syn on BACE1 raises 
the question of whether it is physiological. Samples of rat brain striatum allowed the 
relationship between physiological levels of α-syn and BACE1 to be probed. The individual 
animals had a range of basal α-syn expression levels in the striatum of one hemisphere, which 
were slightly increased in the striatum of the other hemisphere where the neighbouring 
substantia nigra was transduced with α-syn lentivirus. Importantly, there was a significant 
correlation between BACE1 and α-syn expression across the individual animals in all samples, 
regardless of whether or not α-syn levels were artificially induced. The correlation of BACE1 
expression with physiological levels of α-syn expression, in vivo, gives credibility to data 
obtained from α-syn overexpressing cell models. 
Mutant α-syn SH-SY5Y lines allowed the role of α-syn N-terminal sequences to be 
explored, in terms of changes to ADAM10 and BACE1 expression. Deletion of residues 2-9 
or 71-82 were shown in Chapter 3 to promote amyloidogenic processing, relative to the 
wildtype. Consistent with this, ADAM10 expression was unaffected, BACE1 transcription and 
protein expression was increased, and γ-secretase activity also enhanced in Δ2-9 α-syn cells, 
and to a limited extent Δ71-82 cells. The transcriptional changes are interesting given that 
α-syn has been proposed to regulate gene expression. α-Syn has been shown to reduce the 
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histone acetyltransferase activity of p300 (Jin et al. 2011), which is a co-activator of the 
BACE1 and PS1 promoters (Lu et al. 2014). PS1 is the major catalytic component of γ-
secretase, so a loss-of-function of α-syn could hypothetically increase BACE1 transcription 
and γ-secretase activity, via increased p300 activity. Besides the transcriptional changes seen 
in Δ2-9 cells, post-transcriptional increases in BACE1 expression are also seen in the mutant 
lines E46K, S129A, and S129D. The disease-associated point mutations did not affect 
ADAM10 expression or γ-secretase activity, so elevated BACE1 protein levels could be 
responsible for their increased amyloidogenic processing of APP. However, BACE1 protein 
levels do not perfectly match the changes in amyloidogenic processing measured by APP-
Gal4. A30P and A53T significantly increased APP-Gal4 cleavage, but not BACE1 protein 
expression. Furthermore, S129A and S129D had opposing effects on APP-Gal4 cleavage, but 
the same effects on BACE1 protein expression. Potentially, these mutants may additionally 
alter the sub-cellular localisation of APP with β-/γ-secretase, which was not studied.  
Further investigation is clearly needed to pinpoint the effects of mutating α-syn upon APP 
processing. As yet, one can only conclude that truncations of the α-syn N-terminus activate 
APP amyloidogenic processing through a distinct mechanism compared with wild-type α-syn. 
In contrast, the point mutations largely have the same effects as wild-type α-syn. Both 
mechanisms appear to converge on BACE1, increasing BACE1 protein levels. Although not 
perfect consistent, BACE1 protein expression most closely follows APP-Gal4 cleavage, out 
of the assays used for secretase expression and activity. Thus the upregulation of BACE1 
expression by α-syn is worth further investigating, to probe the underlying mechanisms.  
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5.1.1 Narrowing the focus onto BACE1 expression 
In Chapter 3, increased amyloidogenic processing of APP was demonstrated in α-syn 
overexpressing cells. A number of factors can affect amyloidogenic processing of APP, 
including increased β-secretase (BACE1) and γ-secretase activity, or decreased α-secretase 
(ADAM10) activity. Furthermore, increased localisation of APP with lipid rafts and BACE1-
positive endosomes can increase amyloidogenic processing. Chapter 4 showed that BACE1 
protein levels appear to follow the same pattern as levels of amyloidogenic APP processing, 
and that BACE1 expression correlates with α-syn expression. γ-Secretase activity was not 
enhanced, and expression of mature surface-localised ADAM10 was not reduced. The 
localisation of APP with BACE1 was not studied, and if altered could have a major effect on 
amyloidogenic processing. However, BACE1 protein levels appear to be a convenient and 
reproducible “readout” for the effects of α-syn on the amyloidogenic pathway. The purpose of 
the current chapter is to explore the mechanisms by which α-syn may promote β-secretase-
mediated processing of APP, using BACE1 expression to test their likely involvement.  
A comprehensive literature search was performed to determine known regulators of 
BACE1 protein levels, and the cell processes that activate these regulators. The major cell 
processes that control BACE1 protein levels are largely stress-induced, and can be grouped 
into four themes: protein degradation, intracellular calcium signalling, oxidative stress, and 
endoplasmic reticulum (ER) stress. The following literature review will outline the four 
themes of BACE1 regulation, and additionally the literature supporting a role for α-syn in 
each.  
CHAPTER 5: POTENTIAL MECHANISMS UNDERLYING THE EFFECT OF α-SYN 
ON BACE1 
106 
5.1.2 Proteasomal and lysosomal degradation pathways 
5.1.2.1 BACE1 is degraded primarily, but not exclusively, by the lysosome 
BACE1 is targeted to plasma membranes by the secretory pathway, yet its activity as a 
β-secretase is greatest in the acidic environment of endosomes. A dileucine motif directs 
BACE1 to be sorted to endosomes, where it may then be recycled back to the plasma 
membrane or degraded by the lysosome (Koh et al. 2005). Lysosomal degradation additionally 
requires ubiquitination of the dileucine motif, which recruits GGA3 (Golgi-Associated, 
Gamma Adaptin Ear Containing, ARF Binding Protein 3) for lysosomal targeting of BACE1 
(Kang et al. 2012). GGA3 levels are depleted in AD brain samples, most likely due to cleavage 
by caspase-3 (Tesco et al. 2007). BACE1 is relatively stable with a half-life of 12-16 hours, 
so recycling may occur a number of times before degradation (Huse et al. 2000). Lysosomal 
degradation of BACE1 is clearly the main route of clearance, yet BACE1 has also been 
reported to accumulate in the presence of proteasomal inhibitors (Qing et al. 2004). This result 
has not been corroborated independently (Koh et al. 2005), but most likely proteasomal 
inhibition is adequately compensated for by induction of autophagy (Shen et al. 2013; Ding et 
al. 2003), which would have a greater effect on BACE1 protein levels. The clearest evidence 
for proteasomal degradation of BACE1 is recent work on the E3 ubiquitin ligase CHIP 
(C-terminus of Hsc70 Interacting Protein). CHIP overexpression was found to decrease 
BACE1 protein levels, and could be prevented by proteasome inhibition (Singh & Pati 2015).  
5.1.2.2 α-Syn impairs the proteasome and is linked to defective macroautophagy 
α-Syn may indirectly impact upon BACE1 levels through impairment of protein 
degradation pathways. Proteasome block by soluble oligomers of α-syn has been demonstrated 
in vitro, using both PC12 cell-derived mutant protein (Emmanouilidou, Stefanis, et al. 2010) 
and WT recombinant oligomers (Snyder et al. 2003; Lindersson et al. 2004). In the context of 
stably-overexpressing cell lines, WT α-syn has little effect on the proteasome, whereas 
aggregate-promoting mutations A53T and A30P strongly impair proteasomal activity 
(Stefanis et al. 2001; Tanaka et al. 2001). Proteasome inhibition may thus be an aggregate-
specific phenomenon. More importantly in the case of BACE1, over-expressed α-syn is also 
hypothesised to impair the autophagy-lysosome pathway (Perrett et al. 2015). A number of 
α-syn transgenic cells and animal models have been found to accumulate autophagosomes, but 
the interpretation of various studies is contradictory, citing either defective autophagic flux or 
increased autophagosome formation. The subject is reviewed excellently in (Xilouri et al. 
2016). Convincing evidence of defective autophagy was found in Lewy body dementia brains 
(Crews et al. 2010). Neurons with particularly high α-syn levels had elevated mToR, a negative 
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regulator of autophagy. α-Syn transgenic mice additionally exhibited higher mToR levels, and 
pharmacological inhibition of mToR led to a redistribution of α-syn, and ameliorated dendritic 
pathology (Crews et al. 2010). The mechanism for which α-syn affects autophagy is not clear. 
Insoluble α-syn aggregates are resistant to degradation and impair autophagosome clearance 
in cells (Tanik et al. 2013), but it is likely that unaggregated α-syn affects the early formation 
of autophagosomes (Xilouri et al. 2016). One proposed mechanism is through impaired vesicle 
fusion events in the cell (Gitler et al. 2008; Perrett et al. 2015). A number of α-syn-induced 
vesicle trafficking deficits in PD models have shown to be rescued by overexpression of Rab 
GTPases (Cooper et al. 2006; Breda et al. 2015), including Rab1a in the case of autophagy 
(Winslow et al. 2010). In transgenic mice, A30P α-syn co-immunoprecipitates with multiple 
Rab GTPases, suggesting a functional connection (Dalfó et al. 2004).  
5.1.3 Dysregulated intracellular calcium signalling 
5.1.3.1 BACE1 transcription is activated by high intracellular concentrations of calcium  
Intracellular calcium is one potential cell mediator between α-syn and BACE1. The BACE1 
promoter appears to be activated by calcium signalling. Increased intracellular calcium 
activates calcineurin, which dephosphorylates NFAT (Nuclear Factor of Activated T-cells). 
The neuron-specific NFAT1/3 isoforms, and the astrocyte-specific NFAT4 isoform, have all 
been shown to bind the BACE1 promoter and increase BACE1 transcription (Mei et al. 2015; 
Jin et al. 2012; Cho et al. 2008). Calcium also activates calpain proteases. Overexpression of 
m-calpain increases BACE1 expression in cell lines, whereas calpain inhibition reduces 
BACE1 expression and β-amyloid deposition in a transgenic mouse model of AD (Liang et al. 
2010). The effect of calpain on BACE1 may be due to increased formation of p25, a product 
of calpain processing of p35 (Liang et al. 2010). p25/cdk5 complexes activate STAT3, a 
transcriptional activator of BACE1 (Wen et al. 2008).  
5.1.3.2 α-Syn may have a physiological connection to calcium signalling 
The physiological role of α-syn in the cell has not been fully defined. It has been suggested 
that α-syn may regulate intracellular calcium signalling, based on two observations. Firstly, 
the calcium-activated protein calmodulin (CaM) binds and co-immunoprecipitates with α-syn. 
This interaction is enhanced by α-syn overexpression in SK-N-SH cells and transgenic mouse 
brain (Yang et al. 2013). Detailed NMR structural analysis shows that the acetylated 
N-terminus of α-syn binds directly to calcium-bound CaM, and that this may act as a switch 
releasing α-syn from membrane-binding (Gruschus et al. 2013; Lee et al. 2002). The purpose 
of the interaction with CaM is not clear, but Yang et al. (2013) suggest that the complex 
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activates Src kinase, which leads to phosphorylation and inhibition of protein phosphatase 2A 
(Yang et al. 2013). Secondly, α-syn may regulate calcium release from the ER. Cali et al. 
(2012) showed that α-syn overexpression in cell lines enhances the mitochondrial uptake of 
calcium, during agonist-stimulated release of ER calcium stores. This appears to be due to 
increased tethering of the ER and mitochondrial membranes, which occurs in WT but not 
C-terminal truncated α-syn cells (Calì et al. 2012).  
5.1.3.3 α-Syn overexpression disturbs intracellular calcium homeostasis 
α-Synucleinopathy models exhibit abnormal calcium homeostasis. The application of 
recombinant soluble oligomers of α-syn to cells has been repeatedly shown to create cytosolic 
calcium spikes and activate calcineurin (Danzer et al. 2007; Schmidt et al. 2012; Martin et al. 
2012). Stable overexpression of α-syn in SH-SY5Ys results in greater calcium entry after 
plasma membrane depolarisation. This result was obtained independently by two groups, but 
they did not agree on whether basal cytosolic calcium levels were enhanced (Hettiarachchi et 
al. 2009; Furukawa et al. 2006). Yeast studies have shown that α-syn-induced calcium spikes 
originate from the release of intracellular calcium stores (Caraveo et al. 2014; Büttner et al. 
2013). Caraveo et al. generated yeast strains expressing different inducible levels of α-syn. 
Upon induction, intracellular calcium levels increased dose-dependently with the level of 
α-syn expression, and were prolonged in the most toxic strain. Furthermore, the importance of 
calcium-induced calcineurin activation was demonstrated in primary rat neurons. Moderate 
levels of the calcineurin inhibitor FK506 rescued rat neurons from the toxicity induced by 
virally transduced α-syn (Caraveo et al. 2014). Calcineurin activation is relevant to BACE1 
transcriptional regulation, as mentioned previously, due to the downstream activation of 
transcription factor NFAT. In α-syn transgenic mice, the increased activation of NFAT3 and 
NFAT4 was confirmed by their greater nuclear staining. Increased NFAT4 nuclear staining 
was also detected in human PD and DLB brain sections, particularly in areas associated with 
α-syn pathology (Caraveo et al. 2014). 
5.1.4 Oxidative stress 
5.1.4.1 The BACE1 promoter is activated by oxidative stress 
It has long been known that BACE1 expression follows β-amyloid levels, implying the 
existence of a positive feedback loop. Aβ42 is likely to mediate positive feedback. Disease-
associated mutations of presenilin-1 (PS1) that increase the formation of Aβ42 species have 
been shown to increase BACE1 expression (Giliberto et al. 2009). Oxidative stress also 
increases PS1 and γ-secretase activity, which appears to promote BACE1 expression in a 
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mechanism involving β-amyloid. Crucially, oxidative stimuli do not enhance BACE1 
expression in PS1 KO mouse embryonic fibroblasts, unless they are transfected with PS1 
(Tamagno et al. 2008; Jo et al. 2010). The γ-secretase inhibitor DAPT also reduces BACE1 
expression in oxidative stress-stimulated SH-SY5Ys and unstimulated AD model mice (Jo et 
al. 2010). The effect of oxidative stress on BACE1 may be partly mediated by transcriptional 
activation of the BACE1 promoter by NF-κB or AP-1. Pharmacological inhibition of NF-κB 
abrogates Aβ-induced or 27-hydroxycholesterol-induced BACE1 transcription (Buggia-
Prevot et al. 2008; Marwarha et al. 2013). Furthermore, a polyphenol inhibitor of BACE1 
transcription has been found to work by disrupting the p65 complex of NF-κB (Zheng et al. 
2015). However, Tamagno et al. (2008) attribute oxidative stress-induced BACE1 expression 
to the c-jun N-terminal kinase (JNK) pathway, and activation of the transcription factor AP-1. 
Use of a JNK-1 inhibitor peptide, or JNK KO cell model prevents induction of BACE1 mRNA 
by oxidative stress (Tamagno et al. 2008). 
5.1.4.2 Oxidative stress induces de-repression of BACE1 translation  
Promoter activation of BACE1 by oxidative stress cannot be the full story, given that 
BACE1 is normally translationally repressed by a CG-rich 5’-UTR (Lammich et al. 2004). 
Phosphorylation of eIF2α by eIF2 kinases during conditions of cell stress allows improved 
BACE1 translation (O’Connor et al. 2008). The eIF2 kinase PKR (protein kinase R) controls 
cell survival in response to a variety of signals, including oxidative stress, calcium stress, and 
ER stress, as reviewed in (Marchal et al. 2014). PKR activation by virus dsRNA has been 
shown to lead to β-amyloid accumulation (ILL-Raga et al. 2011), and PKR genetic silencing 
in mice prevents the induction of BACE1 expression by oxidative stress or neuro-
inflammation (Mouton-Liger et al. 2015; Carret-Rebillat et al. 2015). Hydrogen peroxide-
stimulated SH-SY5Ys exhibit phosphorylation of eIF2α and PKR activation, in addition to 
BACE1 protein upregulation. In this scenario, pharmacological inhibition of PKR abrogates 
BACE1 expression, whereas inhibition of eIF2α phosphatase activity potentiates BACE1 
expression (Mouton-Liger et al. 2012).  
There is far from a consensus on the relative contribution of transcriptional or translational 
pathways, upregulating BACE1 in response to stress. Two studies challenge the importance 
of eIF2α phosphorylation in regulating BACE1 expression. In the first study, the genetic 
reduction of eIF2α phosphorylation was achieved in primary neurons and AD model mice by 
two approaches: overexpression of GADD34, which targets the phosphatase to eIF2α, or 
knock-in of non-phosphorylatable S51A eIF2α. Yet low eIF2α phosphorylation failed to 
prevent the induction of BACE1 protein levels in response to Aβ oligomers (Sadleir et al. 
2014). The study convincingly demonstrates that BACE1 expression is not entirely dependent 
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upon translational de-repression by eIF2α. However, it does not prove that eIF2α does not 
have a significant role in BACE1 expression, since silencing eIF2α would likely upregulate 
other stress pathways, including those that regulate BACE1 transcription. The second 
independent study, used primary neurons infected with adenovirus containing tagged BACE1. 
In response to Aβ oligomers, the adenovirus BACE1 protein increased. Interestingly, this 
exogenous BACE1 did not have a 5’-UTR for eIF2α to control, or an ordinary promoter, 
therefore the authors concluded that the effect was post-translational (Mamada et al. 2015). 
Oxidative stress-induced changes to BACE1 subcellular localisation have been observed 
previously, and may provide another layer of regulation to β-secretase activity (Tan et al. 
2013). Clearly the literature detailing the control of BACE1 expression and activity in 
neurodegenerative disease is still incomplete. 
5.1.4.3 α-Syn enhances oxidative stress 
One point of consensus is that oxidative stress clearly has a stimulatory effect on BACE1-
mediated processing of APP. α-Syn is strongly linked to oxidative stress. Enhanced oxidative 
stress has been demonstrated in α-syn overexpressing cell models, measured by enhanced free 
radical production and levels of antioxidant protein glutathione (Hsu et al. 2000; Junn & 
Mouradian 2002). Furthermore, in α-syn transgenic mice, elevated transcription of Nrf2-
regulated antioxidant enzymes has been detected, indicating a response to oxidative stress 
(Béraud et al. 2013). Cremades et al. (2012) attribute oxidative stress to α-syn oligomers, 
which they created recombinantly and applied to α-syn transgenic rat neurons. Cytoplasmic, 
but not mitochondrial, ROS production was induced by oligomers, but not monomers or fibrils 
(Cremades et al. 2012). Iron and copper chelators are able to block the α-syn oligomer-induced 
oxidative stress of transgenic rat neurons, and additionally iPSC-derived SNCA triplication 
human neurons (Deas et al. 2016). The clear implication is that the effect of α-syn aggregates 
is mediated by metals. Supporting this, α-syn is a ferrireductase and uses copper redox cycling 
to aid iron reduction. Fe(II) can produce hydrogen peroxide through the Fenton reaction if not 
adequately sequestered (Davies, Moualla, et al. 2011; Davies, Wang, et al. 2011). Hydrogen 
peroxide by copper-bound α-syn has been detected independently in vitro (C. Wang et al. 
2011).  
5.1.4.4 α-Syn indirectly promotes mitochondrial production of free radicals 
The mitochondrial respiratory chain is responsible for most of the free radical production 
in cells, and this increases if mitochondrial homeostasis is disturbed. Impairs mitochondrial 
function in α-syn transgenic mice is apparent in the absence of α-syn toxic oligomers or 
insoluble aggregates (Sarafian et al. 2013). Several α-syn models have been identified to 
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contain mitochondria with disturbed respiration (Devi et al. 2008; Luth et al. 2014), 
fragmented networks (Nakamura et al. 2011), and reduced import of respiratory substrates 
through the VDAC and TOM40 channels (Rostovtseva et al. 2015; Bender et al. 2013). Yet it 
appears increasingly likely that ER calcium stores mediate the effect of α-syn on mitochondrial 
function (Su et al. 2010). Mitochondria are coupled to ER membranes, where they take up ER-
released calcium in order to sense and respond to local energy demands. High calcium release 
stimulates oxidative phosphorylation and free radical production in ER-tethered mitochondria 
(Hayashi et al. 2009). Wildtype α-syn is localised to sub-domains of the ER membrane that 
are tethered to mitochondria (Guardia-Laguarta et al. 2014). Indeed, increased calcium transfer 
from the ER to mitochondria has been shown to occur in α-syn overexpressing cells (Calì et 
al. 2012). α-Syn-induced free radical production in yeast can be prevented by depleting ER 
calcium stores, through genetic reduction of functioning PMR1. PMR1 is a Ca2+-ATPase 
transporter of the Golgi and ER (Büttner et al. 2013). 
5.1.5 Endoplasmic reticulum stress 
5.1.5.1 BACE1 translation is enhanced by the eIF2 kinase PERK 
Translation of BACE1 is controlled by the phosphorylation status of the translation 
initiation factor eIF2α, as discussed previously. A number of eIF2 kinases phosphorylate eIF2α 
in response to different intracellular stress pathways, including PKR, GCN2 (general control 
non-derepressible 2 kinase), HRI (heme-regulated inhibitor kinase), and PERK (PKR-like ER 
kinase) (O’Connor et al. 2008). PKR has been associated with oxidative stress-mediated 
translational regulation of BACE1 expression (Mouton-Liger et al. 2012). HRI could be 
involved in glutamatergic stimulation of BACE1 expression in hippocampal neurons, 
activated in response to nitrous oxide production (ILL-Raga et al. 2015). GCN2 is thought to 
be activated by nutrient deprivation, and is not thought to be important in animal models of 
AD. Genetic depletion of GCN2 in 5xFAD AD model mice actually resulted in enhanced 
eIF2α phosphorylation and BACE1 protein expression. The unexpected result was discovered 
to coincide with over-activation of PERK, which only occurred in GCN2-/- 5xFAD mice and 
not GCN2-/- mice (Devi & Ohno 2013). PERK is localised to the ER membrane and is activated 
by ER stress, where ER chaperone-PERK complexes dissociate to deal with an excess of 
misfolded protein. PERK phosphorylation of eIF2α is a key signalling pathway of the 
‘unfolded protein response’ (Hoozemans et al. 2012). The importance of PERK to elevated 
BACE1 expression was subsequently confirmed, using the 5xFAD mouse model of AD. In 
PERK +/- 5xFAD mice, the genetic depletion of PERK restores BACE1 expression almost to 
wildtype levels (Devi & Ohno 2014). On the other hand, in a different AD mouse model the 
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conditional knockout of PERK did not reduce BACE1 expression. APP-PS1 mice with 
reduced PERK expression exhibited less eIF2α phosphorylation in the hippocampus and 
prefrontal cortex, but no change to BACE1 (Ma et al. 2013). Ostensibly, this would support 
the study showing no effect of eIF2α genetic depletion upon BACE1 expression (Sadleir et al. 
2014). This conclusion is questionable, since the APP-PS1 mouse does not have higher 
BACE1 expression than the wildtype mouse to start with, in contrast with the aggressive 
5xFAD model (Ma et al. 2013; Devi & Ohno 2014). 
5.1.5.2 α-Syn causes ER stress, resulting in activation of PERK 
ER stress is a ubiquitous feature of protein misfolding diseases. It is therefore unsurprising 
that PERK phosphorylation and other markers of the unfolded protein response are higher in 
PD and AD brains relative to age-matched controls (Hoozemans et al. 2012; Hoozemans et al. 
2007; Selvaraj et al. 2012). In the synucleinopathies, α-syn misfolding may play a role in 
perpetuating ER stress. A study of PERK activation in PD brains showed that phosphorylated 
PERK was only present in neurons with α-syn immunostaining, although the majority of 
α-syn-positive neurons were free of detectable phosphorylated PERK (Hoozemans et al. 
2007). ER stress has been studied more extensively in cell and animal models of 
synucleinopathy. Wildtype α-syn, in addition to more easily misfolded mutant forms such as 
A53T or 1-120, commonly induces ER stress in transgenic neuronal cell lines with stable or 
inducible expression (Belal et al. 2012; Smith et al. 2005; Bellucci et al. 2011; Colla et al. 
2012). This appears to be accompanied by activation of PERK signalling, where studied 
(Bellucci et al. 2011). Wildtype and A53T α-syn transgenic rodents also demonstrate increased 
activation of the PERK-eIF2α signalling pathway in two independent studies (Gorbatyuk et 
al. 2012; Belal et al. 2012). A third did not detect enhanced eIF2α phosphorylation, instead 
finding that the XBP-1 branch of the unfolded protein response was activated (Colla et al. 
2012). It would be unwise to interpret too much from individual studies, because the unfolded 
protein response is complex and dynamic. The relative activation of PERK-eIF2α and the 
IRE-1-XBP-1 pathways can vary substantially between experimental systems and over time 
(Hetz et al. 2015).  
5.1.5.3 α-Syn- induced ER stress may arise from defective ER-Golgi transport 
Delayed or blocked ER-Golgi transition has been uncovered in studies of wildtype α-syn 
overexpressing neuronal cell and yeast models (Thayanidhi et al. 2010; Oaks et al. 2013; 
Cooper et al. 2006). One outcome may be reduced plasma membrane localisation of dopamine 
transporter DAT, instead accumulating within ER microsomes of α-syn neuroblastoma cells 
(Oaks et al. 2013). In yeast models, α-syn expression dose-dependently impairs ER-Golgi 
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trafficking and activates ER stress and growth arrest. Interestingly, a reduction in α-syn 
toxicity was achieved by overexpressing genes that promote ER-Golgi transition, particularly 
orthologs of Rab-GTPases Rab1, Rab3a, and Rab8a (Cooper et al. 2006; Gitler et al. 2008). 
α-Syn may directly interact with and sequester Rab protein. Rab8a, a Rab-GTPase essential 
for trans-Golgi transport, co-immunoprecipitates with α-syn from A30P transgenic mouse 
brain homogenates (Dalfó et al. 2004). NMR studies show Rab8a binding directly to the 
C-terminal tail of α-syn, and overexpression of its ortholog in α-syn transgenic Drosophila was 
neuroprotective (Yin et al. 2014). Disruption of ER-Golgi transition could be through 
mislocalisation of Rab-GTPases, but there is also evidence that α-syn directly impacts vesicle 
docking or fusion through SNARE complexes. α-Syn binds to ER/Golgi SNAREs in vitro 
(Burré et al. 2014; Burré et al. 2010; Thayanidhi et al. 2010). Although non-aggregated α-syn 
is an aid to SNARE-complex formation, large toxic oligomers of α-syn appear to inhibit 
SNARE-mediated vesicle docking (Burré et al. 2010; Choi et al. 2013). 
5.2 Aims 
It is clear from the literature that there are a number of likely routes by which α-syn 
overexpression can be hypothesised to impact BACE1 levels in a cell. The aim of this chapter 
is to uncover the cellular pathway that drives elevated BACE1 expression in α-syn-
overexpressing SH-SY5Ys. Intracellular pathways, selected from the literature, were probed 
for their contribution to BACE1 expression, and compared in α-syn SH-SY5Ys with empty 
vector cells. Protein clearance, calcium homeostasis, oxidative stress, and ER stress will 
separately be considered for their likelihood of being involved in the mechanism. 
The following experiments will seek to answer a number of questions, which will be 
referred to in the discussion:  
 Is there impaired degradation of BACE1 in α-syn cells, and is this likely to be 
responsible? 
 Does reducing intracellular calcium release in α-syn cells restore BACE1 protein 
levels? 
 Is there enhanced oxidative stress in α-syn cells? 
 Could BACE1 expression be upregulated by transcription factors NF-κB or AP-1, 
in α-syn cells? 
 Is there increased activation of eIF2α phosphorylation in α-syn cells, and could this 
be upregulating BACE1 translation? 
 Does PKR mediate translational upregulation of BACE1 in response to oxidative 
stress in α-syn cells? 




5.3.1 Perturbation of protein degradation pathways leads to higher accumulation of BACE1 
in α-syn SH-SY5Ys 
Elevated BACE1 protein levels in WT α-syn SH-SY5Ys could be a result of increased 
expression. However, there is another possibility, which is that degradation of BACE1 and/or 
other proteins is impaired. BACE1 is known to be degraded by macroautophagy and by the 
ubiquitin-proteasome system. In some cell models α-syn has been shown to inhibit the 
proteasome, but no link to impaired macroautophagy has been made in the literature. The 
hypothesis that α-syn reduces BACE1 degradation was tested by incubating WT α-syn and 
empty vector SH-SY5Ys with chemical inhibitors of proteasome and lysosome function. 
Proteasomal degradation was inhibited with clastolactacystin-β-lactone (CLβL), and 
lysosomal acidification was inhibited with ammonium chloride (NH4Cl). BACE1 protein 
levels were measured by western blotting. Accumulation of BACE1 in response to an inhibitor 
would indicate that that process is indispensable for BACE1 degradation. The magnitude of 
accumulation is controlled by the existing rate of BACE1 clearance, but also the rate of 
BACE1 synthesis. To control for changes in BACE1 synthesis, the protein synthesis inhibitor 
cycloheximide (CHX) was included. CHX alone should lead to decreased BACE1 levels, due 
to clearance, and when combined with CLβL and NH4Cl there should be no change in BACE1 
levels. However, CHX failed to prevent BACE1 accumulating in the presence of combined 
autophagy and proteasome inhibitors over the six-hour experiment, which means that 
translation was not inhibited. The control for protein synthesis was therefore a failure, which 
affects the conclusions of the experiment. 
In empty vector cells, proteasome and lysosomal inhibitors were used individually and in 
combination to set a benchmark of how BACE1 levels respond. As expected, analysis of 
variance indicates that BACE1 protein levels in empty vector cells differed significantly 
between the treatment groups (F value= 6.79 for 5 and 12 degrees of freedom, p< 0.01). The 
significant changes, calculated by a post-hoc Tukey HSD test, are outlined in Figure 5.1a. An 
important finding is that lysosome inhibition and proteasome inhibition on their own did not 
significantly induce BACE1 accumulation. However, combined proteasome and autophagy 
inhibition caused a very large accumulation of BACE1. The simplest explanation for this is 
that BACE1 can be degraded by either the lysosome or the proteasome, within SH-SY5Ys, 
and one will compensate for the other if inhibited. Yet the lysosome is likely to be the preferred 
and more effective route, since its inhibition appeared to lead to a small accumulation of 
BACE1.  
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The treatments were run in parallel with WT α-syn cells, to discover whether 
proteasome/lysosomal inhibitors had a similar effect on BACE1 protein levels. Between the 
treatment groups there were once again significant differences in BACE1 protein levels, 
shown by analysis of variance (F value= 7.31 for 5 and 12 degrees of freedom, p< 0.01). Figure 
5.1b illustrates that the single most significant result was the ability of lysosome inhibitor 
ammonium chloride (NH4Cl) to induce huge BACE1 accumulation, greater than any other 
treatment. On average, NH4Cl had a greater effect upon BACE1 levels in WT cells (~2x) than 
empty vector cells (~1.5x). As well as being more sensitive to lysosome inhibition, WT cells 
appear to be slightly sensitive to proteasome inhibition, resulting in a small increase in 
BACE1. This was not significant in post-hoc tests, but appears distinct in Figure 5.1b. Note 
that in combination, lysosome and proteasome inhibition did not further potentiate BACE1 
levels. Potentially the combined inhibition may have led to high cell death in the WT α-syn 
cells, but cell viability was not investigated.  
In summary, WT α-syn cells appear more sensitive to both proteasome and lysosome 
inhibition. Most likely the latter has the greatest effect because BACE1 is preferentially 
degraded by the lysosome. There are two possible interpretations of the distinctive response: 
either (i) increased BACE1 protein synthesis leads to it accumulating faster when protein 
degradation is perturbed, or (ii) lysosomal and proteasomal degradation are both impaired. The 
protein synthesis control did not work, so the former cannot be ruled out. Without further 
investigations of autophagic or proteasomal health it is not possible to confirm the latter. Thus 
the experiment once again highlights the influence of α-syn upon BACE1 levels, but is 
inconclusive as to the mechanism. 
 




Figure 5.1 Accumulation of BACE1 protein with proteasome and lysosome inhibitors. 
(A) Empty vector SH-SY5Ys, (B) WT α-syn SH-SY5Ys. Protein synthesis was inhibited with 
100 µg/ml cycloheximide (CHX), proteasomal degradation was inhibited with 20 µM 
clastolactacystin-β-lactone (CLβL), and lysosomal acidification was inhibited with 2 mM 
NH4Cl, all treatments for 6 hours. Whole cell lysates were tested for BACE1 and α-tubulin by 
western blotting. Mean BACE1 OD: α-tubulin OD for 3 independent experiments ± S.E. 
Probability values calculated by one-way ANOVA with post-hoc Tukey’s HSD, with all 
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5.3.2 BACE1 protein expression is not potentiated by increased calcium signalling 
α-Synuclein is known to strongly influence the balance of intracellular calcium levels in 
cells where it is over-expressed (Hettiarachchi et al. 2009). In particular, a recent study showed 
that α-syn expression dose-dependently increases the release of calcium ions from intracellular 
stores in yeast strains (Caraveo et al. 2014). Calcium is also known to play a role in the 
induction of BACE1 transcription, through downstream signalling pathways. Calcium spikes 
trigger calcineurin-mediated activation of transcription factors NFAT3/4 that bind the BACE1 
promoter (Mei et al. 2015; Jin et al. 2012), and also a poorly-defined effect mediated by 
calpains (Liang et al. 2010). If α-syn increases the tendency of intracellular calcium stores to 
be released, then it could promote BACE1 expression. To support this hypothesis, the effect 
of calcium on BACE1 needed to first be confirmed. Chemical inducers of intracellular 
calcium, predicted to increase BACE1 expression, and chemical inhibitors of calcium release 
or signalling, predicted to reduce BACE1 expression, were used.  
BACE1 protein levels were measured in WT α-syn SH-SY5Ys following 2 hours of 
chemical or drug treatment. This was sufficient time to see changes to BACE1 transcription 
or translation, but short enough that cell viability was not severely reduced by calcium toxicity. 
Intracellular calcium was increased by either the calcium ionophore A23187 (Jin et al. 2012), 
or by potassium chloride (KCl) treatment, which depolarises the plasma membrane and 
activates voltage-gated Ca2+ channels (Sousa et al. 2013). Small rises in intracellular calcium 
activates ryanodine receptors on the ER, which are calcium-activated Ca2+ channels, leading 
to release of intracellular calcium stores. This process was inhibited by treatment with 
dantrolene, which blocks activation of ryanodine receptors. Another drug, FK-506, was used 
to inhibit calcineurin activation. After 2 hours, no individual drug treatment significantly 
altered BACE1 levels compared with the control (Figure 5.2a). Yet collectively the drug 
treatments did significantly modulate BACE1, shown by analysis of variance (F value= 5.33 
for 4 and 15 degrees of freedom, p< 0.01). Post-hoc analysis reveals a pattern whereby the 
calcium signal-inducing treatments, KCl and A23187, provided significantly different BACE1 
expression to the calcium signal-suppressing treatments, dantrolene and FK-506. 
Unexpectedly, the pattern is in opposition to the hypothesis, because calcium signal 
suppressors resulted in greater BACE1 protein expression than calcium signal inducers.  
The effects of calcium-modulating compounds on BACE1 were studied in this instance 
within WT α-syn SH-SY5Ys, because it was expected that the elevated BACE1 levels would 
more clearly show calcium-induced differences. Empty vector cells were not studied to the 
same extent, but one compound, dantrolene, was used for comparison with WT α-syn cells.  




Figure 5.2 Intracellular calcium appears to negatively regulate BACE1 protein levels. 
(A) WT α-syn SH-SY5Ys treated with pharmacological and chemical modulators of 
intracellular calcium, for 2 hours. Depolarising agent potassium chloride (KCl), 50 µM, and 
ionophore A23187, 1 µM, were used to depolarise the plasma membrane and increase calcium 
influx into the cell. Dantrolene, 10 µM, was used to inhibit calcium-induced calcium release 
from the ER. FK-506, 1 µM, was used to inhibit calcium-activated calcineurin signalling. (B) 
Empty vector SH-SY5Ys treated with 10 µM dantrolene for 2 hours. Whole cell lysates were 
tested for BACE1 and α-tubulin by western blotting. Mean BACE1 OD: α-tubulin OD for 4 
independent experiments ± S.E. Probability values calculated by one-way ANOVA with post-
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BACE1 levels were slightly enhanced in dantrolene-treated empty vector cells (Figure 
5.2b). The difference is not significant, but follows the same direction as WT α-syn SH-
SY5Ys. It seems likely, therefore, that α-syn does not increase BACE1 expression through 
changes in intracellular calcium. 
5.3.3 WT α-syn increases oxidative stress  
BACE1 protein expression is known to be upregulated by a variety of oxidative stressors, 
so it was hypothesised that over-expressed α-syn may be acting as an oxidative stress 
generator. α-Syn is a copper-binding protein with iron-reducing activity (Davies, Moualla, et 
al. 2011), and has been associated with oxidative stress in the literature. For example, α-syn 
potentiates copper-induced or dopamine-induced oxidative stress (Xu et al. 2002). Basal levels 
of oxidative stress in α-syn overexpressing cells are of more relevance to this thesis, but have 
not been described in the literature. To measure oxidative stress in α-syn SH-SY5Ys, the cells 
were loaded with a fluorescent molecular probe for hydrogen peroxide (CM-H2DCFDA) and 
monitored for 60 minutes (Figure 5.3a). α-Syn significantly increased basal levels of hydrogen 
peroxide production, although the effect is small. In the literature, the redox activity of α-syn 
negatively correlates with its α-helical folding. Theoretically, disruption of α-syn folding with 
mutations could therefore enhance oxidative stress (Zhou et al. 2013). To test this hypothesis, 
Δ2-9 and E46K mutant α-syn overexpressing SH-SY5Ys, were additionally assayed for 
oxidative stress (Figure 5.3a). Compared with WT α-syn SH-SY5Ys, neither significantly 
increased oxidative stress, yet hydrogen peroxide production appeared to be higher in Δ2-9 
α-syn cells. 
A different ferrireductase enzyme, Steap3, was compared with α-syn, to see whether 
reduced iron production would have a measurable effect on oxidative stress in cells. Steap3 
was previously generated by cloning the human Steap3 sequence (RefSeq accession number 
NG_042823.1) into a pcDNA3.1(+) vector, and stably transfected into SH-SY5Ys (Figure 
5.3b). Steap3 overexpression led to more than a doubling of the rate of hydrogen peroxide 
production (Figure 5.3a). Ferrireductase activity can be inferred to significantly affect ROS 
production in cells, and therefore could potentially explain oxidative stress in α-syn 
SH-SY5Ys.  
  






Figure 5.3 Overexpression of the ferrireductases α-syn and Steap3 increases oxidative 
stress. (A) Basal rates of ROS production in WT and mutant α-syn SH-SY5Ys, and Steap3 
SH-SY5Ys. Oxidative stress was measured in live unstimulated cells using a fluorometric 
CM-H2DCFDA probe for hydrogen peroxide. Mean rate of fluorescence increase ± S. E. for 4 
independent experiments. * p<0.05 relative to the empty vector, no significant differences 
exist between mutant and WT α-syn lines, calculated by Student’s t-test. (B) Steap3 expression 
in Steap3 SH-SY5Ys, compared with the empty vector. Western blotting was used to test 
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5.3.4 BACE1 expression is not upregulated by NF-κB or AP-1 in SH-SY5Ys 
A wealth of literature exists on the induction of BACE1 expression by oxidative stress. 
Two transcription factors appear to mediate oxidative stress-induced BACE1 transcription: 
NF-κB and AP-1. To determine whether α-syn could potentially increase BACE1 levels 
through oxidative stress, the abilities of NF-κB and AP-1 to induce BACE1 expression were 
investigated using small molecule inhibitors/activators. 
In the literature, activation of NF-κB leads to an induction of BACE1 transcription in 
SH-SY5Ys (Zheng et al. 2015), although has been shown to repress BACE1 transcription 
within neuronal cells in a previous study (Bourne et al. 2007). NF-κB can be activated by 
protein kinase C (PKC) signalling, and this can be achieved experimentally using the small 
molecule phorbol myristyl acetate (PMA) (Holden et al. 2008). NF-κB can be inhibited using 
sc-514, a selective small molecule inhibitor of IκB kinase 2 (IKK2), the kinase that 
phosphorylates and activates NF-κB. BACE1 expression was measured by western blotting. 
Incubation of WT α-syn SH-SY5Ys with PMA, to activate NF-κB, did not lead to significant 
change in BACE1 protein levels (Figure 5.4a). Inhibition of NF-κB with sc-514, however, 
significantly enhanced BACE1 protein expression in WT α-syn SH-SY5Ys (Figure 5.4b). This 
unexpected finding implies that NF-κB negatively regulates BACE1 expression. 
Activation of the transcription factor AP-1 by Jun kinase (JNK-1) has also been shown in 
the literature to upregulate BACE1 transcription (Tamagno et al. 2008). JNK-1 can be 
inhibited by the small molecule inhibitor SP600125. When applied to WT α-syn SH-SY5Ys, 
SP600125 appeared to increase BACE1 protein levels, although this was not statistically 
significant (Figure 5.4b). The similarity with the effect of NF-κB inhibitor sc-514 is striking. 
One possible explanation for the apparent BACE1-enhancing effects of inhibiting these 
transcription factors, is that both NF-κB and AP-1 may compete for the transcriptional co-
activator CREB Binding Protein (CBP). Inhibiting NF-κB, for instance, could allow more CBP 
to be available for binding AP-1 in active transcription complexes, and increase the activity of 
AP-1. Zheng et. al. characterised a pharmacological inhibitor of BACE1 transcription that 
partially acted by limiting the CBP available to NF-κB, through activation of competing 
CREB/c-Jun pathways (Zheng et al. 2015). To investigate this, sc-514 and SP600125 were 
incubated together as well as separately. No enhancement or diminishment of BACE1 relative 
to the individual compounds was evident. The lack of additional BACE1 expression with 
combined sc-514 + SP600125 suggests that the individual effects of the drugs are not entirely 
independent. However, since the effects of the two inhibitors do not ‘cancel out’, there is no 
evidence that they are driven by strong competition for CBP. Therefore the most likely 
explanation is the simplest: NF-κB and AP-1 both directly suppress BACE1 expression.  




Figure 5.4 BACE1 protein expression is paradoxically increased by inhibitors of NF-κB, 
JNK-1, and γ-secretase. (A) WT α-syn SH-SY5Ys incubated 2 hours with an activator of 
NF-κB, PMA (phorbol 12-myristate 13-acetate; 1 µM). (B) WT α-syn SH-SY5Ys incubated 
2 hours with inhibitors of NF-κB, sc-514 (50 µM), and JNK-1, SP600125 (2 µM). (C) Empty 
vector and WT α-syn SH-SY5Ys incubated 6 hours with a selective γ-secretase inhibitor, 
DAPT (2 µM). Whole cell lysates were tested for BACE1 and α-tubulin by western blotting. 
Mean BACE1 OD: α-tubulin OD for 4 independent experiments ± S.E. * p<0.05 relative to 
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γ-Secretase activity, potentiated by oxidative stress, has been proposed to drive BACE1 
transcription through an AP-1-dependent route. Tamagno et al. showed that increased 
γ-secretase activity causes greater β-amyloid production, which activates JNK-1 signalling and 
AP-1 (Tamagno et al. 2008). Therefore, pharmacological inhibition of γ-secretase would be 
anticipated to have a similar effect as inhibiting JNK-1. DAPT was used to inhibit γ-secretase 
in both empty vector and WT α-syn SH-SY5Ys, and changes to BACE1 expression measured 
by western blotting (Figure 5.4c). Although basal levels of BACE1 are higher in the α-syn 
SH-SY5Ys, both lines respond to DAPT with significant BACE1 upregulation. This agrees 
with the findings that inhibiting oxidative stress-responsive transcription factors NF-κB and 
AP-1 potentiates BACE1 expression. It is also clear that α-syn overexpression itself does not 
have a significant impact on the changes seen. To summarise, the apparently induced oxidative 
stress in WT α-syn SH-SY5Ys is unlikely to enhance BACE1 expression via the transcription 
factors NF-κB and AP-1.  
5.3.5 α-Syn overexpression enhances levels of eIF2α phosphorylated at Ser-51  
BACE1 is translationally repressed under normal conditions, since the 5’UTR of BACE1 
mRNA is GC-rich and is predicted to form stable secondary structure (Lammich et al. 2004). 
An effective route to upregulating BACE1 expression would be to promote phosphorylation 
of eIF2α, which enhances BACE1 translation (O’Connor et al. 2008). So far it has become 
apparent that WT α-syn increases BACE1 protein levels but decreases BACE1 promoter 
activation (Chapter 4), so an increase in translation was hypothesised. Studying BACE1 
protein synthesis by itself is not straight-forward. However, phosphorylation of eIF2α is easily 
detectable by western blotting, and could signal changes to BACE1 translation. Western blots 
of cell extracts from multiple WT α-syn SH-SY5Y lines were probed with a Ser51 
phosphorylation-specific antibody for eIF2α, and re-probed for total eIF2α (Figure 5.5a). On 
average, the WT lines collectively had a significantly higher ratio of phosphorylated: total 
eIF2α. The enhanced eIF2α phosphorylation indicates potential de-repression of BACE1 
translation. 
Phosphorylation of eIF2α was also measured in two truncated (Δ2-9 & ΔNAC) and two 
disease-mutant (E46K & A53T) α-syn SH-SY5Y lines (Figure 5.5b). Δ2-9 and A53T lines 
had significantly enhanced eIF2α-phosphorylation when compared with WT (v1), but ΔNAC 
and E46K did not. This does not closely follow previously described patterns of BACE1 
expression across the lines, since BACE1 protein levels were higher in ΔNAC and E46K than 
WT α-syn SH-SY5Ys.  
  






Figure 5.5 eIF2α phosphorylation in SH-SY5Y lines. Levels of ser-51 phosphorylated 
eIF2α in (A) WT α-syn SH-SY5Ys, (B) α-syn mutant SH-SY5Ys. Whole cell lysates were 
tested for phospho-eIF2α and eIF2α by western blotting. Mean phospho-eIF2α OD: eIF2α OD 
for 3-5 independent experiments ± S.E. # p <0.05 relative to empty vector, * p <0.05, ** p 
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5.3.6 α-Syn does not affect basal or tunicamycin-induced eIF2α phosphorylation  
Phosphorylation of eIF2α is induced by a number of different eIF2 kinases in response to 
cell stresses, and constitutive dephosphorylation is performed by the GADD34/PP1 complex. 
Prolonged block in translation due to phosphorylated eIF2α results in cell death, thus a healthy 
cell line is unlikely to have constantly high phosphorylated eIF2α (Hetz et al. 2015). However, 
elevated basal levels of eIF2α phosphorylation have been previously reported in an 
overexpressing cell model of Alzheimer’s disease, as a long-term adaptation to ER stress 
(Lewerenz & Maher 2009). Cell overexpression of α-syn in the literature induces ER stress 
(Belal et al. 2012; Bellucci et al. 2011; Colla et al. 2012; Smith et al. 2005), therefore it was 
hypothesised that overexpression of α-syn in SH-SY5Ys may cause a small chronic increase 
in eIF2α phosphorylation. eIF2 kinase activity can be isolated with salubrinal, a selective 
inhibitor of eIF2α dephosphorylation by GADD34/PP1 (Boyce et al. 2005). The WT (v3) and 
empty vector SH-SY5Ys were incubated with salubrinal for 0.5 and 1 hour, before western 
blotting for phosphorylated and total eIF2α (Figure 5.6a). Levels of BACE1 protein were also 
measured in the same cell extracts (Figure 5.6b). As expected, levels of phosphorylated eIF2α 
appeared to accumulate in empty vector cells (not statistically significant). BACE1 protein 
increased correspondingly. In WT α-syn SH-SY5Ys, phosphorylated eIF2α did not 
significantly accumulate during salubrinal treatment, although BACE1 protein levels rose. It 
is likely that accumulation of phosphorylated eIF2α did occur in salubrinal-treated WT cells, 
since BACE1 protein levels increased, and was perhaps subject to high noise. Yet for WT 
α-syn SH-SY5Ys to have elevated basal eIF2 kinase activity, one would expect a more robust 
response to salubrinal, in comparison to empty vector cells. This does not appear to be the 
case, and it is possible that basal eIF2α phosphorylation is tightly regulated. 
Another possible source of differences in eIF2α phosphorylation between SH-SY5Y lines 
is a heightened sensitivity of α-syn cells to stress stimuli. Heightened sensitivity would mean 
that eIF2 kinases may be activated greater and for longer in response to any stressor. This 
theory was tested by incubating α-syn cells and empty vector cells with tunicamycin, which is 
a well-established ER stress inducer that activates the eIF2 kinase PERK (Harding et al. 2000). 
Levels of eIF2α dephosphorylation were controlled for by simultaneously treating cells with 
salubrinal. WT α-syn SH-SY5Ys had higher levels of phosphorylated eIF2α to empty vector 
cells when unstimulated, as noted previously. Tunicamycin appeared to induce eIF2α 
phosphorylation in both lines, and co-incubation with salubrinal potentiated the effect, as 
expected (Figure 5.7). α-Syn appears to have little effect on the extent of eIF2α 
phosphorylation under conditions of PERK stimulation. Therefore, there is no evidence that 
α-syn overexpression confers an enhanced sensitivity to ER stress.  





Figure 5.6 Salubrinal causes accumulation of phosphorylated eIF2α and a consistent 
increase in BACE1 protein expression over time. Empty vector and WT α-syn SH-SY5Ys 
were treated with 20 µM salubrinal for 0.5 or 1 hour, to inhibit de-phosphorylation of eIF2α. 
(A) Levels of eIF2α phosphorylation. Mean phospho-eIF2α OD: eIF2α OD for 6 independent 
experiments ± S.E. (B) Concurrent expression of BACE1 protein. Mean BACE1 OD: 
α-tubulin OD for 6 independent experiments ± S.E. * p<0.05, ** p <0.01 relative to control, 
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Figure 5.7 ER stressor tunicamycin induces eIF2α phosphorylation, potentiated by 
salubrinal in SH-SY5Ys. Tunicamycin was used at 1 µg/ml and salubrinal at 20 µM, for 1 
hour before lysis. Mean phospho-eIF2α OD: eIF2α OD for 3 independent experiments ± S.E. 
* p<0.05, ** p <0.01 relative to control, calculated by one-way ANOVAs with post-hoc 
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5.3.7 Pharmacological inhibition of the oxidative stress-activated eIF2 kinase ‘PKR’ does 
not reduce eIF2α phosphorylation 
So far there it has been shown that WT α-syn SH-SY5Ys have a greater proportion of eIF2α 
phosphorylated at Ser-51, and that BACE1 expression will increase in response to a selective 
block of eIF2α dephosphorylation. However, WT α-syn SH-SY5Ys do not appear to be more 
sensitive to activation of the eIF2 kinase PERK by ER stress stimuli. Other eIF2 kinases could 
be responsible for eIF2α phosphorylation in α-syn cells. It was shown earlier in this chapter 
that α-syn overexpression causes higher production of ROS. Oxidative stress is known to 
activate the eIF2 kinase ‘protein kinase R’ (PKR). Therefore, it was proposed that PKR may 
be more activated in WT α-syn SH-SY5Ys, and drive BACE1 translation. A chemical inhibitor 
of PKR was obtained, as a cost-effective and quick method to test this hypothesis. If PKR had 
an important role, then its inhibition ought to reduce eIF2α phosphorylation and BACE1 
protein levels in WT α-syn SH-SY5Ys, but not empty vector cells. Empty vector and WT (v3) 
SH-SY5Ys were treated with high and low doses of PKR inhibitor for 2 hours (Figure 5.8). 
PKR inhibitor slightly reduced BACE1 expression, but the effect was not statistically 
significant, and not limited to the WT (v3) line. Furthermore, eIF2α phosphorylation was 
strongly induced by the PKR inhibitor, rather than suppressed. Induced eIF2α phosphorylation 
suggests that there is compensatory activation of other eIF2 kinases. The fact that this does not 
increase BACE1 expression suggests that PKR may be important for BACE1 expression in 
SH-SY5Ys. Further concentrations of PKR inhibitor would be necessary to ascertain whether 
WT (v3) SH-SY5Ys are more sensitive than empty vector cells. 
  






Figure 5.8 PKR inhibitor induces eIF2α phosphorylation, and not BACE1 expression. 
Empty vector and WT α-syn SH-SY5Ys were treated with 1 µM or 10 µM PKR inhibitor for 
2 hours. (A) Levels of eIF2α phosphorylation. Mean phospho-eIF2α OD: eIF2α OD for 3 
independent experiments ± S.E. (B) Concurrent expression of BACE1 protein. Mean BACE1 
OD: α-tubulin OD for 3 independent experiments ± S.E. ** p <0.01 relative to control, 
calculated by one-way ANOVAs with post-hoc Tukey’s HSD for the individual cell lines. No 
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α-Syn overexpression in a neuronal cell model correlates both with increased 
amyloidogenic processing of APP, and increased BACE1 expression, suggesting the existence 
of a novel pathway. Understanding the mechanistic details of this pathway could improve 
understanding of synucleinopathy diseases. The data presented in this chapter is a preliminary 
exploration of different lines of enquiry, using BACE1 protein expression as an easy readout. 
Indirect cellular mechanisms were chosen for investigation based on a strong body of literature 
supporting both their instigation by α-syn overexpression, and their effect upon upregulating 
BACE1 expression. The experiments and their results are summarised in Table 4.  
The proposed indirect mechanisms are unlikely to exclusively alter BACE1 expression, 
since the activities of the β-, γ-, and α-secretases are linked by a complex web of signalling 
pathways. For example, calcium activates α-secretase. Activation of NMDA receptors, leading 
to high Ca2+ influx, is known to promote retention of ADAM10 at the plasma membrane, thus 
increasing α-secretase cleavage of APP (Marcello et al. 2013). Concurrently, transport of 
mature ADAM10 to the plasma membrane is rapidly induced, in a mechanism mediated by 
classical PKC signalling (Saraceno et al. 2014). Calcium may also affect the conformation and 
synaptic localisation of γ-secretase, enhancing Aβ42 secretion at the synapse (Kuzuya et al. 
2016). Oxidative stress also increases γ-secretase activity, by increased presenilin-1 
transcription (Oda et al. 2010). In fact γ-secretase appears to be integral to initiating 
transcriptional upregulation of BACE1 in response to oxidative stressors (Tamagno et al. 
2008). A γ-secretase inhibitor was used to specifically probe the contribution of γ-secretase to 
BACE1 expression in SH-SY5Ys. Surprisingly, this increased BACE1 protein levels rather 
than suppressing BACE1 expression, highlighting the complexity of secretase interactions. ER 
stress can halt γ-secretase mediated cleavage of APP, by stalling exit of proteins from the ER 
(Wiley et al. 2010). Paradoxically, ER stress also activates PERK, which is believed to 
increase BACE1 expression (Devi & Ohno 2014). As previously discussed, phosphorylated 
eIF2α promotes BACE1 translation as part of a sub-set of stress-response proteins. γ-Secretase 
may be indirectly upregulated by phosphorylated eIF2α, as well. In response to amino acid 
deprivation, γ-secretase transcription is transactivated by ATF4, an eIF2α-inducible stress-
response protein (Mitsuda et al. 2007). 
Furthermore, the mechanisms chosen for investigation are by no means the only 
possibilities by which α-syn could affect APP. Two major areas have been omitted: (a) Direct 
protein interactions with α-syn; (b) Epigenetic influences of α-syn. Direct interactions between 
α-syn and BACE1 or APP were not investigated, since the main focus was a neuronal cell 
model of synucleinopathy. Interestingly, unbiased proteomics of α-syn interactors have 






Table 4 Summary of Chapter 5 results. For individual experiments, the change to BACE1 
predicted from the literature is shown, followed by the real result. The final column comments 
on whether the BACE1 change is potentiated by α-syn overexpression, i.e. α-syn specific, or 
the same in both α-syn and empty vector SH-SY5Ys. ns: not statistically significant. ?: not 
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identified APP as a hit, but not BACE1 (Mcfarland, Ellis, Markey, & Nussbaum, 2008). Direct 
protein-protein interactions could affect the co-localisation of APP and BACE1, alter the 
kinetics of secretase cleavage, or alter the stability and half-life of APP/BACE1. α-Syn could 
also affect gene transcription, in a way that indirectly affects APP processing. There is limited 
evidence to suggest that α-syn can bind to histone H3 and reduce H3 acetylation (Kontopoulos, 
Parvin, & Feany, 2006; Snead & Eliezer, 2014). Reduced activity of the p300 histone 
acetyltransferase has also been shown in α-syn overexpressing N2A cells, with the outcome 
of decreased PKCδ expression (Jin et al. 2011). PKCδ is a PKC isoform that potently activates 
α-secretase processing of APP (Yi et al. 2012). The rest of this discussion will focus upon 
answering the questions raised in the introduction, before making new hypotheses on the 
mechanism by which α-syn influences BACE1 expression. 
5.4.1 Is there impaired degradation of BACE1 in α-syn cells, and is this likely to be 
responsible? 
BACE1 is cleared by the proteasome and lysosome (Figure 5.9). A clear difference in the 
effectiveness of proteasomal and lysosomal degradation of BACE1 can be seen between α-syn 
and empty vector SH-SY5Ys. BACE1 protein levels accumulated significantly when α-syn 
cells were treated with an autophagy inhibitor, and slightly accumulated in the presence of a 
proteasome inhibitor. In contrast, empty vector cells only achieved significant BACE1 
accumulation when both autophagy and the proteasome were inhibited together, with only a 
small response to the autophagy inhibitor alone. The apparently increased sensitivity of α-syn 
cells to inhibition of the proteasome and lysosome could be due to proteasome block or 
defective autophagy, or both. It is not possible to differentiate the two using this type of 
experiment, due to the cross-talk between the ubiquitin-proteasome system and autophagy. 
Proteasome inhibition causes autophagy induction, whereas autophagy inhibition impairs 
proteasome degradation as well (Korolchuk et al. 2009). BACE1 clearance as a whole relies 
more on autophagy, since it is a relatively long-lived membrane protein (Huse et al. 2000), 
and this is evident in higher response to autophagy inhibition than proteasome inhibition for 
both cell lines. Autophagy inhibition is thus more likely to make an impact on BACE1 levels. 
Furthermore, in the literature proteasome inhibition appears to be associated with α-syn 
aggregates (Tanaka et al. 2001; Stefanis et al. 2001), which have not been detected in the WT 
α-syn SH-SY5Ys used for this study. It is thus unlikely to be the proteasome that is impaired 
in α-syn SH-SY5Ys. An alternative explanation for the data is that there is a higher translation 
rate of BACE1 in α-syn SH-SY5Ys, which may cause it to accumulate faster where protein 
clearance is inhibited. This cannot be ruled out, since the protein synthesis inhibitor used as a  
 








Figure 5.9 BACE1 protein levels can be enhanced by a reduction in degradation of 
BACE1 by the proteasome or lysosome. The E3 ligase CHIP binds and ubiquitinates 
BACE1, causing it to be targeted to the proteasome. GGA3 is an adaptor protein that delivers 
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control was ineffective. A more detailed study of BACE1 intracellular localisation would be 
necessary to confirm whether less is trafficked to the lysosome. While the preliminary data is 
intriguing, there is insufficient evidence to conclude that impaired BACE1 degradation 
elevates BACE1 expression in α-syn cells. 
5.4.2 Does reducing intracellular calcium release in α-syn cells restore BACE1 protein 
levels? 
Increased intracellular calcium levels have been linked to α-syn overexpression in the 
literature (Caraveo et al. 2014; Furukawa et al. 2006). BACE1 transcription appears to be 
enhanced by calcium signalling, as illustrated in Figure 5.10 (Cho et al. 2008; Mei et al. 2015; 
Jin et al. 2012; Liang et al. 2010). It was therefore hypothesised that BACE1 expression in 
α-syn SH-SY5Ys would be reduced by inhibitors of ER calcium store release (dantrolene) and 
calcineurin signalling (FK-506). By the same logic, potassium chloride and A23187, which 
increase intracellular calcium levels, would be expected to increase BACE1 expression. In fact 
the complete opposite was found. Inhibiting calcium signalling increased BACE1 protein 
levels in α-syn SH-SY5Ys, and activating calcium signalling had a slight suppressive effect. 
The effect is not likely to be specific to α-syn cells, since dantrolene also appeared to enhance 
BACE1 expression in empty vector cells. Although calcium clearly has an impact on BACE1 
expression, the effect appears to be one of negative regulation in SH-SY5Ys. This does not 
support a role for intracellular calcium as a positive mediator of α-syn-induced BACE1 
expression. 
5.4.3 Is there enhanced oxidative stress in α-syn cells? 
Rates of hydrogen peroxide production in wildtype and mutant α-syn SH-SY5Ys were 
measured, to study oxidative stress. Basal levels of oxidative stress have not been previously 
described in the literature for any α-syn cell model, although copper and dopamine are known 
to induce an oxidative stress response (Xu et al. 2002). In vitro experiments appear to show 
hydrogen peroxide being produced from α-syn, dependent on its binding of copper, and the 
toxicity of α-syn application to cells can be prevented by catalase (C. Wang et al. 2011). α-Syn 
is suggested to be a ferrireductase, and uses bound cooper to aid the redox-cycling of iron 
(Brown 2013; Peng et al. 2010). Considerably elevated levels of free cellular Fe(II) compared 
with Fe(III) have been demonstrated in WT α-syn SH-SY5Ys, which is likely to generate 
hydrogen peroxide through Fenton reactions (Davies, Moualla, et al. 2011). Oxidative stress 
was indeed significantly elevated in wildtype α-syn SH-SY5Ys, although the magnitude of the 
change was small. N-terminal truncation of α-syn appears to further elevate oxidative stress in 
cells. Although the effect of Δ2-9 is not statistically significant, it is compelling due to the  







Figure 5.10 BACE1 protein levels can be enhanced by increased transcription. BACE1 
promoter activity can be stimulated by oxidative stressors and Aβ, through protein kinase C 
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hugely upregulated BACE1 transcription and protein levels measured in Δ2-9 SH-SY5Ys in 
Chapter 4. Cells overexpressing Steap3 were also included, since Steap3 is an unrelated 
protein that has robust ferrireductase activity. The high production of hydrogen peroxide in 
Steap3 shows that ferrireductase activity could potentially contribute to the oxidative stress 
measured in α-syn overexpressing cells.  
5.4.4 Could BACE1 expression be upregulated by transcription factors NF-κB or AP-1, in 
α-syn cells? 
Since there is evidence of elevated oxidative stress in α-syn SH-SY5Ys, oxidative stress 
could potentially mediate an effect on BACE1 transcription (Figure 5.10). In the literature, 
BACE1 promoter activity is enhanced by the oxidant H2O2, in a mechanism involving the 
transcription factors NF-κB and AP-1 (Tamagno et al. 2008; Marwarha et al. 2013). 
27-hydroxycholesterol, 4-hydroxynonenal, and Aβ peptides, also activate the BACE1 
promoter by similar means, although these are not exclusively oxidants (Buggia-Prevot et al. 
2008; Marwarha et al. 2013; Tamagno et al. 2008). For example, 27-hydroxycholesterol 
increases ROS generation, but also appears to promote iron accumulation through a 
mechanism involving ER stress (Prasanthi et al. 2011). Iron has been suggested to increase 
BACE1 and ADAM10 transcription, APP translation, and C99 and C83 APP CTFs in cell 
culture (Kim & Yoo 2013; Guo et al. 2014). No evidence of higher BACE1 promoter 
activation was found in Chapter 4, in wildtype α-syn SH-SY5Ys with a luciferase reporter. 
Therefore, promoter upregulation of BACE1 is not evident in α-syn SH-SY5Ys. A specific 
contribution of NF-κB and AP-1 to BACE1 protein levels were investigated in the current 
chapter. NF-κB and JNK-1 inhibitors had been shown in the literature to suppress BACE1 
expression, but unexpectedly augmented BACE1 protein levels in α-syn SH-SY5Ys. The 
contribution of Aβ to BACE1 levels was additionally assessed using a γ-secretase inhibitor, 
and this potentiated BACE1 expression in α-syn and empty vector cells. According to the 
literature, Aβ42 activates NF-κB and JNK-1 (Tamagno et al. 2008). Jo et al. (2010) found that 
γ-secretase inhibition reduces BACE1 expression in SH-SY5Ys, but this was in the context of 
acute oxidative stress stimuli (Jo et al. 2010). Two published studies have found that NF-κB 
represses the BACE1 promoter in neuronal cells under physiological conditions, whereas 
pathological levels of Aβ switch NF-κB into being stimulatory (Chami et al. 2012; Bourne et 
al. 2007). In light of this, the effect of NF-κB inhibition in this chapter makes more sense. 
Clearly, WT α-syn SH-SY5Ys do not experience enough oxidative stress or Aβ production for 
the switch in NF-κB activity to occur, and NF-κB remains repressive. With this biphasic model 
of NF-κB, the BACE1 promoter study (Chapter 4) can be re-interpreted. WT α-syn SH-SY5Ys 
had reduced BACE1 promoter activity compared with the empty vector, potentially as a 
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consequence of repressive NF-κB activity. In contrast Δ2-9 α-syn SH-SY5Ys had increased 
BACE1 promoter activity, perhaps indicating that NF-κB is switched to stimulatory mode in 
these cells, which had particularly high β-amyloid production (Chapter 3). More research 
would be needed to test these theories. Regardless, the current data suggests that oxidative 
stress does not upregulate BACE1 transcription in α-syn cells. 
5.4.5 Is there increased activation of eIF2α phosphorylation in α-syn cells, and could this 
be upregulating BACE1 translation? 
BACE1 expression can be regulated by translational de-repression, which occurs when cell 
stress activates the phosphorylation of eIF2α, illustrated in Figure 5.11. BACE1 expression 
appears to be upregulated post-transcriptionally in α-syn SH-SY5Ys, so it was hypothesised 
that translational de-repression is involved. α-Syn expression increased levels of 
phosphorylated eIF2α in SH-SY5Ys, creating permissive conditions for BACE1 translation. 
Although prone to noise, the average increase was almost a doubling of phosphorylated eIF2α, 
as a ratio of total eIF2α. Interestingly the Δ2-9 mutation, which had the highest BACE1 protein 
levels in Chapter 4, significantly enhanced eIF2α phosphorylation relative to the wildtype. Yet 
correlation does not necessarily mean causation, so levels of eIF2α phosphorylation were 
additionally manipulated pharmacologically in α-syn and empty vector cells. Salubrinal 
reduces the targeting of phosphatase to eIF2α, so phosphorylated eIF2α should accumulate, 
highlighting any differences in basal eIF2 kinase activity between the cell lines. Accumulation 
of phosphorylated eIF2α was weak, but both cell lines experienced significantly upregulated 
BACE1 protein. Overall there was not a clear difference in the response of α-syn cells to 
salubrinal, i.e. the basal eIF2 kinase activity. Since basal eIF2α phosphorylation rates seemed 
similar, eIF2α phosphorylation was subsequently stimulated to see whether α-syn cells were 
more sensitive to stress-mediated eIF2 kinase induction. Specifically, the response of eIF2 
kinase PERK to stimulation by tunicamycin was tested in α-syn and empty vector cells. 
Tunicamycin reduces N-glycosylation of proteins in the ER, which prevents many proteins 
from folding adequately and leaving the ER (Bassik & Kampmann 2011). Since α-syn 
overexpression is thought to impair ER-Golgi transition (Cooper et al. 2006; Oaks et al. 2013; 
Thayanidhi et al. 2010), it was predicted that the cells would be particularly sensitive to 
tunicamycin-induced ER stress. However, the response of α-syn cells to tunicamycin was 
similar to control cells, with respect to eIF2α phosphorylation as a biomarker of stress. It is 
thus not clear that the α-syn cells have a specific sensitivity to ER stress. Another mechanism 
must be responsible for the enhanced eIF2α phosphorylation in α-syn SH-SY5Ys, perhaps 
independent of the ER. 
 






Figure 5.11 BACE1 protein levels can be enhanced by translational de-repression. 
BACE1 translation is stimulated by stress-mediated activation of eIF2 kinases, PERK, PKR, 
GCN2, and HRI, which phosphorylate eIF2α. A GADD34/PP1 complex constitutively 
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5.4.6 Does PKR mediate translational upregulation of BACE1 in response to oxidative 
stress in α-syn cells? 
It is not yet clear whether a particular eIF2 kinase is upregulated in α-syn SH-SY5Ys. As 
discussed, PERK was investigated indirectly by observing the effect of tunicamycin on cell 
eIF2α phosphorylation. Another eIF2 kinase of interest is PKR, which is activated by oxidative 
stress, but also ER stress and calcium stress (Marchal et al. 2014). To judge the potential role 
of PKR, a pharmacological inhibitor was used on α-syn and empty vector SH-SY5Ys. 
Relatively low concentrations of PKR inhibitor caused strong upregulation of eIF2α 
phosphorylation in both lines, rather than the predicted reduction. The result suggests 
compensatory over-activation of another eIF2 kinase, a phenomenon previously described in 
the literature. Devi & Ohno reduced GCN2 expression by genetic means in mice, and found 
that PERK became over-activated, causing BACE1 expression to increase (Devi & Ohno 
2013). One would expect BACE1 expression to follow suit. Yet PKR inhibitor treatment did 
not increase BACE1 protein levels, and a slight reduction was detected. The apparent 
uncoupling of BACE1 expression from eIF2α phosphorylation may indicate that PKR 
promotes BACE1 expression by a different route, independent from its activity as an eIF2 
kinase. PKR has many functions in signal transduction, including the activation of NF-κB and 
inactivation of p53, so the effects of inhibition are manifold (Baltzis et al. 2007; Marchal et al. 
2014). Pharmacological inhibition of PKR could allow active p53 to accumulate, leading to 
strong transcriptional repression of BACE1 (Singh & Pati 2015). 
5.4.7 New hypotheses 
To summarise, a couple of potential mechanisms for α-syn-induced BACE1 expression 
have been rendered improbable by the data gathered. It is unlikely that intracellular calcium is 
directly involved, or that the effect on BACE1 is transcriptionally regulated through NF-κB or 
AP-1. Other putative mechanisms, translational upregulation and impaired degradation, 
remain viable. In future it would be worthwhile investigating further: (i) eIF2α-mediated 
upregulation of BACE1 translation, (ii) decreased BACE1 targeting to lysosomes. The new 
hypotheses are displayed in Figure 5.12. 
Elevated eIF2α phosphorylation in α-syn SH-SY5Ys was observed, and could have a role 
in BACE1 expression. However, induced eIF2α phosphorylation did not consistently lead to 
enhanced BACE1 protein levels, suggesting that another layer of regulation, perhaps involving 
BACE1 degradation, is at play. Post-translational effects have not been fully investigated, and 
there is some support for changes to BACE1 degradation in α-syn SH-SY5Ys. The effect is 
likely to be specific to BACE1 or a sub-set of proteins, and could involve reduced proteasomal 
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or autophagic degradation. A global impairment of proteasomal degradation or autophagy 
ought to elevate levels of many other proteins, and decrease the fitness of the cell population, 
neither of which appears to be the case. Specific changes to BACE1 proteasomal degradation 
may be mediated by the E3 ligase CHIP, known to target BACE1 to the proteasome (Singh & 
Pati 2015). Alternatively, reduced lysosomal degradation of BACE1 may be a result of less 
GGA3, which specifically targets BACE1 to the lysosome (Kang et al. 2012). 
  







Figure 5.12 New hypotheses for future investigation of the effect of α-syn upon BACE1. 
Elevated phosphorylation of eIF2α in WT α-syn SH-SY5Ys suggests translational 
upregulation of BACE1. A mechanism involving translational upregulation of BACE1 would 
be supported by identification of the eIF2 kinase responsible, through genetic deletion of 
individual eIF2 kinases and acute α-syn overexpression. Impaired BACE1 degradation is 
implied by its over-accumulation in WT α-syn SH-SY5Ys treated with lysosome/proteasome 
inhibitors. The mechanism is speculated to involve reduced recruitment of GGA3 (lysosome) 
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The major findings from this thesis can be summarised as follows. Chapter 3 established 
that the overexpression of α-syn in neuronal cell lines increases β-γ-secretase-mediated 
metabolism of APP, resulting in greater secretion of β-amyloid. Furthermore the effect appears 
to be potentiated by α-syn N-terminal mutations. Data in Chapter 4, on the expression and 
activity of secretase enzymes, showed changes to both BACE1 and ADAM10 expression in 
response to α-syn, but no apparent alteration to γ-secretase activity. Total protein levels of 
BACE1 were elevated, and ADAM10 reduced, but mature ADAM10 was enriched in the 
plasma membrane where it is reputedly more active. BACE1 levels correlated with α-syn 
expression in several models, and some exploration of the potential cell mechanisms 
connecting BACE1 to α-syn were outlined in Chapter 5. The results indicated that WT α-syn 
overexpressing cells exhibit biomarkers of cell stress, i.e. hydrogen peroxide production, and 
eIF2α phosphorylation. BACE1 levels in these cells were also particularly sensitive to 
lysosome inhibition. 
The effects of α-syn on various components of APP metabolism have been described in the 
individual chapter discussions. The purpose of this final discussion is to highlight other areas 
of research to which this thesis contributes.  
6.2 α-Syn and APP in normal cell physiology 
6.2.1 α-Syn and APP are connected by intracellular processes 
The findings of this thesis support an intracellular connection of α-syn with APP 
processing. Fragments of α-syn and APP protein were demonstrated in 1993 to co-localise in 
amyloid plaques (Uéda et al. 1993), and have since been shown to co-aggregate in vitro (Ono 
et al. 2012; Tsigelny et al. 2008; Choi et al. 2015). Majd et al. showed that α-syn aggregates 
applied to primary neurons increased β-amyloid secretion (Majd et al. 2013). However, this 
may be the first time that a potential intracellular link between the proteins has been explored 
in any detail.  
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Until recently, α-syn and APP were believed to physiologically localise to completely 
separate membranes in a neuron, and interact only as a result of pathology (Marsh & Blurton-
Jones 2012; Mandal et al. 2006). APP localises to post-synaptic membranes, whereas 
membrane-bound α-syn may predominantly localise to pre-synaptic vesicles (Maroteaux et al. 
1988; Hoey et al. 2009). Cytosolic α-syn is distributed throughout the cell, but is thought to be 
unfolded and ‘inactive’ in this form. Yet APP and the β-secretase were discovered to localise 
to pre-synaptic vesicles and the pre-synaptic membrane (Groemer et al. 2011; Del Prete et al. 
2014; Laßek et al. 2013). Similarly α-syn has been found at a number of other membranes, 
including ER and mitochondria, and alters the secretory pathway when over-expressed in 
several cell models (Snead & Eliezer 2014; Oaks et al. 2013; Thayanidhi et al. 2010).  
The work detailed in this thesis confirms that distinct subcellular localisation does not 
prevent intracellular metabolic interactions between α-syn and APP metabolism. One 
limitation of this work is the simple cell model. Undifferentiated neuronal precursors were 
used, allowing ease of genetic manipulation, but with less well-defined postsynaptic and 
presynaptic compartments. Future work could study β-amyloid production from α-syn 
transgenic primary neurons, or differentiated iPSCs of an SNCA triplication patient (Devine 
et al. 2011).  
6.2.2 N-terminal mutations of α-syn appear to cause a gain of function 
A notable feature of the effect of α-syn on APP metabolism is that it was strongly 
potentiated by truncations within the N-terminus of the protein (Δ2-9 and ΔNAC), and disease-
associated point mutations had only a small effect. Strikingly, truncation of the extreme 
N-terminus or NAC domain are both known to inhibit aggregation of α-syn (Wang et al. 2010; 
Periquet et al. 2007). Toxic α-syn aggregates are therefore unlikely to be involved in the 
enhanced amyloidogenic processing of APP in α-syn cells. It would be natural to look to the 
physiological function of α-syn for answers.  
α-Syn has two major properties that may be involved in its physiological function. Firstly, 
α-syn binds membranes with an N-terminal amphipathic helix (residues 1-95). The interaction 
of α-syn with membranes appears to regulate membrane tubulation and vesicle fusion events 
(Kamp et al. 2010; Lai et al. 2014; Jao et al. 2008; Varkey et al. 2010). Overexpression of WT 
and mutant α-syn could have a variety of different effects on cell membranes, a few of which 
are suggested by the literature. At the ER, WT α-syn maintains contacts with mitochondria, 
whereas A53T mutant α-syn reduces ER-mitochondrial contacts and induces mitochondrial 
fragmentation (Guardia-Laguarta et al. 2014). At the Golgi, over-expressed WT α-syn impedes 
docking and fusion of ER vesicles, potentially causing ER stress as well as delaying the 
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secretory pathway (Thayanidhi et al. 2010; Oaks et al. 2013; Gitler et al. 2008; Bellucci et al. 
2011). In this role, the A53T mutation appears to exacerbate the ER-Golgi transport block, 
and exacerbates ER stress (Thayanidhi et al. 2010). At synaptic vesicles, WT α-syn promotes 
the assembly of exocytic machinery, and this effect is not altered by disease-associated point 
mutations such as A53T (Burré et al. 2012).  
The effect of truncations Δ2-9 and ΔNAC on the membrane-binding of the N-terminus 
could be subtle. The affinity of ΔNAC α-syn for membranes has not been studied, but some 
literature exists on Δ2-9 suggesting only a small reduction in α-syn membrane binding, if any 
(Burré et al. 2012; Vamvaca et al. 2011; Wang et al. 2010). In Chapter 3 of this thesis a uniform 
cytosolic stain for α-syn was observed in Δ2-9 SH-SY5Ys, suggesting reduced plasma 
membrane localisation. Without further evidence from western blotting, the result is equivocal. 
Overall, it seems likely that the N-terminal mutations had similar subcellular localisation to 
WT α-syn. This is supported in the literature by the normal synaptic targeting of α-syn, and 
normal α-syn-induced synaptic SNARE complex assembly in cells overexpressing Δ2-9, 
A53T, or E46K (Burré et al. 2012). A potential model to explain the gain of APP 
amyloidogenic processing when the α-syn N-terminus is mutated, is a scenario where reduced 
negative regulation of α-syn occurs, e.g. reduced lysosomal targeting. This would increase or 
prolong α-syn activity, which could lead to greater ER-Golgi block and ER stress, or could 
have consequences for the co-localisation/stability of APP and the secretases.  
Another known property of α-syn is its ability to reduce iron (Davies, Moualla, et al. 2011). 
This could potentially mediate the elevated levels of ROS production in α-syn SH-SY5Ys 
(Chapter 5). ROS stimulates the expression and activity of β- and γ-secretases on APP, so there 
is a well-understood link between ROS and APP metabolism (Tamagno et al. 2008; Jo et al. 
2010). Unpublished work from our laboratory suggest that the effect of over-expressed α-syn 
upon β-amyloid production can be mitigated by treatment with an iron chelator, deferoxamine. 
It has been previously established that WT α-syn SH-SY5Ys contain higher than usual levels 
of reduced iron (Davies, Moualla, et al. 2011). Iron has been shown to increase the 
amyloidogenic processing of APP in an AD mouse model, and deferoxamine both inhibits 
β-amyloid accumulation and improves memory retention (Guo et al. 2013). Furthermore, 
deferoxamine reduces the sensitivity of A30P α-syn expressing M17 cells towards oxidative 
stress (Liddell et al. 2013). This supports a potential involvement of iron in β-amyloid 
production, via oxidative stress. Given that Δ2-9, ΔNAC, and the disease-associated point 
mutations have high amyloidogenic processing of APP, one would predict that these enhance 
iron reduction in cells. Δ2-9 protein also appeared to potentiate cell ROS production in 
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Chapter 5. So far, published (Davies, Moualla, et al. 2011) and unpublished data is 
inconclusive on whether these mutations increase iron reduction. 
6.2.3 Perspective on the role of α-Syn toxic oligomers in cell dysfunction  
In synucleinopathies, α-syn aggregation is widely regarded to be a key driver of cell 
dysfunction. Increased expression of wildtype α-syn is sufficient to induce α-syn aggregation 
in some models. When wildtype and disease-associated point mutations of α-syn are over-
expressed in mice, the same changes to gene expression are seen, suggesting a shared 
pathophysiology (Miller et al. 2007). The common denominator is generally interpreted to be 
‘toxic oligomers’ of α-syn, stabilised by molecular crowding or certain point mutations 
(Lashuel et al. 2013).  
The stable cell lines used in this thesis have been selected to survive and proliferate with 
elevated α-syn expression. Yet the WT and mutant α-syn SH-SY5Ys exhibited biomarkers of 
cell stress, namely enhanced ROS production and phosphorylation of eIF2α. Expression of 
mutant α-syn forms that are believed to be incapable of forming β-rich α-syn oligomers, ΔNAC 
and Δ2-9, did not appear to reduce β-amyloid production or cell stress. In fact, these cells had 
higher levels of APP amyloidogenic processing than WT α-syn cells. The evidence does not 
support a leading role for α-syn toxic oligomeric species. It is likely that over-expressed 
wildtype α-syn acts on APP metabolism through an oligomer-independent mechanism. 
Potentially, APP metabolism could form a novel connection between α-syn function and 
disease. 
There exists a great diversity of shapes and sizes of α-syn ‘toxic oligomer’ species, which 
exert numerous changes to cell signalling, metabolism and transport (Roberts & Brown 2015; 
Lashuel et al. 2013; Plotegher et al. 2014). The only factor apparently connecting these toxic 
oligomers is their β-rich structure, which is also shared with toxic oligomers of other proteins. 
In several unrelated amyloid-forming proteins, including Aβ42, the toxicity of oligomers 
appears correlated with the exposure of hydrophobic residues, revealed by ANS binding. 
Additionally, particular structural epitopes in several unrelated toxic oligomers are recognised 
by ‘oligomer-specific’ antibodies (Bolognesi et al. 2010; Yoshiike et al. 2007; Kayed et al. 
2003). Yet some of the biological effects of α-syn oligomers are not shared by others. For 
example, α-syn oligomers activate the IRE1 branch of the unfolded protein response, but 
PrP106-126 and ABri1-34 oligomers do not (Castillo-Carranza et al. 2012). What is unique about 
α-syn toxicity? Part of the answer may be that α-syn oligomers act by disrupting the 
physiological function of α-syn. Metastable α-syn aggregates may bind the ‘normal’ protein 
binding partners of α-syn, or sequester α-syn itself (Lashuel et al. 2013). This possibility has 
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not been explored extensively in the literature, but connections have been made between α-syn 
function and disease. For example, both monomers and large oligomers of α-syn were shown 
to bind synaptobrevin-2 in SNARE. Yet only large oligomers, and not monomers, impaired 
SNARE-mediated lipid mixing in vitro, and reduced exocytosis in PC12 cells (Choi et al. 
2013). Another example of α-syn function-meeting-pathology is the putative role of α-syn in 
maintaining ER-mitochondrial contacts. The A53T α-syn disease mutant protein inhibits ER-
mitochondrial contacts, and they can be rescued by increased expression of the wildtype 
protein (Guardia-Laguarta et al. 2014). There is therefore a precedent for A53T, and other 
disease-mutants, to exert an effect on APP metabolism by disturbing α-syn function. 
6.2.4 APP metabolism is proposed be an evolved mechanism to cope with cell stress 
Secretase-mediated processing of APP undergoes subtle and complex regulation. The 
expression, turnover, and subcellular localisation of all three secretase enzymes and APP are 
critical to the outcome of processing. It is difficult to fully explain the altered APP processing 
in α-syn cells without prolonged and detailed study, yet it is clear that expression of BACE1 
and ADAM10 are altered, which is likely to contribute. BACE1 protein levels were enhanced, 
and ADAM10 protein appeared to have increased retention at the cell surface, suggesting an 
increase in β-secretase and α-secretase activity. An interesting question to ask is whether APP 
processing serves as an adaptive response to α-syn overexpression. To understand why APP 
processing could be a homeostatic mechanism, one needs to consider the physiological 
functions of amyloidogenic and non-amyloidogenic processing of APP in a cell.  
Amyloidogenic and non-amyloidogenic processing are constitutive in neuronal cells, but 
are upregulated or downregulated by changes to secretase expression and activity. Broadly-
speaking, BACE1 expression is upregulated in response to cell stresses, e.g. high intracellular 
ROS or calcium, ischaemic injury (Zhang et al. 2007; Tamagno et al. 2008; Cho et al. 2008). 
ADAM10 targeting to the plasma membrane is upregulated by neuronal activity, and this 
increases α-secretase processing of APP. PKC signalling from muscarinic receptors mediates 
the effect, which promotes binding of TGN-localised ADAM10 to a plasma membrane-
targeting adaptor protein, SAP97 (synapse-associated protein 97) (Saraceno et al. 2014; 
Marcello et al. 2007).  
Several APP fragments result from secretase-mediated processing of APP, potentially with 
different functions. Researchers looking for differences in the activity of β-cleavage fragments 
versus α-cleavage fragments have had limited success. The ectodomains sAPPα and sAPPβ 
appear to both induce neural differentiation and proliferation (Freude et al. 2011; Lazarov & 
Demars 2012). Interestingly a new role in cholesterol regulation has been defined for the 
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ectodomain fragments, where they have distinct roles. sAPPα increases cholesterol 
biosynthesis, whereas sAPPβ decreases cholesterol production, in a mechanism involving the 
transcription factor SREBP2 (sterol regulatory element-binding protein-2). The C-terminal 
fragments C99 and C83 have also received some attention. Two proteins have been found to 
preferentially bind C99 (β-CTF) over C83 (α-CTF): ShcA and Pin1 (Repetto et al. 2004; 
Akiyama et al. 2005). ShcA activates MAPK signalling, and Pin1 is a prolyl isomerase that 
may recruit γ-secretase, or other adaptor proteins (van der Kant & Goldstein 2015). Overall it 
appears that β-cleavage and α-cleavage fragments have similar functions and little 
specialisation. 
Even Aβ, the small peptide products of C99 cleavage by γ-secretase, are thought to have a 
function. Although associated with cytotoxicity, studies using a range of Aβ doses have 
revealed that it has the property of ‘hormesis’. Hormesis is where a factor has increasingly 
beneficial effects at low doses, but becomes less beneficial and even harmful at high doses. 
This can be thought of as an ‘inverted-U’ dose-response relationship. Hormesis is ubiquitous 
in drugs that are used to improve memory. The comparison is apt as, perhaps surprisingly, Aβ 
has many features in common with these drugs, illustrated in Figure 6.1 (Morley & Farr 2012; 
Puzzo & Arancio 2013). At picomolar concentrations, Aβ enhances synaptic plasticity and 
memory (Puzzo & Arancio 2013). Picomolar levels of Aβ stimulates the release of excitatory 
neurotransmitters from synapses, and also increase the activation of α7- nicotinic acetylcholine 
receptors. Conversely, higher doses of Aβ are inhibitory to neurotransmitter release (Abramov 
et al. 2009; Mura et al. 2012). Aβ is both neurotrophic, in low doses, and neurodegenerative 
in high doses (Yankner et al. 1990). Additionally, at low concentrations Aβ acts as an 
antioxidant, binding to free copper, iron and zinc, and quenching free radicals (Nadal et al. 
2008; Baruch-Suchodolsky & Fischer 2009; Kontush et al. 2001; Morley & Farr 2012; 
Pedersen et al. 2016). Higher levels of Aβ result in aggregation, the early stages appearing to 
produce a burst of hydrogen peroxide, and leading to oxidative damage in cell models (Mark 
et al. 1997; Tabner et al. 2005). The outcome of enhancing β-/γ-secretase processing of APP 
therefore may depend on both baseline levels of Aβ and the degree of the increase. 
How does this relate to the response of cells to α-syn overexpression? It is possible that the 
resulting increase in β-/γ-secretase processing of APP is simply a side-effect of overexpressing 
a protein that interferes with the secretory and endocytic pathways. Alternatively, increased 
β-/γ-secretase processing of APP may be an adaptive response to cell stress caused by the 
α-syn. Secreted Aβ levels were only doubled by the α-syn overexpression, and likely to be in 
the range at which Aβ is antioxidant and neuroprotective. Indirectly supporting this, the use of 
a γ-secretase inhibitor to suppress Aβ production in α-syn overexpressing cells had the effect 
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of enhancing BACE1 expression. The effect on BACE1 indicates a feedback pathway to 
restore amyloidogenic processing, suggesting that this serves a useful function. 
6.3 α-Syn and APP in neurodegenerative disease 
6.3.1 Lewy Body dementias 
The novel finding that increased α-syn increases the production of Aβ could shed some 
light on the relationship between PD and AD. A spectrum of Lewy Body dementias (PDD and 
DLB) is thought to exist, shown in Figure 6.2. Both PDD and DLB are classified as 
synucleinopathies but have some of the pathophysiological features of AD, including the 
occurrence of amyloid plaques and neurofibrillary tangles (Berg et al. 2014). As high as 80% 
of PD patients develop dementia within a decade of PD diagnosis (Emre et al. 2007). Although 
dementia is common in old age, α-syn accumulation is likely to contribute. Increased 
expression of wildtype α-syn occurs in patients with SNCA duplication; all known cases of 
SNCA duplication were diagnosed with DLB, rather than pure PD. Autopsy reveals 
widespread Lewy bodies in the neocortex, which is known to correlate strongly with cognitive 
impairment (Konno et al. 2016). Cortical Lewy bodies may be important to the development 
of dementia in PD patients, but researchers are intrigued by the potential involvement of 
concomitant amyloid plaques and neurofibrillary tangles, the key features of AD pathology. 
New research is uncovering the significance of Aβ pathology to development of dementia 
in PD. Several studies have used cerebrospinal fluid (CSF) biomarkers of α-syn and Aβ 
pathology, to study cognitive decline in live patients with early stages of PD. Decreasing levels 
of CSF Aβ42 are an established predictive biomarker for cognitive decline in AD, and linked 
to increasing amyloid plaque deposition (McKhann et al. 2011). Similarly, studies of early PD 
show that a decrease in CSF Aβ42 appears to immediately precede cognitive impairments, and 
has predictive power for PD patients that develop dementia (Stav et al. 2015; Vranová et al. 
2014; Hall et al. 2015; Skogseth et al. 2015; Terrelonge et al. 2015; Alves et al. 2014). PET 
imaging of patients using the Pittsburgh compound B (PiB) can also be performed to detect 
areas of Aβ insoluble aggregates in the brain, and agrees with the CSF data (Petrou et al. 2015). 
Furthermore, the idea of a PD-AD disease spectrum is supported by CSF Aβ42 measurements 








Figure 6.1 Proposed physiological and pathological roles of Aβ in synaptic plasticity and 
memory. Taken from (Puzzo & Arancio 2013).  
 
 
Figure 6.2 The PD-AD spectrum. A simplified model of the way that clinical presentation 
may relate to cortical α-syn and Aβ pathology. Taken from (Berg et al. 2014).  
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Although amyloid plaques in the striatum contribute to cognitive impairment, amyloid 
deposition does not appear to correlate with the degeneration of nigrostriatal neurons in PD 
(Chiaravalloti et al. 2014; Shah et al. 2015). This suggests that Aβ pathology is secondary to 
α-syn pathology in PD. Of particular interest, some studies find that CSF α-syn levels are low 
in PD patients with early cognitive impairment, and also closely correlate with CSF Aβ42 
(Skogseth et al. 2015; Buddhala et al. 2015). The implication of this is that changes to α-syn 
pathology occur at the same time as Aβ deposition, signifying a relationship rather than mere 
coincidence. CSF α-syn is not prognostic of dementia to the same degree as CSF Aβ42, but is 
not an extensively validated biomarker of brain α-syn pathology (Parnetti et al. 2014). One 
may surmise from the current evidence that both α-syn and Aβ contribute to the development 
of dementia in PD. 
The question remains: what relationship do α-syn and Aβ have in the brains of PD patients? 
Three hypotheses will be discussed, also illustrated in Figure 6.3, which are not mutually 
exclusive. 
(A) α-Syn and Aβ pathology directly enhance one another’s aggregation. A direct 
effect of α-syn in ‘templating’ the assembly of Aβ42 amyloid fibrils has been 
observed in vitro, and vice versa (Atsmon-Raz & Miller 2015; Mandal et al. 2006; 
Ono et al. 2012; Masliah et al. 2001). This is known as ‘cross-seeding’. However 
although the two proteins co-immunoprecipitate from AD/PD brains (Tsigelny et 
al. 2008), cross-seeding does not manifest in mouse models. In fact, α-syn may 
inhibit amyloid plaques in mice. In AD model mice, the overexpression of A30P 
α-syn appears to reduce Aβ deposition, and appeared to reduce the seeding activity 
of Aβ aggregates (Bachhuber et al. 2015). Conversely, knock-out of α-syn 
increases plaque load in AD mice (Kallhoff et al. 2007). 
 
(B) A common upstream event, perhaps an acute cellular insult, upregulates both 
α-syn and Aβ aggregation. Cells in ageing brains are less well-equipped to cope 
with disordered proteins such as α-syn and Aβ, due to an age-related decline in the 
activity of protein degradation pathways, molecular chaperones, and antioxidants. 
Support for this concept comes from studies of exposure to toxins that induce 
parkinsonism. For example, manganese exposure in primates causes accumulation 
of both intracellular α-syn aggregates and diffuse extracellular Aβ aggregates in 
the frontal cortex, associated with neurodegeneration (Verina et al. 2013). 
Nigrostriatal neurons were spared in this model, but PET imaging showed 
markedly reduced dopamine release in the striatum (Guilarte et al. 2008). Once 
α-syn and Aβ aggregation has been triggered, the pathology may become self-
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sustaining through similar cell mechanisms. α-Syn and Aβ aggregates arise from 
accumulation of copper and iron, high ROS production, and impaired protein 
degradation, but also create a positive feedback effect on these same factors, 
reviewed in (Jomova et al. 2010; Malkus et al. 2009). Yet with this scenario it is 
difficult to explain why most synucleinopathy is absent of significant Aβ 
pathology, and why α-syn pathology is limited in AD (Berg et al. 2014). 
 
(C) α-Syn aggregation could occur first, and over time promote Aβ deposition. 
This thesis provides a mechanism by which this could occur, through the enhanced 
amyloidogenic processing of APP, although there is not yet any evidence that this 
does occur in disease. Pathological studies support that cognitive decline in PDD 
and many, but not all, cases of DLB are primarily driven by cortical α-syn 
pathology (Deramecourt et al. 2006). Indeed, in several studies amyloid pathology 
has been absent in most PDD brains, and is significantly more widespread in DLB 
(Petrou et al. 2015). Ruffman et al. found that DLB brains also have significantly 
higher levels of α-syn aggregates in the temporal and parietal lobes than PDD 
brains, and this correlates with a shorter time interval between motor and dementia 
symptoms (Ruffmann et al. 2015). Of course, there remains a question of why 
many PD patients do not develop Aβ accumulation and deposition, if this is 
promoted by α-syn. The answer could be that Aβ deposition develops in PD 
patients with a genetic predisposition. Some genetic component has been found to 
PDD and DLB, in a study of 174 patients that discovered rare missense variants of 
known AD or PD-associated genes (e.g. PSEN2, PARK2) in 6.8% of the cohort. 
Among the DLB patients there was significant prevalence of major AD risk allele 
ApoE ε4, and in the PDD/ DLB cohort a greater frequency of variants of the PD 
risk gene glucocerebrosidase was detected (Meeus et al. 2012). However, the 
extent of genetic predisposition is uncertain.  
6.3.2 Alzheimer’s disease 
Although this thesis has only explored one side of the relationship between α-syn and APP/ 
Aβ, it is possible that the relationship goes two ways, i.e. there is an effect of APP/ Aβ on 
α-syn. A two-way relationship may explain why some cases of DLB with late parkinsonism 
exhibit only limited α-syn pathology that may be secondary to Aβ. Support for this hypothesis 
arises from coincident pathology in AD.  
  




Figure 6.3 Three types of relationship between α-syn and Aβ that have been hypothesised 
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Lewy bodies are frequently widespread in AD brains, in the absence of parkinsonism, 
estimated to occur in ~25-40% of AD by the time of death (Jellinger 2003; Uchikado et al. 
2006; Schneider et al. 2009). One study found Lewy bodies in 30% of sporadic AD brains and 
27% of genetic (autosomal dominant) AD brains. The extent of Lewy body pathology was 
scored significantly greater in the sporadic cases compared with genetic AD (Ringman et al. 
2016). Cell experiments also support a potentially indirect effect of Aβ on α-syn. Majd et al. 
found that recombinant Aβ42 aggregates added to hippocampal neurons increased total 
intracellular levels of α-syn protein (Majd et al. 2013). Swirski et al. took a different approach, 
studying insoluble, S129-phosphorylated α-syn, which is scarce in healthy cells but 
predominates in Lewy bodies. Exposure of α-syn SH-SY5Ys to Aβ aggregates increased the 
proportion of insoluble α-syn that was phosphorylated at S129, which suggests an increase in 
α-syn fibril-formation (Swirski et al. 2014). Future exploration of this effect would be 
informative, and could complement studies of the effect of α-syn on APP. 
6.4 Future work 
This thesis has sketched out the rudiments of the effect of α-syn upon APP processing, and 
future work should focus on fleshing out some of the mechanistic detail. Primarily, I would 
like to ascertain the extent to which BACE1 controls α-syn-mediated β-amyloid production, 
for example with RNA-interference to reduce its activity. The endosomal co-localisation of 
BACE1 and APP in α-syn cell models should also be explored, since cell localisation is 
thought to have a major impact on APP processing. Increased BACE1/APP co-localisation 
could result from reductions in the lysosomal targeting and degradation of BACE1. 
Preliminary evidence suggested that BACE1 degradation in α-syn SH-SY5Ys was impaired, 
so exploring this could prove fruitful. A translational effect of BACE1 could also be confirmed 
with a BACE1 5’UTR luciferase reporter (ILL-Raga et al. 2011). Likely mechanistic 
connections between α-syn and BACE1 expression include the activation of eIF2 kinases by 
oxidative stress or ER stress. Perhaps overexpression of constitutively active GADD34, to 
repress eIF2α phosphorylation, could be used to assess the contribution of BACE1 
translational de-repression (Sadleir et al. 2014). Activation of individual eIF2 kinases, PKR, 
PERK, GCN2, and HRI, could be biochemically characterised. It may also be interesting to 
see whether the effect of α-syn on APP can be mitigated by approaches to decrease oxidative 
stress, such as antioxidants. α-Syn is known to impair secretory pathway trafficking in a way 
that is rescuable by Rab GTPase overexpression (Cooper et al. 2006; Dalfó et al. 2004), so 
studying the overexpression of specific Rab GTPases on α-syn-mediated β-amyloid 
production could be a fascinating tangent to the project. Indeed, the interaction of α-syn with 
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Rab8a has been shown to be dependent of α-syn S129 phosphorylation (Yin et al. 2014), which 
appeared to have a small impact on APP amyloidogenic processing in Chapter 3. 
The intriguing role of S129 phosphorylation in the effect of α-syn on APP processing is 
indicative of an underlying structure-function relationship that could be further explored. It is 
still not clear what features of α-syn contribute to its effect on APP, particularly since none of 
the mutations studied significantly mitigated the effect. Perhaps significant reduction of α-syn 
membrane association would eliminate the effect of α-syn on APP. Perhaps removal of the 
C-terminus, a site for binding physiological interactors such as synaptobrevin-2 (Burré et al. 
2010), would decrease APP amyloidogenic processing. It may also be interesting to see 
whether α-syn knock-down in cells has the opposite effect to overexpression. 
6.5 Concluding remarks 
Previous research into the potential interactions between α-syn and APP have focussed on 
aggregation, of α-syn and/or the Aβ peptide, to the detriment of investigating the underlying 
cell biology. The discovery that α-syn alters secretase-mediated APP processing in this thesis, 
and dissection of the underlying changes to secretase activity, has shown that the cell biology 
connecting these two proteins is interesting and worth further study. A precise mechanism is 
yet to be defined, despite attempts in this thesis to find it, but will surely prove to be 
enlightening. From the perspective of treating diseases such as DLB, where both α-syn and 
Aβ pathology appears within a short frame of time, understanding the connecting cell biology 
could be vital. If, for example, the Aβ production is a cellular response to a pre-existing 
synucleinopathy, then it may be unnecessary or even harmful to suppress Aβ production with 
β-secretase inhibitors. Ultimately, further development of this study may allow it to shape the 
future of therapeutics in synucleinopathy disease.  
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